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Abstract
Thrombomodulin (TM) is known mostly for its role in the regulation of
hemostasis, but it has also been shown to play an antimetastatic role in cancer. A
previous study showed that the anitmetastatic effects of TM were dependent on thrombin
binding. However, it is not known which substrate of thrombin-TM, protein C or TAFI, is
responsible for these antimetastatic effects. We hypothesized that TAFI is responsible for
the antimetastatic effects of TM, specifically tumour angiogenesis, due to its role in the
inhibition of pericellular plasminogen activation. We determined the effect of TAFIa on
tumour angiogenesis through inhibition of TAFIa and manipulation of cofactor ability of
TM. We found inhibition of TAFIa resulted in increased proliferation, invasion, tube
formation, and ECM proteolysis. We also found an inhibitory effect of TAFI activation
by thrombin-TM on tube formation and ECM proteolysis. Our results suggest that TAFIa
inhibits tumour angiogenesis in breast cancer cells.
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Chapter 1 Introduction
1.1 Cancer

The body contains over 30 trillion cells whose growth and proliferation is highly
controlled [1]. When these processes become uncontrolled a cell can become transformed
[1]. There are more than one hundred different types of cancer and almost every tissue in
the body is capable of forming tumours [1, 2]. Cancer is the leading cause of death in
Canada [3]. In 2009, 40% of Canadians were expected to develop cancer in their
lifetimes, and 25% of Canadians were expected to die from cancer [3]. There are multiple
different theories of the mechanisms by which cancer arises, and it is likely that multiple
combinations of these mechanisms lead to the disease.
The development of a malignant tumour involves a multistep process of
consecutive alterations in many oncogenes, microRNAs, and tumour-suppressor genes in
somatic cells [2, 4]. Germ-line mutations of these genes are also possible which could
predispose a person to a heritable cancer [4]. Mutations can be caused from chemical
compounds, viruses, and radiation [5]. Epigenetic events, such as promoter methylation,
can lead to cancer [5]. Mutated cells have a greater survival advantage compared to nonmutated cells, which could lead to carcinogenesis [5]. Tumours are usually heterogeneous
due to secondary and tertiary genetic alterations [4]. This heterogeneity of tumours can
make treatment difficult because there are multiple different populations of cancer cells
with differing vulnerability to treatment [4].
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There are hallmark capabilities that most cancer cells exhibit. The six main
hallmarks of cancer are: sustaining proliferative signaling, evading growth suppressors,
enabling replicative immortality, resisting apoptosis, inducing angiogenesis, and
activating invasion and metastasis [2, 6]. There are also two emerging hallmarks of
cancer: reprogramming energy metabolism and evading immune destruction. Cancer cells
can acquire sustained proliferative signaling by producing their own growth factors,
overexpressing growth factor receptors, influencing tumour-associated stroma to secrete
growth factors, and compromised negative feedback loops that inhibit proliferative
signaling [2, 6]. Cancer cells can evade growth suppressors by disruptions in cell cycle
progression pathways, or redirection of an antiproliferative pathway such as the TGF-β
pathway towards activating the epithelial-mesenchymal transition (EMT) [2, 6]. Another
hallmark is enabling replicative immortality which can be attributed to telomere
maintenance and prevention of senescence [2, 6]. Cancer cells can resist apoptosis
through the loss of tumour suppressor function, downregulating pro-apoptotic factors,
increase in expression of anti-apoptotic regulators, or increasing expression of survival
factors [2, 6]. During tumour formation the “angiogenic switch” occurs where normally
quiescent vasculature becomes activated by increasing activation or expression of proangiogenic factors and decreasing expression or activation of anti-angiogenic factors [2,
6]. Metastasis of tumour cells is responsible for 90% of cancer deaths [2]. Activation of
invasion and metastasis in cancer cells can occur through activation of extracellular
proteases, altered binding specificities of integrins, cadherins, and cell-cell adhesion
molecules [2, 6]. An emerging hallmark of cancer is the reprograming of energy
metabolism by relying on glycolysis which leads to an “aerobic glycolysis” state that
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fuels cell growth and uncontrolled proliferation [6]. The second emerging hallmark,
evading immune destruction, has not been completely solved but it seems that tumours
manage to avoid being destroyed by the immune system by disabling components of the
immune system that have been sent to destroy them [6]. These hallmarks of cancer
showcase the complexity of the disease and how treatment of the disease is complicated
due to the amount of contributing factors.
Due to the prevalence and complexity of cancer there has been extensive research
invested in finding new pathogenic pathways to better understand and treat this disease.

1.2 Angiogenesis
Angiogenesis is the process in which preexisting blood vessels sprout new
capillaries. In adults, new vessels are formed predominantly through angiogenesis, as
opposed to vasculogenesis which is the process of blood vessel formation from
endothelial-cell precursors [7]. In adults, the vasculature is quiescent and is only normally
activated through wound healing and female reproductive processes such as ovulation
[8].
New capillaries from quiescent vasculature can be formed in response to a
stimulus which activates the vasculature [8]. Once activated, endothelial cells locally
degrade the vascular basement membrane and extracellular matrix allowing the cells to
invade the surrounding stroma [8, 9]. The endothelial cells begin to proliferate into the
perivascular space toward the stimulus forming a migrating column [8, 9]. Extravascular
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fibrin is deposited and acts as a temporary matrix scaffold for the migrating endothelial
cells [10]. The endothelial cells in the migrating column enter a differentiation zone
where the cells stop proliferating and begin to change shape and tightly adhere to each
other to form the lumen of the new capillary [8, 9]. The sprouting tubes fuse and coalesce
into loops allowing circulating blood to flow through the new capillary [8]. Finally, there
is further proliferation in the blood vessel wall to increase diameter, and perivascular
cells are attracted to the new vessel to form a new basal lamina [9]. Once the new blood
vessel has formed, the vessel becomes quiescent.
The process of angiogenesis in normal processes like the female reproductive
cycle and wound healing is usually not harmful, but overactive angiogenesis can lead to
many diseases. Angiogenesis is overactive in macular degeneration, endometriosis,
psoriasis, rheumatoid arthritis, and cancer [11, 12].

1.3 Tumour Angiogenesis

Sustained angiogenesis is one of the hallmarks of cancer [2, 6]. The key role that
angiogenesis plays in cancer has been recognized since the early 1970s. In 1971,
Folkman published an article stating that vascularization of a tumour was necessary for
expansion of the tumour [13]. His group found that tumours could not grow beyond 1-2
mm3 in size without angiogenesis because the tumour could not receive enough oxygen
and nutrients [14]. Without angiogenesis, the tumour maintains a balance of proliferation
and apoptosis preventing growth and causing it to be dormant [11]. Folkman’s initial
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findings were controversial since it was widely believed that tumour growth was not
dependent on angiogenesis [15]. Moreover, there was a general belief that tumours grew
around existing vasculature and recruitment of blood vessels was not possible [15].
Eventually, the scientific evidence grew to support Folkman’s initial findings and a vast
amount of research has gone into discovering how tumour angiogenesis occurs. Now it is
firmly established that highly angiogenic tumours have a higher metastatic potential than
less vascular tumours [16].
When blood vessels are quiescent, there is a balance between pro-angiogenic
factors and anti-angiogenic factors. Where there is an increase in pro-angiogenic factors
and a decrease in anti-angiogenic factors, the “angiogenic switch” occurs and
angiogenesis is activated [8]. Tumour angiogenesis goes through two phases separated by
the “angiogenic switch”: an avascular phase and a vascular phase [9]. In the avascular
phase the dormant tumour is in a steady state of proliferation and apoptosis [9]. Only a
small subset of the avascular tumours reach the vascular phase in which exponential
tumour growth occurs due to tumour angiogenesis [9]. Tumours can release diffusible
angiogenic factors, such as VEGF and bFGF, that can signal quiescent vasculature to
begin angiogenesis [8]. Negative regulators of angiogenesis, such as thrombospondin-1
and endostatin, must also be decreased for tumour angiogenesis to occur [11]. Different
factors such as hypoxia in the tumour can cause an increase in VEGF secretion from
tumour cells and surrounding stromal cells [9]. The tumour suppressor gene p53
upregulates thrombospondin-1; p53 is lost in half of all cancers which could lead to a
decrease of thrombospondin-1 [6, 9].
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The blood vessels formed through tumour angiogenesis differ from blood vessels
formed through normal angiogenesis. Vessels formed by tumour angiogenesis do not
become quiescent, and the constant growth of new blood vessels within a tumour causes
them to have a different physiology [9]. Structurally, tumour blood vessels are dilated,
irregularly shaped, have dead ends, and can have cancer cells integrated into the vessel
wall [9]. The blood vessels aren’t organized into normal structures like capillaries,
arterioles, and venules: they are instead chaotically organized with excessive vessel
branching [17]. The blood flow in tumour vessels is erratic, it is slow moving and
sometimes oscillating; this leads to acidic and hypoxic regions in tumours [9, 18].
Tumour vessels are leaky due to overproduction of VEGF and thus experience
microhemorrhaging [9]. There is high interstitial pressure within the tumour due to the
leakiness of the tumour vasculature [17]. Tumour vessels have altered endothelial cellpericyte interactions, which results in defective surrounding basement membrane [17].
The endothelial cells within the tumour vessel have abnormal gene expression and
require growth factors for survival [17]. Overall, tumour vessels are functionally and
structurally different than normal blood vessels.
Blood vessels within the tumour can act as an escape route for a tumour to
metastasize. Metastasis follows a step-wise sequence sometimes referred to as the
invasion-metastasis cascade [6, 19]. First, tumour cells locally invade and intravasate into
the blood vessel within or surrounding the tumour [19]. The cancer cells then travel and
survive through the blood stream, arrest in a capillary bed, and extravasate from the blood
stream into the parenchyma of distant tissues [19, 20]. The cancer cells proliferate in their
new environment and form a micrometastatic lesion, through the process of colonization
6

[19]. Once the micrometastatic lesion has formed, vascularization of the new tumour can
occur and the process of metastasis can begin again [19]. Cancer cells can metastasize
through either blood vessels or through lymphatic vessels [19].
The process of tumour angiogenesis is necessary for the growth of a tumour past a
dormant avascular stage [9, 11, 13, 14]. Tumour angiogenesis provides nutrients and
oxygen to a tumour and also can act as an escape route allowing metastasis to occur [14,
19].

1.4 Vascular Endothelial Growth Factor

Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis.
VEGF is responsible for vascular permeability and growth [21]. Originally, VEGF was
identified by different groups as two different proteins named based on its two main
activities [21]. Senger and colleagues first identified a protein they named “tumour
vascular permeability factor” (VPF) in 1983 and suggested that this protein could be
responsible for the high permeability of tumour blood vessels [22]. Ferrara and Henzel
identified a protein they named “vascular endothelial growth factor” (VEGF) in 1989 due
to the protein being an endothelial cell specific mitogen [23]. Eventually, cDNA cloning
of both VPF and VEGF determined that they were the same protein [21]. VEGF is also
referred to as VEGF-A, as it belongs to a family of proteins including VEGF-B, VEGFC, VEGF-D, and placenta derived growth factor (PDGF) [21]. The other VEGF proteins,
VEGF-B, VEGF-C, and VEGF-D do not play a role in endothelial angiogenesis [21].
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VEGF-C and VEGF-D play a role in lymphatic angiogenesis [21]. VEGF-A (hereafter
referred to simply as “VEGF”) exists as four main isoforms produced by alternative
splicing: VEGF121, VEGF165, VEGF189, and VEGF206, with VEGF165 being the most
prominent isoform [21]. VEGF binds to two receptors, VEGFR-1 and VEGFR-2, both of
which are receptor tyrosine kinases [21]. VEGF binding to VEGFR-2 leads to the
mitogenic activity while VEGFR-1 acts as a decoy receptor by sequestering VEGF
leading to less VEGF availability for VEGFR-2 [21].
VEGF expression is upregulated most effectively by hypoxia due to the
transcription factor hypoxia-inducible factor 1 (HIF-1) [21]. The inflammatory cytokines
IL-1 and IL-6 upregulate the expression of VEGF [21]. Many growth factors upregulate
VEGF expression such as PDGF, TGF-α, TGF-β, FGF, and EGF; these growth factors
are frequently expressed by tumours [21, 24]. Activation of Ras and mutations in the
Wnt-signaling pathway result in increased VEGF expression [21]. VEGF expression can
also be upregulated by mutations in the tumour suppressors PTEN and p53 [21, 25].
Biologically active VEGF189, VEGF206, and, to a lesser extent, VEGF165 can be released
from the extracellular matrix (ECM) by the proteolytic enzyme plasmin or the
glycosaminoglycan heparin [26].

1.4.1 Role of VEGF in Cancer
VEGF acts as a key mediator of angiogenesis by promoting endothelial cell
growth, vascular permeability, chemotaxis, extracellular matrix (ECM) degradation, and
endothelial cell survival [21, 25]. In endothelial cells, VEGF induces the expression of
8

the anti-apoptotic proteins Bcl-2 and survivin [21]. VEGF induces expression of
urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator (tPA),
and plasminogen activator inhibitor-1 (PAI-1) [27]. uPA is involved in extracellular
proteolysis and cell migration [27]. VEGF also upregulates the expression of urokinasetype plasminogen activator receptor (uPAR) in endothelial cells; uPAR greatly increases
the rate of plasminogen activation [28]. In retinal pigment epithelium (RPE) cells there is
a positive feedback loop that exists between VEGF and matrixmetaloproteinase-9
(MMP9), where MMP9 is involved in ECM degradation [29].
VEGF is the key mediator of angiogenesis and it is upregulated by hypoxia,
growth factors frequently expressed in tumours, loss of tumour suppressors, and overactivation of oncogenes [21, 24, 25]. VEGF has been found to be overexpressed in many
human tumours including kidney, colon, pancreas, bladder, breast, stomach, and
glioblastomas [30]. VEGFR-1 and VEGFR-2 are expressed in many human tumours [31].
Elevated levels of VEGF in cancer are associated with a poorer prognosis [24]. Due to
these factors inhibiting the VEGF became an attractive cancer therapeutic target. Many
drugs have been made to target VEGF and the VEGFRs. While these drugs have been
successful in treating mouse tumours, they only have modest effects on human cancers
[32]. Bevacizumab, a human antibody against VEGF-A, was the first FDA approved drug
for cancer treatment that inhibited VEGF [21]. Bevacizumab seems to be only slightly
beneficial to advanced colon cancer patients by prolonging life for 4 to 5 months [32].
The FDA has revoked the approval of bevacizumab for the treatment of metastatic breast
cancer [33]. In phase III clinical trials VEGF or VEGFR inhibitors were shown to have
modest effects on human cancers [32, 34]. A potential explanation for the minimal
9

benefit of these therapies is the tumour cells that are resistant to anti-VEGF therapy could
upregulate many other growth factors that can stimulate tumour angiogenesis [32]. The
failure of the anti-VEGF therapeutics suggests that new molecular targets need to be
found to treat tumour angiogenesis [32].

1.5 Urokinase Plasminogen Activation System
The urokinase plasminogen activation system (uPAS) is involved in many
different processes including tissue and vascular remodeling, cell migration, cell
invasion, cell adhesion, tumour development, angiogenesis, and metastasis [35]. uPAS
consists of urokinase-type plasminogen activator (uPA), urokinase-type plasminogen
receptor (uPAR), and two inhibitors: plasminogen activator inhibitor-1 (PAI-1), and
plasminogen activator inhibitor-2 (PAI-2) [36]. The uPAS system is involved in the
conversion of the zymogen plasminogen to the active enzyme plasmin (Fig. 1.1) [36].
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Figure 1.1 Activation of plasminogen by the urokinase plasminogen activation
system
Urokinase-type plasminogen activator receptor (uPAR) can bind both the zymogen
urokinase-type plasminogen activator (pro-uPA) and the active form uPA with the same
affinity. Plasmin can activate pro-uPA to uPA, and uPA can activate plasminogen to
plasmin. Both of these processes are more efficient when the zymogen forms are bound
to their cell surface receptors, uPAR or plasminogen receptor. Plasmin degrades the
extracellular matrix (ECM) and activates and releases matrix metalloproteinases (MMPs).
Both plasmin and the active MMPs can activate and release growth factors from the
ECM. uPA bound to uPAR can bind to the ECM protein vitronectin. uPA-uPAR bound to
vitronectin can interact with integrins to activate intracellular signaling events. uPA is
antagonized by plasminogen activator inhibitor 1 (PAI-1) and plasminogen activator
inhibitor 2 (PAI-2). Plasmin activity can be inhibited by α2-antiplasmin. (Image adapted
from ref. 41).
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Plasminogen is the zymogen form of plasmin, its activation plays a role in
fibrinolysis, inflammation, and cancer [37]. Plasminogen is produced by the liver and
circulates at a relatively high concentration through interstitial fluids and plasma [38].
The concentration of plasminogen can be upregulated in response to injury or
inflammation [38]. Plasminogen circulates under physiological conditions as Gluplasminogen [37]. Glu-plasminogen consists of a single chain with a carboxyl-terminal
serine protease domain, five kringle domains, and an amino-terminal glutamic acid [37].
Plasminogen can bind to proteins with carboxyl-terminal lysine through the lysinebinding site in kringle domains 1, 2, 4, and 5 [37]. Glu-plasminogen is in a tight
conformation; proteolysis by plasmin of the amino-terminal portion results in the
cleavage of the amino-terminal portion and generates Lys-plasminogen [36].
Plasminogen is in the tight conformation under physiological conditions to limit the
amount of plasminogen activation in the blood [36]. Lys-plasminogen is in an open
conformation and is susceptible to cleavage from proteolytic enzymes such as uPA and
tissue-type plasminogen activator (tPA) to form plasmin [36].
There are more than twelve known plasminogen receptors possibly present on the
cell surface, most with a carboxyl-terminal lysine residue to which the kringle domains of
plasminogen can bind [39]. Activation of plasminogen by uPA or tPA is enhanced
through binding of plasminogen to a cell surface plasminogen receptor [39]. Plasmin is
protected from inhibitors by being bound to a plasminogen receptor [37]. Binding of
plasminogen to a cell surface plasminogen receptor localizes plasminogen activation to
the cell surface (Fig. 1.1) [37].
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Plasmin is a serine protease with activity toward a broad range of substrates. In
the blood, fibrin is the main substrate of plasmin [40]. Plasmin mediates fibrinolysis by
degrading and clearing fibrin blood clots [41]. Plasmin also degrades a range of basement
membrane and ECM components including proteoglycans, fibronectin, vitronectin, type
IV collagen, and laminin (Fig. 1.1) [36]. Plasmin can release many growth factors from
the ECM that promote migration, growth and angiogenesis such as VEGF, EGF, bFGF,
and TGF-β (Fig. 1.1) [36]. Many of these growth factors then act to upregulate the
expression of uPAR, uPA, and PAI-1 [36]. Plasmin also activates many matrix
metalloproteinases (MMPs) that can further degrade the ECM and release growth factors
(Fig. 1.1) [38]. Plasmin activates MMP1, 2, 3, 9, 13, and 14 [38]. Plasmin has been
shown to have activity toward osteopontin (OPN); proteolytic cleavage of OPN can result
in increased cell adhesion of tumour cells [42]. Angiostatin, an inhibitor of angiogenesis,
is a fragment of plasminogen and plasmin that can be produced from plasmin
autoproteolysis or degradation by MMPs [35]. Overall, plasmin acts to regulate
fibrinolysis and tissue remodeling.
There are two different plasminogen activators: uPA and tPA [43]. tPA is
involved in plasminogen activation in the blood which leads to the lysis of fibrin clots
[38]. uPA is involved in plasminogen activation which leads to tissue remodeling [43].
uPA is secreted as a single-chain zymogen pro-uPA [35, 36]. Single chain pro-uPA can
be converted to the two chain active form of uPA by proteases such as plasmin and
trypsin [35, 36]. There is reciprocal zymogen activation between plasmin and uPA:
plasmin is the main activator of pro-uPA, and plasminogen is the main substrate of uPA
(Fig. 1.1)

[36]. Pro-uPA and uPA bind with the same affinity to uPAR, and the
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conversion of pro-uPA to uPA is more efficient when pro-uPA is bound to uPAR (Fig.
1.1) [35, 36]. This localization of the activation of pro-uPA to uPAR leads to pericellular
generation of uPA [36].
uPAR is involved in regulating extracellular proteolysis, cell signaling, and cell
adhesion [41]. uPAR localizes to cell-cell contacts, cell-ECM contacts, and the leading
edge of migrating cells [36]. uPAR has low expression in normal cells and it is
upregulated by injury and inflammation and during ECM remodeling [41]. uPAR does
not contain a transmembrane domain: instead it is associated with the cell surface by a
glycosyl phosphatidylinositol (GPI) anchor [36]. uPAR binds both pro-uPA and uPA and
it enhances the production of uPA at the cell surface (Fig. 1.1) [36]. Another ligand of
uPAR is the ECM protein vitronectin [36, 43]. Vitronectin binds to a different location on
uPAR than pro-uPA/uPA; therefore, both vitronectin and pro-uPA/uPA can
simultaneously bind to uPAR [41]. Binding of uPAR to vitronectin is enhanced by uPA
binding to uPAR [41]. Vitronectin binding to uPAR results in cell adhesion [41]. The GPI
anchor attached to uPAR allows it to localize to lipid rafts which have a higher
concentration of vitronectin and integrins [41]. Integrins are cell surface receptors that
transduce signals from the extracellular environment; some integrins are co-receptors of
vitronectin [40]. uPAR or uPAR associated with vitronectin may interact with integrins
which results in cell signaling leading to cell survival, cell proliferation, cytoskeleton
remodeling, and cell mobility (Fig. 1.1)

[41, 43]. uPAR regulates extracellular

proteolysis through uPA, cell adhesion through vitronectin, and cell signaling through
vitronectin and potentially through integrins [41].
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There are inhibitors of the uPAS which act to regulate the amount of uPA and
plasmin generation: PAI-I, PAI-2, α2-antiplasmin, and α2-macroglobin [36, 37, 43]. PAI1 and PAI-2 are plasminogen activator inhibitors while α2-antiplasmin and α2macroglobin inhibit plasmin [36, 37, 43]. PAI-1 and PAI-2 are serine protease inhibitors
(serpins). PAI-1 is considered the main inhibitor of uPA and tPA (Fig. 1.1) [43]. PAI-2
can inhibit tPA and uPA, albeit to a lesser extent than PAI-1 (Fig. 1.1) [35]. PAI-1
inactivates tPA and uPA in a 1:1 ratio and it can also moderately inhibit plasmin [36, 43].
PAI-1 is stabilized in its active conformation by an interaction with vitronectin and PAI-1
bound to vitronectin can still bind to uPA [43]. PAI-1 bound to uPA loses its affinity for
vitronectin [35]. uPA bound to uPAR is not protected from inhibition by PAI-1 and PAI2 [43]. α2-antiplasmin is the main inhibitor of plasmin (Fig. 1.1) [35]. Cell surface bound
plasmin is protected against inhibition from α2-antiplasmin and α2-macroglobin
circulating in the plasma, this acts to restrict active plasmin to the cell surface [43].

1.1.1 Urokinase Plasminogen Activation System in Cancer
uPA, uPAR, and PAI-1 expression has been found to be upregulated in cancer and
associated with a poorer prognosis [36]. These uPAS components are upregulated in
many cancers including lung, bladder, breast, colon, ovary, cervix, kidney, stomach,
brain, thyroid, bladder, and endometrium [36]. In breast cancer specifically, high levels
of uPA and PAI-1 are robust prognostic markers associated with poor relapse-free
survival and overall survival [44]. The uPAS system is involved in tumour cell migration,
invasion, tumour angiogenesis, proliferation and adhesion [36].
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The uPAS has been implicated in tumour angiogenesis. While uPA and uPAR
levels are undetectable in normal quiescent endothelial cells, their production is induced
at the leading edge of migrating endothelial cells by pro-angiogenic factors such as
VEGF [10, 27, 45]. PAI-1 is highly expressed in tumour associated endothelial cells [10].
The major angiogenic stimulator hypoxia can induce uPAR and PAI-1 [10]. MMPs
released from the ECM and activated by plasmin play a role in angiogenesis by degrading
the ECM and basement membrane of existing vasculature to allow movement and
proliferation of endothelial cells into the surrounding stroma [36]. uPA expression can be
induced by NFκB; in many cancers NFκB is constitutively active [36]. The uPA
promoter has also been found to be hypomethylated in many cancer cells leading to
increased uPA production [36]. The tumour suppressor p53 can bind to a sequence in the
untranslated region of uPAR mRNA, resulting in an increase in its mRNA degradation by
other proteins [36]. In more than 50% of cancers there are loss-of-function mutations of
p53 which could account for the upregulation of uPAR in many cancers [36].
The upregulation of PAI-1 in cancers seems paradoxical since PAI-1 inhibits
uPA. A study from Bajou et al. showed prevention of tumour vascularization and
invasion of transplanted keratinocytes in PAI-1 deficient mice [46]. When PAI-1
expression was restored in the PAI-I deficient mice there was invasion and tumour
vascularization of the transplanted keratinocytes [46]. This study showed that PAI-1
expression is essential for tumour angiogenesis and invasion [46]. Excessive ECM and
basement membrane proteolysis hinder angiogenesis because there is the absence of a
scaffold for migrating endothelial cells to adhere [10]. PAI-1 prevents excessive
proteolysis which therefore supports angiogenesis [10]. PAI-1 can bind to vitronectin,
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and when PAI-1 binds to uPA it loses affinity for vitronectin [35, 43]. In this manner,
PAI-1 could regulate cell adhesion: when PAI-1 interacts with vitronectin it inhibits cell
adhesion while when PAI-1 complexes with uPA adhesion is promoted [47]. In the
absence of uPA, cells would be nonadherent and motility of the cells would increase [47].
When PAI-1 is bound to vitronectin it can block the binding of vitronectin to integrin
αvβ3 which leads to a decrease in migration on the substratum [48]. Binding of PAI-1 to
uPA restores binding of vitronectin to integrin αvβ3, therefore increasing cell migration on
the substratum [48]. PAI-I can regulate both adherence and migration on the cell surface
[47, 48]. PAI-1 could favour tumour progression by preventing excessive proteolysis,
regulating cell adhesion, and regulating migration on the substratum [10, 47, 48].
Inhibiting different components of the uPAS has become an attractive target for
cancer therapeutics. Drugs targeting the uPAS have showed promise in vitro and in vivo
and many have entered clinical trials [36]. For example, WX-UK1, an inhibitor of uPA,
has shown promise in phase I and II clinical trials [36]. However, there have also been
many drugs that showed promise in vitro and in vivo but have failed in clinical trials such
as surmin, a competitive inhibitor of uPA binding to uPAR [36]. Plasminogen receptors,
like uPAR, also localize plasmin generation to the cell surface which is essential for the
metastatic role of plasmin [37, 39]. It may be more beneficial to target cell surface
plasminogen receptors than uPAR because they are directly involved in the localization
of plasminogen activation on the cell surface [39]. Therefore a potential therapeutic target
could be the inhibition of pericellular plasminogen activation.
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1.6 Matrix Metalloproteinases
Matrix metalloproteinases (MMPs) constitute a family of 23 zinc-dependent
endopeptidases known mainly for their involvement in extracellular proteolysis [10].
MMPs play a role in organ development, regulating inflammatory processes, and tissue
remodeling [49]. They also play a role in diseases such as rheumatoid arthritis and cancer
[49, 50]. MMPs can be placed into two broad structural categories: secreted MMPs and
membrane-type MMPs (MT-MMPs) [10]. Most MMPs share three common domains: a
pro-domain with a conserved cysteine residue, a catalytic domain containing a zinc ion,
and a carboxyl-terminal hemopexin-like domain linked to the catalytic domain with a
hinge region [49, 50]. MMPs are synthesized as zymogens, and are kept inactive through
a covalent coordination of the zinc ion in the catalytic domain to the conserved cysteine
in the pro-domain [50]. MMPs are activated through a mechanism called cysteine switch,
during which the cysteine zinc coordination is disturbed either by chemical modification
of the cysteine residue or proteolytic removal of the pro-domain [51]. Plasmin is a major
protease involved in the removal of the pro-domain and subsequent activation of MMPs
[52].

While there are many inhibitors of MMPs such as α2-macroglobin and α1-

proteinase inhibitor, the main inhibitors of MMPs are tissue inhibitors of
metalloproteinases (TIMPs) [49]. TIMPs form reversible 1:1 complexes with active
MMPs [49]. MMPs degrade components of the ECM including collagens, proteoglycans,
and glycoproteins [53]. MMPs are also involved releasing growth factors embedded in
the ECM [53]. Other MMP substrates include cytokines, chemokines, growth factor
receptors, tyrosine kinase receptors, and cell adhesion molecules [50, 53].
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1.1.2 Involvement of Matrix Metalloproteinases in Cancer
MMPs are upregulated in many cancers and high levels of MMPs are correlated
with poorer prognosis [50]. MMPs are expressed in many cells found in the tumour
microenvironment including fibroblasts, endothelial cells, and inflammatory cells [49].
MMPs degrade the ECM which leads to cell invasion and metastasis [49]. MMPs are
involved in increasing the bioavailability of many growth factors in the tumour
microenvironment leading to cell proliferation [49]. MMPs are also involved in the
regulation of apoptosis through cleavage of receptors or ligands that are pro-apoptotic
[49]. MMPs can activate many inflammatory mediators which can lead to tumourassociated inflammation [49]. MMPs have been found to be highly involved in tumour
angiogenesis [49]. Many MMPs have been found to have tumour-suppressing functions
as well, such as the production of angiostatin formed through proteolytic cleavage of
plasminogen by MMP2, 3, 7, 9, and 12 [35, 53].
MMPs have been implicated in tumour angiogenesis, specifically MMP2, 9, and
14 [53]. Endothelial cells have been found to express MMP2, 3, 7, 14, and 19 as well as
TIMP1, and 2 [49]. Mice deficient in MMP2 have reduced tumour angiogenesis [54].
Mice deficient in MMP9 and MMP14 have impaired angiogenesis during development
[55, 56]. MMP2 and MMP9 are known as gelatinases since one of their substrates is
gelatin, but they can also degrade other substrates such as collagen type IV, laminin, and
fibrin [53]. MMP14 is a MT-MMP that can degrade substrates such as collagen types I,
II, III, fibrin, and fibronectin [53]. These MMPs could be playing a role in tumour
angiogenesis by degrading the vascular basement membrane and ECM [53]. MMP9 can
release VEGF from the ECM [49]. MMP9 has been shown to be in a positive feedback
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loop with VEGF in RPE cells [29]. MMP3, 7, 9, and 16 can cleave matrix-bound VEGF
producing truncated versions that cause vascular dilation of existing vessels, whereas
non-truncated VEGF induces vessel sprouting [57]. The angiostatin that MMPs can
create from plasminogen can act to inhibit angiogenesis [35, 53]. The effects that MMPs
have on angiogenesis are diverse since they can generate pro- and anti-angiogenic effects.
Since MMPs have been associated with multiple cancers there have been many
MMP inhibitor drugs made. They have, however, had disappointing results in clinical
trials [49]. Many of these drugs lacked specificity toward particular MMPs as many
MMPs are structurally similar [53]. Another potential reason for the failure of these drugs
could be that they were tested on late-stage tumours that had already metastasized and/or
had established vasculature [53]. Since MMPs are implicated in tumour angiogenesis,
MMP inhibitor drugs may be more beneficial in treating early-stage tumours to prevent
tumour angiogenesis and metastasis [53].

1.7 Coagulation and Fibrinolysis
While the activation of plasmin on the cell surface is involved in cancer amongst
other effects, its activation in the blood plays a key role in the fibrinolytic system [41, 43,
58]. Maintaining vascular blood fluidity an essential physiological process [59]. There is
a delicate balance between blood clot deposition and removal known as hemostasis that
occurs under normal physiological conditions [59]. Normal hemostasis regulates the
maintenance of blood fluidity while protecting against excessive bleeding resulting from
vascular injury [59]. The coagulation system is responsible for the formation of a fibrin
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clot at the site of an injury, whereas the fibrinolytic system is responsible for the
degradation of the fibrin clot [59]. Imbalances in hemostasis can lead to the formation of
a thrombus that can occlude blood flow leading to a heart attack or stroke or to diseases
involving a bleeding tendency, such as hemophillia [58, 60]. There are control
mechanisms present in both the coagulation and fibrinoytic systems – as well as between
the systems – that act to ensure the hemostatic balance is maintained [60].
Endothelial cells provide a barrier between blood and tissues, and they act to
maintain

blood

fluidity,

and

protect

against

vascular

injury

by producing

thromboresistant and vasoprotective molecules [61]. Under normal conditions, the
surface of endothelial cells is thromboresistant which ensures that platelets and other
blood cells do not adhere [61]. Upon vascular injury platelets adhere to the endothelial
cell surface due to the loss of endothelial cell protective molecules and expression of
prothrombotic factors and adhesive molecules [61]. Vascular injury can expose ECM
components, mainly collagen, to the blood which platelets can come into contact with
and adhere to [62]. After platelets adhere to the ECM components platelet activation and
aggregation occur [62]. The cycle of platelet adhesion, activation, and aggregation
continues and results in the formation of a platelet plug [61, 62].
The platelet plug is the first hemostatic structure; after it forms the coagulation
cascade is initiated [59, 63]. The function of the coagulation system is to add to the
platelet plug and form a stable fibrin clot at the site of injury to prevent excessive
bleeding [58, 63]. Thrombin is the main enzyme produced in the coagulation cascade,
and is responsible for the formation of the fibrin clot [63]. The coagulation cascade is
further divided into the extrinsic and intrinsic pathways [63]. The extrinsic pathway of
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the coagulation cascade produces the thrombin needed for initial fibrin clot formation,
while the intrinsic pathway of the coagulation cascade leads to a large burst of thrombin
formation within the clot which protects the clot from fibrinolysis (Fig. 1.2) [63, 64].
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Figure 1.2 Coagulation and fibrinolytic pathways
The coagulation cascade is initiated upon vascular injury in which tissue factor (TF) is
exposed to the bloodstream. Initially the extrinsic pathway is activated, by which TF
binds to activated factor VII (VIIa). The TF-VIIa complex activates limited quantities of
factors X and IX. Activated factor X (Xa) along with its cofactor factor Va activate
prothrombin to thrombin (factor IIa) on the surface of activated platelets. IIa converts the
soluble zymogen fibrinogen to the insoluble fibrin. The formation of fibrin forms a fibrin
clot. IIa can activate factor XI, which activates factor IX. TF-VIIa can also catalyze the
production of IXa. IXa along with its cofactor factor VIIIa activate factor X and lead to
further production of IIa. The intrinsic pathway makes large amounts of IIa which can
consolidate the clot forming a thrombus. The fibrinolytic cascade is initiated after the
formation of a thrombus. Initially limited digestion of the fibrin clot occurs by
plasminogen converted by tissue-type plasminogen activator to plasmin forming fibrin’
which contains carboxyl-terminal lysine residues that make fibrin’ an effective cofactor
for plasminogen activation thereby mediating positive feedback in the fibrinolytic
cascade. Digestion of fibrin into soluble fibrin degradation products (FDPs) dissolves the
clot. IIa can bind to the transmembrane cofactor thrombomodulin (TM) to activate
protein C and thrombin-activatable fibrinolysis inhibitor (TAFI). Activated protein C
(APC) along with its cofactor Protein S can inhibit coagulation by degrading factors Va
and VIIIa. TAFIa can remove the carboxyl-terminal lysine residues from fibrin’ therefore
inhibiting the positive feedback loop in fibrinolysis. (Image adapted from ref. 63).
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The initial step in the coagulation cascade involves the expression of membrane
bound tissue factor (TF) [65]. TF is not normally exposed to the blot clotting factors
under physiological conditions, but when blood enters the interstitium after vascular
injury it is exposed to TF [65]. TF recruits circulating factor VIIa and forms a
catalytically active complex [63, 66]. The TF-VIIa complex activates limited quantities
of factors IX and X to factors IXa and Xa (Fig. 1.2) [66, 67]. Factor Xa is involved in the
common pathway while factor IXa is involved in the intrinsic pathway [63]. The extrinsic
pathway proceeds with factor Xa along with its cofactor Va and the activated platelet
surface forming a complex known as prothombinase which activates prothrombin to
thrombin (Fig. 1.2) [66]. Thrombin then cleaves soluble fibrinogen into insoluble fibrin
forming a fibrin clot (Fig. 1.2) [66]. The amount of thrombin generated through the
extrinsic pathway is relatively small, being only around 5% of the total thrombin
generated during coagulation [63]. The TF-VIIa complex is rapidly inactivated by tissue
factor pathway inhibitor (TFPI) which results in trace amounts of Xa formation and
consequently low amounts of thrombin formation formed through the extrinsic pathway
[65]. The small amount of thrombin generated through this pathway is sufficient to form
a fibrin clot but cannot stabilize the clot [63, 67]. The majority of thrombin is generated
through the intrinsic pathway in order to protect the newly formed fibrin clot [63].
Thrombin generated through the extrinsic pathway can activate factor XI, which can then
activate factor IX (Fig. 1.2) [63]. TF-VIIa complex also catalyzes the production of factor
IXa (Fig. 1.2) [66, 67]. Factor IXa along with its cofactor VIIIa and an activated platelet
surface form a complex known as intrinsic tenase [66]. Tenase activates factor X which
can further activate prothrombin to thrombin [66]. This pathway leads to a large
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amplification of thrombin generation (Fig. 1.2) [67]. The thrombin generated can activate
factors V, VIII, and XIII, platelets, and can convert fibrinogen to fibrin [66]. Activated
factor XIII (XIIIa) is a transglutaminase that cross-links fibrin to stabilize the clot [66].
The insoluble fibrin mesh binds to the platelets forming a platelet-fibrin thrombus at the
site of the vascular injury [59].
For wound healing and tissue remodeling to occur after vascular injury the formed
thrombus must be broken down through fibrinolysis (Fig. 1.2) [67]. tPA can activate
plasminogen to plasmin, however this conversion is slow in the absence of a fibrin
cofactor, accounting for the localization of fibrinolysis to the thrombus itself (Fig. 1.2)
[58]. Plasmin can proteolytically cleave fibrin into soluble fibrin degradation products
(FDPs) (Fig. 1.2) [58]. Partial cleavage of fibrin by plasmin generates carboxyl-terminal
lysine residues that can bind tPA and plasminogen greatly enhancing the efficiency of
tPA activation of plasminogen (Fig. 1.2) [68]. These carboxyl-terminal lysines therefore
mediate positive feedback in the fibrinolytic cascade. An additional positive feedback
mechanism mediated by carboxyl-terminal lysines in fibrin is acceleration of plasminmediated conversion of Glu-plasminogen to Lys-plasminogen [62, 67]. Lys-plasminogen
is in an open conformation and is a better substrate for tPA [36]. The serine protease
inhibitors α2-antiplasmin and PAI-1 can downregulate fibrinolysis by irreversibly binding
to plasmin and tPA, respectively [58, 64]. Plasmin bound to carboxyl-terminal lysine
residues on partially-degraded fibrin is protected from inactivation by α2-antiplasmin
[69]. Therefore, the generation of carboxyl-terminal lysine residues on fibrin is an
important regulatory mechanism that promotes fibrinolysis [63].
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Within both the coagulation and fibrinolytic systems there are regulatory
mechanisms such as the anticoagulant pathway involving protein C and the
antifibrinolytic pathway involving thrombin-activatable fibrinolysis inhibitor (TAFI)
(Fig. 1.2) [64]. Both of these mechanisms are mediated by the endothelial transmembrane
enzyme thrombomodulin (TM) in complex with thrombin [64]. TM binds thombin and
prevents it from its procoagulant functions and directs it toward the activation of either
protein C or TAFI [64]. When TM concentrations are low the activation of TAFI is
favoured, whereas high TM concentrations favour protein C activation [70]. Thrombin
bound to TM is both anticoagulant through the activation of protein C and antifibrinolytic
through the activation of TAFI [64]. The protein C anticoagulant pathway is an important
mechanism for controlling thrombosis [71]. The thrombin-TM complex can activate
protein C more than 1000-fold more efficiently than thrombin alone [72]. Once activated
protein C (APC) is formed, it along with its cofactor protein S (PS) can proteolytically
degrade cofactors Va and VIIIa (Fig. 1.2) [66, 73]. This inhibits the formation of
prothrombinase and intrinsic tenase leading to an overall decrease of thrombin production
and an overall downregulation of coagulation [66, 73]. The TAFI antifibrinolytic
pathway is an important mechanism in regulating the positive feedback loop of the
fibrinolytic pathway (Fig. 1.2) [68]. This antifibrinolytic pathway creates a direct
molecular link between the coagulation and fibrinolytic pathways since activation of
coagulation produces thrombin that can then inhibit fibrinolysis through activation of
TAFI [74]. The thrombin-TM complex is the most likely physiological activator of TAFI,
with a 1250-fold increase in activation efficiency over thrombin alone [75]. The burst of
thrombin generation during the intrinsic coagulation cascade can trigger the activation of
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TAFI [68]. TAFIa can cleave carboxyl-terminal lysine and arginine residues from
partially degraded fibrin, therefore attenuating the effect of these residues on positive
feedback via plasminogen activation, Glu- to Lys-plasminogen conversion, and
protection of plasmin from α2-antiplasmin [62, 76, 77]. Therefore, TAFIa leads to a
decrease in plasmin formation and delays the lysis of the fibrin clot [64].

1.8 Thrombomodulin
Thrombomodulin (TM) is transmembrane glycoprotein that plays a role in
regulating vascular hemostasis and has recently been linked to cancer. It is mainly found
on endothelial cells but is also present in monocytes, platelets, megakaryocytes,
chondrocytes, smooth muscle cells, osteoblasts, keratinocytes, astrocytes, and in various
tumour cells [78, 79]. In the vasculature, TM concentration is higher within capillaries
compared to arteries and veins [78]. TM acts as a cofactor for thrombin in the activation
of protein C and TAFI [64].
TM contains 557 amino acids and has a theoretical molecular mass of 75 kDa
[80]. TM is usually present in a highly glycosylated form with an apparent molecular
mass of 100 kDa [80]. TM contains five domains: an amino-terminal lectin-like domain,
six-epidermal growth factor (EGF)-like repeats, a serine-threonine rich domain, a
transmembrane domain, and a carboxyl-terminal cytoplasmic tail (Fig. 1.3) [80]. The
amino-terminal lectin-like domain makes up the majority of the extracellular component
of TM and contains two potential sites for N-linked glycosylation [78]. The lectin-like
domain plays a role in inflammation, cell proliferation, and cell adhesion [78]. The EGF27

like domains are responsible for activation of protein C and TAFI (Fig. 1.3) [78]. EGFlike repeats 5 and 6 are specifically responsible for thrombin binding (Fig. 1.3) [78].
EGF-like repeats 3-6 are essential for TAFI activation, while EGF-like repeats 4-6 are
essential for protein C activation [78]. There are specific residues within the EGF-like
domains that are essential for substrate binding, residing in EGF-like repeat 3 for TAFI
activation and EGF-like repeat 4 for protein C activation [81, 82]. Mutation to alanine of
Val340, Asp341, and Glu343 in EGF-like repeat 3 of TM result in more than a 90%
reduction in TAFI activation with marginal loss in protein C activation [82]. Mutation to
alanine of Phe376 in EGF-like repeat 4 of TM results in a 90% reduction in protein C
activation and retains approximately 80% TAFI activation [81, 82]. Mutation to alanine
of Asp349, Glu357, Tyr358, and Gln387 in EGF-like domain 4 of TM results in loss of
both TAFI and protein C activation [81, 82]. Mutation of Gln387 to proline results in the
greatest loss of both TAFI and protein C activation by abolishing thrombin binding to
TM [81, 82]. The serine-threonine rich domain contains four potential sites for O-linked
glycosylation [78]. The serine-threonine rich domain also supports the attachment of
chondroitin sulfate (CS) (Fig. 1.3) [78]. CS is a glycosoaminoglycan with approximately
20 repeating disaccharide units and a trisaccharide terminus [78]. CS is important for the
protein C cofactor ability of TM and it acts as a second lower affinity binding site for
thrombin [78].
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Figure 1.3 Schematic diagram structure of thrombomodulin
Thrombomodulin (TM) contains five domains: amino-terminal lectin-like domain (D1),
epidermal growth factor (EGF)-like domain (D2), serine-threonine rich domain (D3),
transmembrane domain (D4) and a cytoplasmic tail (D5). The lectin-like domain is
involved in cell proliferation, inflammation and adhesion. The EGF-like domain is
responsible for substrate activation. EGF-like repeats 5-6 are responsible for thrombin
binding (IIa). Activation of thrombin activatable-fibrinolysis inhibitor (TAFI) by the TMIIa complex is achieved through EGF-like repeats 3-6. Activation of protein C by the
TM-IIa complex is achieved through EGF-like repeats 4-6. The serine-threonine rich
domain supports the attachment of chondroitin sulfate (CS). (Image adapted from ref. 78)
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Many factors have been found to modulate TM cellular expression. TM can be
upregulated by factors such as VEGF, thrombin, heat shock, histamines, and statins [78,
83]. Factors that can downregulate TM expression include hypoxia, inflammatory
cytokines, TGF-β, and shear stress [78, 83]. There are also regulatory mechanisms of TM
which can regulate its cofactor activity towards its substrates. Oxidation of Met388 which
is in the linker region between EGF-like repeats 5 and 6 results in an 80% loss in protein
C activation by thrombin-TM but does not affect TAFI activation [82, 84]. Concentration
of TM is another regulatory mechanism for substrate activation of TM: when TM
concentration is high protein C activation is favoured, when TM concentration is low
TAFI activation is favoured [70]. Within the capillaries the concentration of TM is high
which would lead to protein C activation and reduced coagulation [71, 78].
The main function of TM is being a cofactor to thrombin in the activation of
TAFI and protein C, but TM has been shown to play a role in inflammation, cell
adhesion, and cancer [78]. The lectin-like domain plays a role in maintaining cell-cell
adhesion [85]. The lectin-like domain has also been shown to attenuate inflammation
through binding to HMGB1 and Lewis Y antigen [78, 85]. HMGB1 is a proinflammatory protein and binding of HMGB1 to the lectin-like domain of TM sequesters
HMGB1 from its inflammatory pathway therefore inhibiting inflammation [78, 85]. The
Lewis Y antigen is a carbohydrate present in lipopolysaccharide component of the cell
wall of gram-negative bacteria that is highly involved in strong inflammatory processes
during infection [85]. Binding of the lectin-like domain of TM to the Lewis Y antigen can
block the inflammatory reaction [85]. TM can also indirectly inhibit inflammation by
sequestering thrombin [78]. Thrombin has many pro-inflammatory functions, of which
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many are mediated through activation of protease activated receptors (PARs) [78].
Thrombin bound to TM is prevented from activating PARs therefore the proinflammatory effects of thrombin are inhibited [78].

1.1.3 Role of Thrombomodulin in Cancer
Expression of TM has been found to be inversely correlated to tumour
malignancy and prognosis [86, 87]. Patients with TM-positive tumours have a
significantly higher survival rate than patients with TM-negative tumours [88]. In breast
cancer patients low TM is strongly correlated with high relapse rate and poor prognosis
[89]. Soluble TM has been shown to reduce invasion and metastasis in vivo [90]. TM
expression has also been shown to decrease cell proliferation [79, 87]. Zhang et al. found
that TM decreased tumour cell growth and that it was dependent on TM containing a
functional lectin-like domain [79]. Conversely, Horowitz et al. found that TM does not
affect established tumour growth, rather TM has a role in metastatic potential and
survival of newly metastasized tumour cells in the lungs [86, 91]. Horowitz et al. also
found that TM is an important regulator of metastasis and this was dependent on
thrombin binding to TM [91]. They made a strain of mice containing a Q387P mutation
“knocked in” to the gene encoding TM, a mutation that leads to a severe reduction in TM
cofactor activity toward TAFI and protein C by abolishing thrombin binding [82, 91, 92].
The presence of the Q387P mutation in the mice had no effect on tumour growth but
significantly increased metastatic potential and spontaneous metastasis, and increased the
probability of a metastatic focus forming from circulating tumour cells [91]. Furthermore,
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Horowitz et al. performed the same experiments using mice expressing a form of TM
lacking the lectin-like domain and did not find significant impact on metastasis [91].
These findings suggest that thrombin binding to TM, not the lectin-like domain of TM, is
required for the antimetastatic effects of TM [91].
TM has recently been shown to play a role in angiogenesis. Shi et al. reported that
recombinant TM containing the six EGF-like repeats and the serine-threonine rich
domain (rTMD23) promoted angiogenesis [93]. Kuo et al. performed a follow-up to the
work of Shi et al. and made mutations within the rTMD23 of E357A, R385S, and
D400A; these mutations do not allow for the activation of protein C [94]. They found
that the mutations of the rTMD23 increased angiogenesis but did not alter the angiogenic
potential compared to the non-mutated rTMD23 [94]. Their result suggested that
rTMD23 induced angiogenesis in a manner independent of activation of protein C [94].
Kuo et al. published another study suggesting that TM could be inhibiting angiogenesis
through the lectin-like domain [95]. They found that the lectin-like domain of TM could
be inhibiting angiogenesis through interaction with the Lewis Y antigen [95]. The Lewis
Y antigen has been shown to increase angiogenesis, therefore the lectin-like domain
could inhibit angiogenesis by sequestering the Lewis Y antigen [95]. These studies
suggest that TM could be playing both pro- and anti-angiogenic roles and therefore
further studies are required to determine the role of TM in angiogenesis.
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1.9 Protein C
Protein C is plasma zymogen that is activated by thrombin-TM to form activated
protein C (APC) a serine protease involved in inhibiting coagulation [73]. Thrombin can
convert protein C into APC, however this conversion is very slow [73]. Binding of
thrombin to TM can increase the rate of activation of protein C by thrombin 1000-fold
[72]. The endothelial protein C receptor (EPCR), which binds protein C, can increase the
rate of activation of protein C by thrombin-TM another 20-fold [71]. EPCR aligns protein
C to the thrombin-TM [71]. Once formed, APC can decrease thrombin production by
inhibiting both the intrinsic and common coagulation pathways [66, 73]. APC along with
its cofactor protein S can degrade factors VIIIa and Va [66]. APC-mediated degradation
of FVIIIa also requires inactive factor V as a cofactor [66]. The result of decreasing
thrombin production by APC is decreased coagulation as well as enhanced fibrinolysis
(vide infra) [66]. APC has functions independent of the coagulation pathway including
cytoprotective and anti-inflammatory functions [66]. EPCR binds to both protein C and
APC with equal affinity [71]. APC bound to EPCR can activate protease-activated
receptor 1 (PAR-1) [73]. Activation of PAR-1 by APC can result in cytoprotective effects
including anti-apoptotic activities, protection of endothelial cell barrier, antiinflammatory activities and altered gene expression [96].
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1.9.1 Role of Protein C in Cancer
APC may play a role in cancer however there are conflicting reports on whether it
is playing an antimetastatic or prometastatic role. Studies have found that APC promotes
cancer cell invasion, migration, angiogenesis, DNA synthesis, and proliferation as well as
inhibits apoptosis and these effects were due to EPCR-bound APC activation of PAR-1
[97–100]. Conversely, one study found that APC limited cancer cell extravasation
through PAR-1 signaling [101]. Another study found that transgenic mice over
expressing EPCR reduced metastases in the liver and lung [102]. In contrast, another
study found overexpression of EPCR in lung adenocarcinoma cells was prometastatic and
silencing EPCR decreased metastasis [103]. Further studies are needed to determine
whether APC is playing a prometastatic or antimetastatic role in cancer.

1.10 Thrombin-Activatable Fibrinolysis Inhibitor

Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) is a plasma zymogen that
plays a role in attenuating fibrinolysis. TAFI was originally discovered by different
groups as carboxypeptidase U, R, and B. Initially, Hendriks et al. identified a basic
carboxypeptidase in human serum similar to but distinct from the stable basic
carboxypeptidase N (CPN) [104]. This carboxypeptidase showed unstable basic
carboxypeptidase activity at 37°C, it was therefore named ‘unstable’ carboxypeptidase
(CPU) [104]. Campbell and Okada found an unstable enzyme that exhibited
carboxypeptidase activity preferentially towards arginine over lysine residues that was
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generated during coagulation and named it carboxypeptidase R (CPR) [105]. Eaton and
colleagues found a pro-enzyme contaminant that bound to a plasminogen affinity column
when purifying α2-antiplasmin and named it plasma procarboxypeptidase B (pCPB)
because its activated form had similar activity to pancreatic carboxypeptidase B (CPB)
[106]. Wang et al. determined that pCPB and CPU were the same enzyme [107]. At the
same time, Bajzar and coworkers discovered TAFI when trying to solve the conundrum
that the anti-coagulant APC appeared to have profibrinolytic activity [108]. It was
determined that the profibrinolytic effect of APC was actually an indirect effect through
inhibition of thrombin generation by APC which lead to an attenuation of TAFI
activation [108, 109]. Bajzar and coworkers also determined that TAFI was the same
protein as pCPB [108]. TAFI, CPU, CPR, and CPU were all determined to be the same
protein [60, 107, 108].
Plasma TAFI is primarily produced in the liver, but there are extrahepatic sources
of TAFI including monocytes, endothelial cells, adipocytes, macrophages, and
megakaryocytes [110, 111]. Unpublished data from our laboratory indicate that TAFI is
also expressed in breast cancer cells.
The mature TAFI protein has a theoretical molecular mass of 45 kDa and consists
of 401 amino acids after the removal of a 22 amino acid signal peptide [60, 68].
However, TAFI is glycosylated and thus the apparent molecular mass of TAFI on SDSPAGE is 60 kDa [60]. The structure of TAFI consists of an activation peptide containing
92 residues and a catalytic domain containing 309 residues [112]. The activation peptide
contains four N-linked glycosylation sites at Asn22, Asn51, Asn63, and Asn86 that are
always glycosylated [112]. Within the catalytic domain there is a catalytic zinc ion
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coordinated by His159, Glu162, and His288 [112]. Cleavage at Arg92 removes the
activation peptide resulting in the activation of TAFI (TAFIa) [112]. After removal of the
activation peptide, TAFIa has a molecular mass of approximately 35 kDa [113, 114].
There is a dynamic flap with considerable mobility that resides within the catalytic
domain of TAFI from residues 296-350 [112]. When the activation peptide is present, the
dynamic flap (consisting of coil-helix-coil secondary structure) is stabilized by
hydrophobic interactions between Val35 and Leu39 in the activation peptide and Tyr 341
in the dynamic flap [112]. Once the activation peptide is removed the stabilizing
interactions are lost and the dynamic flap becomes mobile [112]. An irreversible
conformational change occurs over time as a consequence movement of the dynamic flap
which disrupts the catalytic site thus inactivating TAFI (TAFIai) [112]. During the
irreversible conformational change TAFIa activity is destroyed due to the displacement
of the critical residues Tyr341 and Asp348 [112]. Tyr341 is involved in stabilizing
interactions and Asp348 is responsible for substrate specificity of TAFI [112]. The
irreversible conformational change also exposes a cryptic thrombin cleavage site at
Arg302 in TAFIai [112].
TAFI can be activated by cleavage at Arg92 by thrombin, plasmin and, most
effectively, by thrombin in complex with TM [75, 106, 109]. Both thrombin and plasmin
are relatively weak activators of TAFI and need high concentrations in order to activate
TAFI. The thrombin-TM complex increases activation of TAFI 1250-fold over thrombin
alone [75]. The large thrombin generation that occurs during the intrinsic coagulation
pathway is sufficient to activate TAFI, even in the absence of TM [60].

36

Glycosaminoglycans, which can be found in the ECM exposed by vascular injury, can
increase the rate of plasmin-mediated TAFI activation by 20-fold [115].
TAFIa has no known physiological inhibitors, and therefore its intrinsic thermal
instability regulates its inactivation [104, 113]. At 37°C, TAFIa has a half-life of
approximately ten minutes [113]. Cleavage by thrombin at Arg302 occurs after
inactivation of TAFI, therefore thrombin cleavage is a consequence of TAFIa inactivation
and not a cause [60, 112]. Plasmin can cleave TAFI at Arg302, Lys327, and Arg330
[116]. Some of these plasmin cleavage sites are available when TAFI is in the zymogen
form, therefore plasmin could cleave the zymogen resulting in a decrease in TAFI
activation [60, 116]. APC indirectly inhibits TAFI activation by decreasing thrombin
generation [108]. Due to the catalytic zinc ion, TAFI is susceptible to inhibition by
chelating agents such as EDTA [68]. There are synthetic TAFIa inhibitors and naturally
occurring inhibitors that have been found to inhibit TAFIa [68]. As an example, potato
tuber carboxypeptidase inhibitor (PTCI) is a reversible inhibitor of TAFIa [76].
TAFIa plays a role in attenuating fibrinolysis after activation by the thrombin
generated through the intrinsic coagulation pathway [68]. Very low concentrations of
TAFIa are required to attenuate fibrinolysis; 1 nM (less than 2% of the total plasma
concentration of TAFI) was shown to be sufficient to half-maximally inhibit fibrinolysis
[75]. TAFIa removes carboxyl-terminal lysine and arginine residues from fibrin partially
degraded by plasmin cleavage [64], thereby interfering with several positive feedback
mechanisms in the fibrinolytic cascade (vide supra). Overall TAFIa attenuates
fibrinolysis which ensures consolidation of the fibrin clot [67].
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1.10.1 Role of TAFI in Inflammation
TAFIa also plays a role in inflammation by cleaving carboxyl-terminal lysine and
arginine residues from inflammatory mediators such as bradykinin (BK), C5a, C3a, and
thrombin-cleaved osteopontin (OPN) [77, 117]. BK is an important part of the
inflammatory response, as it leads to vascular permeability, vasodilation, as well as the
four classic signs of inflammation redness, heat, pain, and swelling [63, 77]. The
anaphylatoxins, C3a and C5a, are potent leukocyte chemoattractants [63, 77]. OPN plays
a role in cell-matrix interactions, adhesion, and inflammatory responses [77]. OPN is a
chemoattractant and it also stimulates cell motility and survival [77]. Thrombin cleavage
of OPN results in a carboxyl-terminal arginine residue (OPN-R) [118]. OPN-R appears to
increase migration, adhesion, and spreading of various cell types [119]. Thrombincleavage of OPN up-regulates the pro-inflammatory properties of OPN while cleavage of
OPN-R by TAFIa decreases these pro-inflammatory effects [77]. Experiments using
TAFI knockout mice revealed that neutrophil recruitment was enhanced and
unexpectedly the mice were protected from liver damage which could potentially be
attributed to increased C3a and C5a levels [120]. These results suggest that TAFIa is
playing a role in downregulating inflammation.

1.10.2 Role of TAFI in Wound Healing
TAFIa has been shown to play a role in two distinct types of wound healing:
cutaneous wounds and colonic anastomoses [121]. The plasminogen activation system
plays an important role in wound healing through regulation of ECM remodeling [35]. In
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plasminogen knockout mice wound healing is impaired [122] . A study done by te Velde
et al. showed that TAFI knockout mice had impaired secondary wound healing of
cutaneous wounds, and impaired healing of colonic anastomoses [121]. Primary wound
healing occurs in sutured wounds, secondary wound healing occurs in unsutured wounds
[121]. Secondary wound healing, as opposed to primary wound healing, involves
epithelial cell migration toward opposite edges of the wound to cover the wound [121].
The general wound healing process involves tissue exudate and clotted blood forming a
scab and the wound is then filled in by granulation tissue beneath the scab [121, 123].
Subsequently, fibroblasts arrive at the wound and begin to make ECM proteins and
angiogenesis occurs [121, 123]. Wound healing is completed through re-epithelialization
and formation of a collagen scar [121, 123]. During re-epithelialization, as well as
formation of granulation tissue, fibrin acts as a provisional matrix [121, 123]. The
collagen scar is formed through contraction of the wound after the degradation of the
provisional matrix [121]. Wound healing is impaired when the balance between
production and degradation of ECM is disrupted [121]. In cutaneous wound healing
migration of keratinocytes is important, whereas wound healing of colonic anastomoses
depends on angiogenesis and matrix remodeling [121]. Colonic anastomoses are a higher
risk wound, where impaired healing can lead to death [121]. During healing of colonic
anastomoses proteolytic degradation of the ECM and ECM remodeling must be
controlled [121]. The TAFI knockout mice had impaired re-epithelialization of
keratinocytes during secondary cutaneous wound healing. However, complete wound
healing of the TAFI knockout mice did occur, albeit significantly delayed [121].
Fibrinogen deficient mice showed similar secondary cutaneous wound healing to TAFI
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deficient mice, as both had impaired keratinocyte migration [121, 124]. This similarity
could indicate absence of TAFI could lead to increased removal of fibrin from the
provisional matrix leading to impaired wound healing [121, 123]. During healing of
colonic anastomoses, TAFI knockout mice had poorer postsurgical recovery [121]. TAFI
knockout mice had decreased anastomotic strength of the healed colon, as well as a
higher rate of postsurgical mortality, peritonitis, and bleeding complications [121]. In this
type of wound healing, absence of TAFI could lead to increased plasminogen activation
leading to increased angiogenesis and matrix remodeling [36, 121]. Healing of colonic
anastomoses requires matrix remodeling which involves pericellilar plasminogen
activation [35, 121]. Many plasminogen activation components and MMPs reside in the
leading edge of migrating cells in wound healing [41, 123]. Crucially, TAFIa has been
shown to inhibit plasminogen binding to cell surface receptors by removing carboxylterminal lysine residues [76, 125]. These experiments show that TAFI plays a role in
wound healing through fibrinolysis and potentially through inhibition of cell surface
plasminogen receptors [76, 121, 123].

1.10.3 Role of TAFI in Cancer
TAFI could also be playing a role in cancer. TAFIa has been shown to reduce
plasminogen binding to the surface of cells [76]. In hepatocytes, silencing of TAFI led to
increased plasmin activity on the cell surface and increased cell proliferation [126].
TAFIa has been shown to remove carboxyl-terminal lysine residues from cell surface
plasminogen receptors leading to inhibition of cell migration in TAFI deficient mice
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[125]. Reijerkerk et al. published a study stating that TAFIa does not affect tumour
growth and metastasis in TAFI deficient mice [127]. However, this study used B16
melanoma cells and Lewis lung carcinoma cells which do not support TAFI activation
[127]. Higuchi et al. found that activation of TAFI by TM in HT1080 fibrosarcoma cells
inhibited plasminogen activation and resulted in decreased cell invasion [128]. Atkinson
et al. found that inhibition of TAFIa leads to increased levels of ECM breakdown due to
decreased inhibition of plasminogen activation by TAFIa [129]. Guimarães et al. showed
that TAFIa can inhibit both endothelial tube formation in a 3D plasma clot matrix and
endothelial cell migration [130]. They suggested that the 3D plasma clot matrix served as
an in vitro model of wound healing angiogenesis since the plasma clot used for
endothelial tube formation mimics a thrombus [130]. This study showed that TAFIa
controlled wound healing angiogenesis through inhibition of plasminogen activation
[130]. Overall these results suggest that TAFI could be playing a role in cancer through
inhibition of pericellular plasminogen activation leading to metastasis, and TAFI could be
playing a role in tumour angiogenesis since it was shown to play a role in wound healing
angiogenesis.

1.11 Research Rationale

The antimetastatic role of TM is well established, however the mechanism of
these effects has not yet been determined. The study by Horowitz et al. showed that the
antimetastatic effects of TM were dependent on its ability to bind thrombin [91].
However this study did not determine which substrate of thrombin-TM, TAFI or protein
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C, was responsible for the antimetastatic effects of TM. With regards to the role of
protein C in cancer, there are conflicting reports of whether it is playing an antimetastatic
or a prometastatic role [97–103]. TAFIa has been shown to inhibit pericellular
plasminogen activation through cleavage of carboxyl-terminal lysine residues in vitro and
in vivo [76, 125, 126]. Pericellular plasminogen activation has been shown to be
upregulated in cancer and plays a role in metastasis and tumour angiogenesis through
degradation of ECM, release of growth factors from ECM, and regulation of MMP
activity [36]. Higuchi et al. found decreased invasion of HT1080 fibrosarcoma cells due
decreased plasminogen activation by TAFIa activated by TM [128]. The study published
by Reijerkerk et al. stated TAFIa did not affect metastasis and tumour growth in TAFI
deficient mice [127]. However, the cell lines used in that study do not support TAFI
activation, therefore this study does not clearly rule out a role for TAFI in cancer. TAFIa
has been implicated in reducing degradation of ECM, this result could be anti-metastatic
in a cancer cell microenvironment [129]. It has also been shown that TAFIa can inhibit
wound healing angiogenesis on a plasma clot [130]. Since TAFIa has been shown to
inhibit pericellular plasminogen activation and angiogenesis on a plasma clot, TAFIa
could be playing a role in inhibition of tumour angiogenesis. Due to the ability of TAFIa
to inhibit pericellular plasminogen activation it is hypothesized that TAFI, and not
protein C, is responsible for the antimetastatic effects of TM (Fig. 1.4).

42

Figure1.4 Hypothesized model of TAFIa inhibition of pericellular plasminogen
activation
TAFI is activated by thrombin (IIa) in complex with the transmembrane cofactor
thrombomodulin (TM). Activated TAFI (TAFIa) can cleave the carboxyl-terminal lysine
(K) residues from cell surface plasminogen receptors. Removal of the carboxyl-terminal
lysine residues from cell surface plasminogen receptors results in inhibition of
plasminogen (Plg) binding to the cell surface receptor, and consequently a decrease in
plasminogen activation. The decrease in pericellular plasminogen activation leads to a
decrease in plasmin (Pln) formation. Plasmin plays a role in many metastatic activities
including: extracellular matrix (ECM) degradation, release and activation of matrix
metalloproteinases (MMPs) from the ECM, and release and activation of growth factors
from the ECM. Cell invasion and migration occur as a result of plasmin activation due to
the breakdown of ECM surrounding the cell. Plasmin can lead to increased angiogenesis
due to increase in growth factors, ECM breakdown, and MMPs. TAFIa inhibits plasmin
formation therefore it is hypothesized that TAFIa can inhibit the pro-metastatic effects of
plasmin.
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1.12 Research Objectives

TAFIa plays a role in inhibiting pericellular plasminogen activation and therefore
is hypothesized to inhibit the prometastatic effects of plasmin specifically, for this thesis,
those on tumour angiogenesis. In breast cancer patients, low TM is strongly correlated
with poor prognosis and high relapse rate [89]. Unpublished data from our laboratory
shows that breast cancer cells express TAFI. Endothelial cells have also been shown to
express TAFI [110]. Unpublished data from our laboratory also shows that TAFIa
inhibits plasminogen activation in breast cancer cells. Therefore endothelial cells and
breast cancer cells will be used in the following objectives to determine the role TAFIa
plays in tumour angiogenesis. It is hypothesized that TAFIa will inhibit tumour
angiogenesis.
The specific objectives to show the role TAFIa plays in tumour angiogenesis are:
1. To inhibit TAFIa activity, with potato tuber carboxypeptidase inhibitor (PTCI), to
determine the role of TAFIa in endothelial cell invasion, proliferation, tube formation,
ECM proteolysis, MMP mRNA expression and secretion either in cultured endothelial
cells alone or in a co-culture system containing both endothelial cells and breast cancer
cells

2. To promote TAFI activation using mutant forms of soluble TM with differing substrate
activation capability to determine the role of TAFIa in endothelial tube formation and
ECM proteolysis either in cultured endothelial cells alone or in a co-culture system
containing both endothelial cells and breast cancer cells.
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Chapter 2 Materials and Methods
2.1 Cell Lines and Culture
SUM149 and MDA-MB-231 cell lines were a gift from Dr. Lisa Porter
(Department of Biological Sciences, University of Windsor, Windsor, ON, Canada), and
the HUVEC cell line was purchased from the American Type Culture Collection (ATCC)
(Manassas,VA, USA).

SUM149 cells were grown in Dulbecco’s Modified Eagles

Medium (DMEM) (Gibco, Mississauga, ON, Canada) supplemented with 10% fetal
bovine serum (FBS) (Gibco), 1% antibiotic/antimycotic (Gibco), 10 μg/mL insulin
(Sigma-Aldrich, Oakville, ON, Canada) and 0.5 μg/mL hydrocortisone (Sigma-Aldrich).
MDA-MB-231 cells were supplemented with DMEM (Gibco) completed with 10% FBS
(Gibco), 1% antibiotic/antimycotic (Gibco). HUVECs were supplemented with
Endothelial Cell Basal Medium-2 (EBM-2) (Lonza, Walkerville, MD, USA) completed
with 2% FBS (Lonza) and Endothelial Cell Growth Media-2 (EGM-2) SingleQuots Kit
(Lonza). HUVECs were used at passage five for all experiments. These cells were
maintained at 37°C and 5% CO2.

2.2 Cloning of rTM EGF3-6 and rTM EGF3-6 mutants
To clone rTM EGF3-6, first the desired mutations, V340A/D341A and F376A,
were made in TM within the puc19TM15 vector (ATCC) using the QuikChange II SiteDirected Mutagenesis Kit (Angilent Technologies, Santa Clara, CA, USA), as per the
manufacturer’s protocol. The primer sequences that were used for the V340A/D341A and
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F376A mutations are located in Table 2.1. The wild-type TM and mutated TM in
puc19TM15 were cut out using EcoRI and ligated to pcDNA4/myc-His A (Invitrogen),
which was linearized using EcoRI.
Next, wild-type, V340A/D341A, and F376A TM within pcDNA4/myc-His A
were used as template DNA in PCR, using Q5 high fidelity polymerase (New England
BioLabs, Whitby, ON, Canada), as per the manufacturer’s protocol. The primers in Table
2.2 were used to amplify the lectin-like domain and EGF-like repeats 1-6 (hereafter
called rTMD12) in wild-type, V340A/D341A, and F376A TM in pcDNA4/myc-His A.
Both the PCR amplicon and pcDNA4/myc-His A were digested with EcoRI and AgeI to
insert rTMD12 into pcDNA4/myc-His A.
The next step in the process of making rTM EGF3-6 involved removal of the
lectin-like domain and EGF1-2 without removal of the signal sequence. Using sitedirected mutagenesis EcoRV restriction sites were engineered. The EcoRV sites were
engineered downstream of the signal peptide and upstream of EGF3. Introduction of
these sites were done simultaneously using the QuikChange II Site-Directed Mutagenesis
Kit (Angilent Technologies) with wild-type rTMD12 in pcDNA4/myc-His A as the
template DNA. The primers used for the introduction of the EcoRV sites using sitedirected mutagenesis are located in Table 2.3. Once the sites were introduced, the
mutagenesis product was ligated back on itself through digestion with EcoRV which
formed rTM EGF3-6.
After rTM EGF3-6 was made, wild-type, V340A/D341A, and F376A rTMD12 in
pcDNA4/myc-His A were digested with KpnI, this was used as the insert. rTM EGF3-6
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was also digested with KpnI, this was used as the vector. The various mutations were
inserted into rTM EGF3-6 producing wild-type, V340A/D341A, and F376A rTM EGF361.
Table 2.1 Primer sequences used for site-directed mutagenesis to make
mutations in TM in puc19TM15
Primer name
V340A/D341A sense
V340A/D341A antisense
F376A sense
F376A anti-sense

Sequence (5’3’)
TAA CTA CGA CCT GGC GGC CGG CGA GTG TGT GG
CCA CAC ACT CGC CGG CCG CCA GGT CGT AGT TA
CTG CGC CGA GGG CGC CGC GCC CAT TCC C
GGG AAT GGG CGC GGC GCC CTC GGC GCA G

Table 2.2 Primer sequences used to amplify rTMD12
Primer name
5’ Primer (TM 5’
EcoRI)
3’ Primer
(EGF3-6 3’ AgeI)

Sequence (5’3’)
GAA TTC GGC AGC GCG CAG CGG CAA GAA
ACC GGT ACA GTC GGT GCC AAT GTG GCG

Table 2.3 Primer sequences for site-directed mutagenesis removal of lectinlike domain and EGF1-2 in rTMD12
Primer name
Signal Peptide EcoRV
sense
Signal Peptide EcoRV
anti-sense
EGF3 EcoRV sense
EGF3 EcoRV antisense

1

Sequence (5’3’)
CCC CGC ACC CGC AGA TAT CCA GCC GGG TGG CAG
C
GCT GCC ACC CGG CTG GAT ATC TGC GGG TGC GGG
G
CTG GCG GCC GAC GAA CAC CGG GAT ATC GAC GTG
GAT GAC TGC ATA CTG
CAG TAT GCA GTC ATC CAC GTC GAT ATC CCG GTG
TTG GTC GGC CGC CAG

Cloning of rTM EGF3-6 was completed by Zainab Bazzi under the supervision of Dr. Michael Boffa
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2.3 Protein Purification and Quantification
The rTM EGF3-6 mutants were transfected using polyethylenimine (SigmaAldrich) into HEK293 cells (ATCC), and stably expressing lines were selected for using
3 mg/mL zeocin (Life Technologies Inc.). The recombinant proteins were purified using
His-tag purification. Briefly, binding buffer (50mM NaH2PO4, 0.5M NaCl, 1mM β-ME,
5mM imidazole, 10% glycerol, pH 7.9) was passed over a nickel column, then the protein
harvest containing the same components as the binding buffer was passed over the
column, a wash was completed (binding buffer with 10mM imidazole), and then protein
was eluted (binding buffer with 400mM imidazole). The eluted protein was dialyzed in
storage buffer (20 mM HEPES, 150 mM NaCl, 10% glycerol, pH 7.9). The dialyzed
samples were concentrated with polyethylene glycol (PEG)-20 000 (Sigma), and dialyzed
in storage buffer. The purified proteins were checked for purity using a silver stain.
Protein concentrations were determined using a Pierce™ BCA Protein Assay Kit (Life
Technologies Inc.) according to the manufacturer’s instructions. rTM EGF3-6 mutants
were stored at -70°C in aliquots until use2.

2.4 TAFIa Activity Assay
An AAFR assay was used to determine the initial rate of TAFI activation with the
rTM EGF3-6 mutants. In a 96-well plate 10 nM of each rTM EGF3-6 mutant was added
in triplicate with and without 25 nM of thrombin (IIa) (Haematologic Technologies Inc.,

2

Production of stable cell lines and some purification of the rTM EGF3-6 proteins were completed by
Zainab Bazzi under the supervision of Dr. Michael Boffa.
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Essex Junction, VT, USA). Rabbit soluble TM was used as a control (Haematologic
Technologies Inc.). All the wells received 5 mM of CaCl2, and 200 nM of TAFI (His-tag
purified), and HBST (20 mM HEPES pH 7.4, 150 mM NaCl, 0.01% (v/v) Tween 20) was
added to each well to make each reaction up to a final volume of 50 μL. Following the
addition of IIa, TAFI was allowed to activate for ten minutes at room temperature. Then
0.24 mM N-(4-Methoxyphenylazoformyl)-Arg-OH · HCL (AAFR) (BaChem, Torrance,
CA, USA), and 200 nM D-phenylalanyl-prolyl-arginyl chloromethyl ketone (PPACK)
(Calbiochem, Darmstadt, Germany) diluted in HBST was added to each well for a final
volume of 100 μL. AAFR is a colorimetric substrate that absorbs strongly at 350 nm.
TAFIa, and other enzymes with carboxypeptidase B activity, can cleave the
anisylazoformyl moiety from AAFR [131]. The resulting products no longer absorb at
350 nm [131]. PPACK inhibits IIa, and therefore stops the reaction. Absorbance was read
at 350 nm for one hour using a SpectraMax Plus384 Absorbance Microplate Reader
(Molecular Devices, Sunnyvale, CA, USA).

2.5 Activated Protein C Activity Assay
An S-2366 assay was used to determine the initial rate of protein C activation in
the rTM EGF3-6 mutants. In a 96-well plate 10 nM of each rTM EGF3-6 mutant was
added in triplicate with and without 25 nM of IIa (Haematologic Technologies Inc.).
Rabbit soluble TM was used as a control (Haematologic Technologies Inc.). All the wells
received 5 mM of CaCl2, and 100 nM of protein C (Haematologic Technologies Inc), and
HBS with 0.1% BSA was added to each well to make each reaction up to a final volume
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of 50 μL. Following the addition of IIa, protein C was allowed to activate for 30 minutes
at

37°C.

Then

200

μM

of

L-Pyroglutamyl-L-prolyl-L-argininep-Nitroaniline

hydrochloride (S-2366) (Chromogenix, Orangeburg NY, USA), and 200 nM PPACK
(Calbiochem) diluted in HBS (20 mM HEPES pH 7.4, 150 mM NaCl) with 0.1% BSA
was added to each well for a final volume of 100 μL. S-2366 is a colorimetric substrate,
which initially does not absorb at 405 nm [132]. Upon cleavage by activated protein C
the products of cleaved S-2366 absorb at 405 nm [132]. Absorbance was read at 405 nm
for one hour using a SpectraMax Plus384 Absorbance Microplate Reader (Molecular
Devices).

2.6 Proliferation Assay
Cell proliferation was determined in HUVECs using the WST-1 assay (Roche
Diagnostics, Laval, QC, Canada). WST-1 is a stable tetrazolium salt that can be cleaved
to formazan due to the glycolytic production of NAD(P)H in viable cells [133]. This
assay measures metabolic activity of viable cells which can be used an index of
proliferation. HUVECs were seeded at 10 000 cells/well in a total volume of 100 µL in a
96-well plate in EBM-2 media (Lonza). Cells were treated in quadruplicate with either 50
ng/mL Vascular Endothelial Growth Factor (VEGF) (VEGF-A165, R&D systems,
Minneapolis, MN, USA), or 25 µg/mL potato tuber carboxypeptidase inhibitor (PTCI)
(Sigma-Aldrich). VEGF was used as a positive control, and PTCI is an inhibitor of
TAFIa. Twenty-four hours after treatment, 10 μL of WST-1 was added to each well and
incubated for 2 hours at 37°C. The cleavage of WST-1 to formazan by metabolically
50

active cells can be measured at 450 nm. Using a SpectraMax Plus384 Absorbance
Microplate Reader (Molecular Devices) absorbance values were measured at 450 nm.

2.7 Endothelial Cell Invasion Assay
Transwell invasion assays were used to assess the effect of inhibiting TAFIa on
endothelial cell invasion. BD Falcon™ Cell culture inserts 8 μm pore size PET tracketched membranes (BD Biosciences, Mississauga, ON, Canada) were coated with 150 μL
of 2 mg/mL Cultrex® Basement Membrane Extract without Phenol Red (Trevigen,
Gaithersburg, MD, USA) in an 24-well plate for one hour. Cultrex was diluted to 2
mg/mL from a stock solution with serum and supplement free EBM-2 media (Lonza).
Following the incubation the inserts were washed thrice with HEPES Buffered Saline
Solution (HBSS) (Lonza). In the bottom of each well in the 24-well plate 600 µL of
supplement free EBM-2 with 0.2% FBS with and 50 ng/mL VEGF or 25 µg/mL PTCI
was added. Coated inserts were placed in the wells and 50 000 HUVECs/well in 100 µL
of serum and supplement free EBM-2 media were added into the coated inserts. Cells
were allowed to invade into the Cultrex for 20 hours, after which non-invaded cells were
removed with a cotton swab, and the invaded cells were fixed in methanol. The invaded
cells were stained with 0.25% Crystal Violet (Sigma-Aldrich). The cells in five different
fields of view were counted under a 20× objective using an Olympus CKX415F2
Inverted Microscope (Olympus America, Center Valley, PA).
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2.8 Tube Formation Assay
2.8.1 HUVEC Tube Formation Assay
HUVECs were grown in T25 flasks to ~80% confluency, washed four times with
HBSS (Lonza), and were labelled with 5 µM Cell Tracker™ Orange CMTMR (Life
Technologies Inc.) in EBM-2 with 0.75% FBS for one hour at 37°C. The labelled cells
were then washed four times with HBSS (Lonza) and incubated in complete EBM-2 for
one hour at 37°C. Next, 50 µL of Cultrex (Trevigen) was used to coat a 35 mm glass
bottom culture dish (MatTek, Ashland, MA, USA), then the coated dish was incubated
for 10 minutes at 37°C to allow the Cultrex to solidify. After incubation with complete
media, 20 000 HUVECs in 50 µL of EBM-2 with 0.75% FBS were seeded on top of the
solidified Cultrex and were allowed to attach for 40 minutes at 37°C. Subsequently,
complete EBM-2 media with 2% Cultrex and treatment (50 ng/mL VEGF, 25 µg/mL
PTCI, 10 nM wild-type rTM EGF3-6, 10 nM rTM EGF3-6 V340A/D341A, and/or 10 nM
rTM EGF3-6 F376A) was added. The assay was incubated at 37°C for 18 hours to allow
formation of tube-like structures [134, 135]. The assay was imaged using an Olympus
IX81 confocal microscope (Olympus America, Center Valley PA, USA). Tube formation
in eight to ten different fields of view was imaged under a 10× objective. Relative tube
length was calculated using ImageJ software by determining total tube length and
dividing by total number of tubes and comparing the values to the control.
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2.8.2 Co-culture Tube Formation Assay
SUM149 or MDA-MB-231 cells were grown in T25 flasks to ~80% confluency,
washed four times with phosphate buffered saline (PBS), and were labelled with 5 µM
CellTrace Far Red DDAO-SE (Life Technologies Inc.) in serum free DMEM (Gibco) for
one hour at 37°C. The labelled cells were then washed four times with PBS, and
incubated in complete DMEM for one hour at 37°C. Next, Cultrex was used to coat a
35mm glass bottom culture dish as previously described in section 2.8.1. After incubation
with complete media, breast cancer cells [20 000 SUM149 cells or 7000 MDA-MB-231
cells in 50 µL serum free DMEM] were seeded on top of the solidified Cultrex, and were
allowed to attach for 40 minutes at 37°C. Then complete DMEM media with 2% Cultrex
was added. The assay was incubated at 37°C for 24 hours, after which the media was
aspirated off. Thereafter, 20 000 HUVECs prelabelled with Cell Tracker™ Orange
CMTMR (Life Technologies Inc.) were seeded on top of the embedded breast cancer
cells using the same procedure as described in 2.8.1. Again treatment included 50 ng/mL
VEGF, 25 µg/mL PTCI, 10 nM wild-type rTM EGF3-6, 10 nM rTM EGF3-6
V340A/D341A, and/or 10 nM rTM EGF3-6 F376A. The assay was incubated at 37°C for
18 hours, and was imaged and quantified as previously described in section 2.8.1.
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2.9 Proteolysis Assay
2.9.1 HUVEC Proteolysis Assay
Proteoysis of DQ-collagen IV by HUVECs was assessed as previously described
[136, 137]. The HUVEC proteolysis assay was set up the same way as the HUVEC tube
formation assay in section 2.8.1, except 50 µL of a solution containing 25 µg/ml DQcollagen IV (Life Technologies Inc.) mixed with Cultrex (Trevigen) was used to coat a
35 mm glass bottom culture dish (MatTek). Again treatment included 50 ng/mL VEGF,
25 µg/mL PTCI, 10 nM wild-type rTM EGF3-6, 10 nM rTM EGF3-6 V340A/D341A,
and/or 10 nM rTM EGF3-6 F376A. The assay was incubated at 37°C for 18 hours, and
was imaged using an Olympus IX81 confocal microscope (Olympus America). Three to
four z-stacks with fourteen 2.5 µm slices were imaged using a 20× objective with a zoom
of three. Amount of proteolysis was determined using ImageJ software by calculating
total fluorescence of the DQ-collagen type IV divided by HUVEC area.

2.9.2 Co-culture Proteolysis Assay
Proteolysis of DQ-collagen IV by co-cultured HUVECs and breast cancer cells
was assessed as previously described [138]. Cultrex mixed with 25 µg/ml DQ-collagen
IV was used to coat a 35 mm glass bottom culture dish as previously described in section
2.9.1. Next, breast cancer cells prelabelled with CellTrace Far Red DDAO-SE (Life
Technologies Inc.) were seeded on top of the DQ-Collagen type IV-Cultrex mixture
seeding the same cell number and using the same procedure as described for the co54

culture tube formation assay in section 2.8.2. Again treatment included 50 ng/mL VEGF,
25 µg/mL PTCI, 10 nM wild-type rTM EGF3-6, 10 nM rTM EGF3-6 V340A/D341A,
and/or 10 nM rTM EGF3-6 F376A. The assay was incubated at 37°C for 18 hours, and
was imaged as previously described in section 2.9.1. Areas to images were selected by
finding areas were HUVEC tubes were in contact with a breast cancer spheroid. Amount
of proteolysis was determined using ImageJ software by calculating total fluorescence of
the DQ-collagen type IV divided by combined HUVEC and breast cancer cell areas.

2.10 Preparation of HUVEC and SUM149 Conditioned Media
Samples
SUM149 cells were seeded into a 6-well plate at 250 000 cells/mL and were
either untreated, or treated with 50 ng/mL VEGF or 25 µg/mL PTCI. After 24 hours of
incubation with treatment, SUM149 cells were washed thrice with PBS and 1 mL of
serum free DMEM was added. HUVECs were seeded into a 6 well plate and were grown
to 60% confluency and were either untreated, or treated with 50 ng/mL VEGF or
25 µg/mL PTCI. After 24 hours of incubation with treatment, HUVECs were washed
thrice with HBSS (Lonza) and 1 mL of EBM-2 with 0.2% FBS media was added. Both
the treated SUM149 cells and HUVECs were serum starved for 24 hours. Then media
was collected and centrifuged for 5 minutes at room temperature at 700 g to pellet cells
[139]. The supernatant was collected and centrifuged for 10 minutes at 4°C at 2000 g to
remove cell debris [139]. Lysates from both cell types were collected by adding 100 µL
of lysis buffer [50 mM Tris-HCl (pH 7.4), 1% Nonidet P-40, 0.25% sodium
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deoxycholate, 150 mM NaCl, 1 mM EDTA], shaking on ice for 10 minutes, and
centrifuging for 10 minutes at 12000 g. Cell lysate concentration was determined using a
Pierce™ BCA Protein Assay Kit (Life Technologies Inc.) according to the
manufacturer’s instructions.

2.11 Treatment of HUVECs with SUM149 Conditioned Media
HUVECs were grown to 60% confluency in a 6-well plate were washed thrice
with HBSS (Lonza) and the supernatant from untreated, VEGF, or PTCI treated SUM149
cells as described in 2.10, was mixed 1:1 with complete EBM-2 media and added to the
HUVECs. Also, a non-treated HUVEC well was seeded as a control. After 24 hours of
incubation with SUM149 conditioned media (CM) the HUVECs were washed thrice with
HBSS and placed in EBM-2 media with 0.2% FBS. Twenty-four hours after incubation
in EBM-2 media with 0.2% FBS, the supernatant and lysate were collected, and lysate
concentration was determined as previously described in section 2.10.

2.12 Gelatin Zymography
MMP2 and MMP9 enzymatic activities in SUM149, HUVEC, and HUVEC
treated with SUM149-CM media samples were determined by SDS-PAGE gelatin
zymography as described by Mohamed et al. [139]. Samples were mixed with 2X SDS
sample buffer and were loaded equally (20 µg/lane SUM149 samples, 6 µg/lane HUVEC
samples) without heating or reducing, and electrophoresed in 10% SDS-PAGE
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containing 1% gelatin (w/v) at 125 V for 2.5 hours at 4°C. Human recombinant MMP2 (5
ng) and MMP9 (2.5 ng) (R&D Systems) were also loaded as positive controls. After
electrophoresis, gels were incubated twice in renaturing buffer (2.5% Triton X-100) for
15 minutes with gentle shaking at room temperature. Thereafter, gels were washed twice
with water for 15 minutes with gentle shaking at room temperature. Gels were then
placed in developing buffer (50 mM Tris-HCl pH 7.8, 5 mM CaCl2, 0.05% Brij 35) and
incubated with gentle shaking overnight at 37°C. Subsequently, gels were stained for one
hour in Coomassie brilliant blue R-250 (50% methanol, 10% acetic acid, 40% water,
0.5% Coomassie brilliant blue R-250), and destained (50% methanol, 10% acetic acid,
40% water) until clear bands of proteolytic activity appeared. Relative proteolytic activity
of the samples was determined by densitometry using FluoroChem® Q imaging system
software (Alpha Innotech Corporation, Santa Clara, CA, USA).

2.13 RNA Extraction
Total RNA was extracted from SUM149, HUVEC, and HUVECs treated with
SUM149-CM cells using RNeasy Mini Kit (Qiagen, Toronto, ON, Canada) as per
manufacturer’s protocol. RNA concentrations were measured using a NanoDrop 2000
UV-Vis Spectrophotometer (Thermo Scientific, Wilmington, DE, USA).
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2.14 Quantitative Real Time PCR
qRT-PCR was carried out using iTaq Universal SYBR Green One-Step Kit
(BioRad, Mississauga, ON, Canada) as per the manufacturer’s protocol on a BioRad
CFX96 Real-Time System to determine relative amounts of MMP2 and MMP9 mRNA in
VEGF or PTCI treated HUVECs, SUM149 cells, and HUVECs treated with SUM149CM. 300 ng of RNA was used in each qRT-PCR experiment. The primer sequences that
were used can be found in Table 2.4, primers were constructed as per Wang et al [140].
Thermocycling conditions used for all reactions were: 50°C for 10 minutes, 95°C for 1
minute, 40 cycles of 95°C for 12 seconds and 60°C for 30 seconds. Also, no reverse
transcriptase controls and a no template control were run as negative controls to ensure
there was no contamination of the RNA samples with genomic DNA, or contamination of
the reagents, respectively. Relative mRNA expression as compared to the control was
calculated using the 2-∆∆CT method [141].
Table 2.4 Primer sequences used for qRT-PCR

Primer Name

Sequence (5’3’)

MMP2 Forward

CAG GGA ATG AGT ACT GGG TCT ATT

MMP2 Reverse

ACTCCAGTTAAAGGCAGCATCTAC

MMP9 Forward

AATCTC TTCTAGAGACTGGGAAGGAG

MMP9 Reverse

AGCTGATTGACTAAA GTA GCT GGA

GAPDH Forward

AGA GAG AGG CCC TCA GTT GCT

GAPDH Reverse

TTG TGA GGG AGA TGC TCA GTG T
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2.15 Statistical Analysis
Results are expressed as a mean ± SEM from at least three independent
experiments. Statistical analysis was performed with IBM SPSS Statistics V22.0 software
using one-way ANOVA test with post-hoc Tukey HSD. p<0.05 was considered
significant.
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Chapter 3 Results
3.1 Inhibition of TAFIa increases endothelial cell proliferation
One of the main steps in angiogenesis involves proliferation of endothelial cells in
response to an angiogenic stimulus [8, 9]. To assess the role that TAFIa plays in
endothelial cell proliferation, potato tuber carboxypeptidase inhibitor (PTCI) was used to
inhibit TAFIa. PTCI is a small 39-residue protein purified from potatoes that binds tightly
to and inhibits both the carboxypeptidase A and B family of proteases [142, 143]. Even
though PTCI can inhibit other proteases, in this system only TAFIa is present. PTCI
specifically inhibits TAFIa, and has no effect on the TAFI zymogen [144]. PTCI
reversibly binds to TAFIa [68]. Human umbilical vein endothelial cells (HUVECs) were
treated with either PTCI or VEGF. After incubation with the treatment, proliferation was
quantified using the WST-1 assay. WST-1 is a tetrazolium salt that can be cleaved to
formazan through a bioreduction mechanism that is dependent on the glycolytic
production of NAD(P)H in viable cells [133]. The production of formazan can be
quantified, and is a measure of metabolically active cells which can be used as an index
of proliferation. VEGF was used as a positive control since it is the key mediator of
angiogenesis [21]. Inhibition of TAFIa by PTCI significantly increased endothelial cell
proliferation, 1.3-fold increase compared to control (Fig. 3.1). Inhibition of TAFIa using
PTCI resulted in same increase in cell proliferation compared to control as VEGF (Fig.
3.1). This result suggests that TAFIa inhibits endothelial cell proliferation, although
further experiments will need to be completed to confirm proliferation is being affected
such as flow cytometry.
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Figure 3.1 Inhibition of TAFIa increases proliferation of endothelial cells
Effect of inhibiting TAFIa with PTCI on HUVEC proliferation determined by WST-1
proliferation assay, measured by absorbance at 450 nm. HUVECs were treated for 24
hours with 50 ng/mL VEGF or 25 µg/mL PTCI. Significantly increased production of
formazan, therefore increased metabolically active cells, was observed by both VEGF
and PTCI treatment of HUVECs represented relative to the control. The amount of
metabolically active cells can be a measure of cell proliferation. Values are expressed as
mean ± SEM from 5-6 independent experiments performed in quadruplicate. ** p <0.01
versus control.
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3.2 Inhibition of TAFIa increases endothelial cell invasion

For angiogenesis to occur, endothelial cells must locally degrade the vascular
basement membrane and invade into the surrounding stroma [8, 9]. Transwell inserts
coated in Cultrex can mimic the basement membrane endothelial cells need to invade
through during angiogenesis. HUVECs were seeded in the top chamber of a Cultrex
coated transwell insert, and either VEGF or the TAFIa inhibitor PTCI were added to the
lower chamber. PTCI significantly increased invasion of HUVECs (Fig. 3.2B). PTCI
increased invasion of HUVECs 4.6-fold relative to the control, while the positive control
VEGF increased invasion of HUVECs 6-fold relative to the control (Fig. 3.2B). This
result suggests that TAFIa could decrease endothelial cell invasion.
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Figure 3.2 Inhibition of TAFIa increases endothelial cell invasion
Effect of inhibition of TAFIa with PTCI on endothelial cell invasion. (A) HUVECs were
added to a transwell chamber coated with Cultrex, either 50 ng/mL VEGF or 25 µg/mL
PTCI were added to the bottom chamber. Cells were allowed to invade for 20 hours after
which cells were fixed, stained and imaged. Images above were obtained at 4×
magnification. (B) Quantification of HUVEC invasion. Cells were counted from 5
different fields of view at 20× magnification, and cell numbers expressed relative to
control. Both VEGF and PTCI significantly increased invasion of HUVECs. Values are
expressed as mean ± SEM from four independent experiments. ** p <0.01 verses control.

63

3.3 Inhibition of TAFIa increases tube formation in endothelial
cells and in co-culture systems containing endothelial and breast
cancer cells
Another aspect of angiogenesis is the formation of tube-like structures [8].
Previous studies have shown that inhibition of TAFIa increases endothelial tube
formation in a 3D plasma clot matrix [130]. This result demonstrated a role for TAFI in
wound healing angiogenesis [130], however, the role of TAFI endothelial tube formation
in regards to tumour angiogenesis has yet to be studied. The role of TAFIa on
angiogenesis was assessed using a plasma clot which consisted of a fibrin matrix as the
ECM [130]. Studies have not been conducted determining a role for TAFIa on tube
formation on reconstituted basement membrane as the ECM. An endothelial tube
formation assay was used to determine the effect on tube formation when TAFIa was
inhibited. HUVECs were seeded on top of reconstituted basement membrane (Cultrex),
and were treated with either VEGF, as a positive control, or the TAFIa inhibitor PTCI.
HUVECs formed capillary tube-like structures on Cultrex (Fig. 3.3A). The formation of
tube-like structures on Cultrex represents a process of attachment, migration, and
differentiation of endothelial cells into tube-like structures in a manner that mimics the in
vivo process of tube formation [135, 145]. PTCI significantly increased relative tube
length (1.3-fold) compared to the control (Fig. 3.3B). PTCI increased relative tube length
similarly to VEGF (Fig. 3.3B).
The effect of inhibition of TAFIa on endothelial tube formation was also
completed with co-culture systems consisting of HUVECs and either SUM149 cells (Fig.
3.4A) or MDA-MB-231 cells (Fig. 3.5A), both of which are breast cancer cell lines. The
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breast cancer cells form spheroid structures on top of the Cultrex, while the endothelial
cells form tube-like structures. These co-culture systems function to mimic a tumour
microenvironment. The tumour cell microenvironment consists of cancer cells as well as
stromal cells, such as endothelial cells [49]. There is a dynamic interplay between cancer
cells and endothelial cells [49]. Both the endothelial cells [110] and the breast cancer
cells could be a source of TAFI (unpublished data from our laboratory).Therefore coculture systems containing endothelial cells and breast cancer cells were used to look the
effect of inhibition of TAFIa on endothelial tube formation by both endothelial and breast
cancer cells in the same environment. Interaction between HUVECs and breast cancer
cells can be seen in merge images combining differential interference contrast (DIC),
HUVEC fluorescence, and breast cancer cell fluorescence images (Fig. 3.4A & Fig.
3.5A). The co-culture systems were treated with either VEGF or PTCI. The co-culture
systems produced nearly identical results between the two breast cancer cell lines used.
PTCI significantly increased relative tube length compared to the control with a 1.4-fold
increase in both the SUM149 and HUVEC co-culture (Fig. 3.4B), and in the MDA-MB231 and HUVEC co-culture (Fig. 3.5B). PTCI treatment increased relative tube length
similar to treatment with VEGF in both co-culture systems (Fig. 3.4B & Fig. 3.5B).
Overall these results suggest that TAFIa could decrease endothelial tube
formation in both endothelial cells in isolation and in and co-culture systems containing
endothelial cells and breast cancer cells.
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Figure 3.3 Inhibition of TAFIa increases endothelial tube formation
Effect of inhibition of TAFIa with PTCI on tube formation of endothelial cells. (A)
HUVECs labelled with Cell Tracker Orange (red) were seeded on top of Cultrex in a 35
mm glass bottom culture dish and treated with either 50 ng/mL VEGF or 25 µg/mL
PTCI. Cells were imaged 18 hours after seeding HUVECs using confocal microscopy.
Images above were obtained at 40× magnification. Scale bar, 400 µm. (B) Quantification
of endothelial tube formation. To quantify tube formation 8-10 images were obtained at
100× magnification. Tube length was determined by measuring total tube length divided
by total tube number, and is expressed relative to that in the control untreated cells.
Treatment with either VEGF or PTCI significantly increased relative tube length of
HUVECs. Values are expressed as mean ± SEM from six independent experiments.
** p< 0.01 verses control.
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Figure 3.4 Inhibition of TAFIa increases endothelial tube formation in a coculture system containing HUVECs and SUM149 cells
Effect of inhibition of TAFIa with PTCI on tube formation of endothelial cells cocultured with SUM149 breast cancer cells. (A) SUM149 cells labelled with Cell Trace
Far Red (green) were seeded on top of Cultrex in a 35 mm glass bottom culture dish.
After 24 hours HUVECs labelled with Cell Tracker Orange (red) were seeded on top of
the SUM149 cells and Cultrex. The co-cultures were treated with either 50 ng/mL VEGF
or 25 µg/mL PTCI. Cells were imaged 18 hours after HUVECs were seeded using
confocal microscopy. Images above were obtained at 40× magnification. Scale bar, 500
µm. (B) Quantification of endothelial tube formation. To quantify tube formation 8-10
images were obtained at 100× magnification. Tube length was determined by measuring
total tube length divided by total tube number, and is expressed relative to that in the
control untreated cells. Treatment with either VEGF or PTCI significantly increased
relative tube length of HUVECs. Values are expressed as mean ± SEM from six
independent experiments. ** p< 0.01 verses control.
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Figure 3.5 Inhibition of TAFIa increases endothelial tube formation in a coculture system containing HUVECs and MDA-MB-231 cells
Effect of inhibition of TAFIa with PTCI on tube formation of endothelial cells cocultured with MDA-MB-231 breast cancer cells. (A) MDA-MB-231 cells labelled with
Cell Trace Far Red (green) were seeded on top of Cultrex in a 35 mm glass bottom
culture dish. After 24 hours HUVECs labelled with Cell Tracker Orange (red) were
seeded on top of the MDA-MB-231 cells and Cultrex. The co-cultures were treated with
either 50 ng/mL VEGF or 25 µg/mL PTCI. Cells were imaged 18 hours after HUVECs
were seeded using confocal microscopy. Images above were obtained at 40×
magnification. Scale bar, 500 µm. (B) Quantification of endothelial tube formation. To
quantify tube formation 8-10 images were obtained at 100× magnification. Tube length
was determined by measuring total tube length divided by total tube number, and is
expressed relative to that in the control untreated cells. Treatment with either VEGF or
PTCI significantly increased relative tube length of HUVECs. Values are expressed as
mean ± SEM from six independent experiments. ** p< 0.01 verses control.
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3.4 Inhibition of TAFIa increases proteolysis of DQ-collagen IV by
endothelial cells and by co-cultured endothelial and breast cancer
cells
Degradation of the ECM is an important aspect of angiogenesis. One of the initial
steps of angiogenesis involves degradation of vascular ECM and basement membrane [8,
9]. Pericellular plasminogen activation has been implicated in angiogenesis and
metastasis though regulation of MMP activity, release of growth factors from the ECM,
and degradation of the ECM [36]. VEGF has been shown to upregulate components of
the plasminogen activation system in the leading edge of migrating endothelial cells [10,
27, 45]. Moreover, tube formation has been shown to spatially correlate to ECM
proteolysis in vitro [146]. TAFIa has been shown to inhibit pericellular plasminogen
activation in vitro and in vivo [76, 125, 126]. Therefore, we wanted to determine the
effect of TAFIa on proteolysis of DQ-collagen IV, the most abundant type of collagen
found in the basement membrane [147], by endothelial cells. HUVECs were seeded on
top of Cultrex mixed with DQ-collagen IV, and were treated with either VEGF or PTCI
(Fig. 3.6A). Once DQ-collagen IV, an initially quenched fluorescent substrate, is cleaved
by proteases DQ-collagen IV degradation products are produced (green) (Fig. 3.6A).
Degradation products of DQ-collagen IV were localized predominantly intracellularly
(Fig. 3.6A), although treatment with VEGF did increase pericellular (outside the cell or
on the cell membrane [146]) localization of DQ-collagen IV degradation products (Fig.
3.6A). Treatment of HUVECs with PTCI significantly increased proteolysis of DQcollagen IV, 2-fold relative to the control (Fig. 3.6B).
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Within the tumour cell microenvironment, consisting of cancer cells and stromal
cells, there is a dynamic interplay between cancer cells and stromal cells, such as
endothelial cells [49]. Degradation of the ECM of endothelial cells can lead to metastasis
of tumour cells [19]. Therefore co-culture systems containing endothelial cells and breast
cancer cells were used to look the effect of inhibition of TAFIa on proteolysis of DQcollagen IV by both endothelial and breast cancer cells in the same environment.
HUVECs co-cultured with SUM149 cells (Fig. 3.7A) or MDA-MB-231 cells (Fig. 3.8A)
were treated with PTCI or VEGF. In both co-culture systems there was a mix of
intracellular and pericellular proteolysis (Fig. 3.7A & Fig. 3.8A). The co-culture system
containing HUVECs and MDA-MB-231 cells exhibited predominately pericellular
proteolysis (Fig. 3.8A).

In both co-culture systems treatment with VEGF or PTCI

increased both pericellular and intracellular proteolysis as compared to the control (Fig.
3.7A & Fig. 3.8A). PTCI significantly increased proteolysis of DQ-collagen IV in the coculture system containing both HUVECs and SUM149 cells, 1.6-fold compared to the
control (Fig. 3.7B). In the co-culture system containing HUVECs and MDA-MB-231
cells, PTCI also significantly increased proteolysis of DQ-collagen IV by the co-cultured
cells, 1.5-fold as compared to the control (Fig. 3.8B). In both co-culture systems,
treatment with PTCI increased proteolysis of DQ-collagen IV similarly to the positive
control VEGF (Fig. 3.7B & Fig. 3.8B).
Taken together these results suggest that TAFIa could be playing a role in
inhibiting ECM proteolysis in both endothelial cells, as well as in a tumour cell
microenvironment containing both endothelial and breast cancer cells.

72

73

Figure 3.6 Inhibition of TAFIa increases proteolysis of DQ-collagen IV by
endothelial cells
Effect of inhibition of TAFIa with PTCI on proteolysis of DQ-collagen IV by endothelial
cells. (A) HUVECs labelled with Cell Tracker Orange (red) were seeded on top of
Cultrex mixed with DQ-collagen IV in a 35 mm glass bottom culture dish and treated
with either 50 ng/mL VEGF or 25 µg/mL PTCI. Cells were imaged 18 hours after
seeding HUVECs using confocal microscopy. DQ-collagen IV cleavage products (green)
were present predominantly intracellularly. Merge images show intracellular (yellow) and
pericellular proteolysis (green). Images were obtained at 600× magnification.
Representative images from the equatorial plane of a Z-stack are shown. Scale bar, 30
µm. (B) Quantification of proteolysis of DQ-collagen IV. To quantify proteolysis three
equatorial planes from 3-4 different images from one experiment were quantified. Total
integrated intensity of DQ-collagen IV florescence divided by total HUVEC area was
calculated and expressed relative to the control. Treatment with either VEGF or PTCI
significantly increased proteolysis of DQ-collagen IV by HUVECs. Values are expressed
as mean ± SEM from 3-5 independent experiments. ** p< 0.01 verses control.
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Figure 3.7 Inhibition of TAFIa increases DQ-collagen IV proteolysis by cocultured HUVECs and SUM149 cells
Effect of inhibition of TAFIa with PTCI on DQ-collagen proteolysis by co-cultured
HUVEC and SUM149 cells. (A) SUM149 cells labelled with Cell Trace Far Red (blue)
were seeded on top of Cultrex mixed with DQ-collagen IV in a 35 mm glass bottom
culture dish. After 24 hours HUVECs labelled with Cell Tracker Orange (red) were
seeded on top of the SUM149 cells and Cultrex mixed with DQ-collagen IV. The cocultures were treated with either 50 ng/mL VEGF or 25 µg/mL PTCI. Cells were imaged
18 hours after HUVECs were seeded using confocal microscopy. DQ-collagen IV
cleavage products (green) were present both intracellularly and pericellularly. Merged
images show pericellular proteolysis (green) surrounding the co-cultured cells. Images
were obtained at 600× magnification. Representative images from the equatorial plane of
a Z-stack are shown. Scale bar, 30 µm. (B) Quantification of proteolysis of DQ-collagen
IV. To quantify proteolysis three equatorial planes from 3-4 different images from one
experiment were quantified. Total integrated intensity of DQ-collagen IV florescence
divided by total combined cell area of HUVECs and SUM149 cells was calculated and
expressed relative to the control. Treatment with either VEGF or PTCI significantly
increased proteolysis of DQ-collagen IV. Values are expressed as mean ± SEM from 5-6
independent experiments. ** p< 0.01 verses control.
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Figure 3.8 Inhibition of TAFIa increases DQ-collagen IV proteolysis by cocultured HUVECs and MDA-MB-231 cells
Effect of inhibition of TAFIa with PTCI on DQ-collagen proteolysis by co-cultured
HUVEC and MDA-MB-231 cells. (A) MDA-MB-231 cells labelled with Cell Trace Far
Red (blue) were seeded on top of Cultrex mixed with DQ-collagen IV in a 35 mm glass
bottom culture dish. After 24 hours HUVECs labelled with Cell Tracker Orange (red)
were seeded on top of the MDA-MB-231 cells and Cultrex mixed with DQ-collagen IV.
The co-cultures were treated with either 50 ng/mL VEGF or 25 µg/mL PTCI. Cells were
imaged 18 hours after HUVECs were seeded using confocal microscopy. DQ-collagen IV
cleavage products (green) were present predominately pericellularly. Merge images show
pericellular proteolysis (green) surrounding the co-cultured cells. Images were obtained
at 600× magnification. Representative images from the equatorial plane of a Z-stack are
shown. Scale bar, 30 µm. (B) Quantification of proteolysis DQ-collagen IV. To quantify
proteolysis three equatorial planes from 3-4 different images from one experiment were
quantified. Total integrated intensity of DQ-collagen IV florescence divided by total
combined cell area of HUVECs and MDA-MB-231 cells was calculated and expressed
relative to the control. Treatment with either VEGF or PTCI significantly increased
proteolysis of DQ-collagen IV. Values are expressed as mean ± SEM from six
independent experiments. ** p< 0.01 verses control.
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3.5 Effect of inhibition of TAFIa on MMP2 and MMP9 mRNA
expression and secretion
Since inhibition of TAFIa was shown to increase proteolysis of DQ-collagen IV
by endothelial cells and by endothelial cells co-cultured with breast cancer cells, we next
wanted to look at whether inhibition of TAFIa increased mRNA expression and secretion
of MMPs involved in ECM proteolysis. Pericellular plasminogen activation is involved in
ECM remodelling, as well as the release and activation of MMPs from the ECM [36].
MMP2 and MMP9 have been shown to be implicated in tumour angiogenesis [54].
MMP2 and MMP9 are gelatinases, but also degrade other ECM proteins such as collagen
type IV [53]. VEGF has been shown to be in a positive feedback loop with MMP9 in
RPE cells [29], therefore it was used as a positive control in these experiments. Gelatin
zymography was used to determine the effect of inhibition of TAFIa on secretion of
MMP2 and MMP9. Using gelatin zymography gelatinolytic activity of latent and active
MMP2 and MMP9 can be visualized [148]. Samples are run using gel electrophoresis
under denaturing and non-reducing conditions [148]. Active and latent MMP2 and
MMP9 can be separated based on their molecular mass [148]. Gels are then renatured
which causes activation of latent forms of these MMPs in the gel [148]. Both latent
MMP2 and MMP9 can then proteolytically degrade gelatin in the gel [148]. After
coomassie blue staining and destaining, clear zones where the staining has disappeared
represent areas of proteolytic activity [148]. Quantitative RT-PCR was used to determine
the effect of TAFIa inhibition on mRNA expression of MMP2 and MMP9.
PTCI or VEGF were used to treat SUM149 breast cancer cells. Bands from the
SUM149 media samples migrated identically to recombinant pro-MMP2 and pro-MMP9
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controls, which suggests that they are likely pro-MMP9 and pro-MMP2 (Fig. 3.9A). It
was determined that PTCI significantly increased secretion of both pro-MMP2 (1.7-fold)
and pro-MMP9 (2.6-fold) compared to the control (Fig. 3.9A). Preliminary qRT-PCR
results suggest that PTCI does not affect the mRNA expression of either MMP2 or
MMP9 (Fig. 3.9B).
PTCI or VEGF were used to treat HUVEC cells. Bands from the HUVEC media
samples migrated identically to recombinant pro-MMP2 which was loaded as a control
(Fig. 3.10A). This suggests that the gelatinolytic activity was likely due to pro-MMP2. It
was determined that PTCI does not significantly affect the secretion of pro-MMP2 (Fig.
3.10A). We could not detect secretion of MMP9 (Fig. 3.10A). Preliminary qRT-PCR
results suggest that PTCI increases the mRNA expression of both MMP2 (1.8-fold) and
MMP9 (2.3-fold) compared to control (Fig. 3.10B).
Conditioned media (CM) from PTCI or VEGF treated SUM149 cells was used to
treat HUVECs. Bands from the HUVEC media samples migrated identically to
recombinant pro-MMP2 which was loaded as a control (Fig. 3.11A). This suggests that
the gelatinolytic activity was likely due to pro-MMP2. Treatment of HUVECs with CM
from untreated SUM149 cells resulted in a 1.2-fold increase in pro-MMP2 secretion
compared to the untreated HUVEC control, although this was not significant (Fig.
3.11A). Treatment of HUVECs with CM from PTCI treated SUM149 cells significantly
increased the secretion of pro-MMP2, 1.6-fold relative to the untreated HUVEC control
(Fig. 3.11A). Preliminary qRT-PCR results show that treatment of HUVECs with CM
from untreated SUM149 cells decreased MMP2 mRNA expression 2-fold and did not
affect MMP9 mRNA expression compared to the untreated HUVEC control (Fig. 3.11B).
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PTCI increased mRNA expression of MMP2 (4.8-fold) and MMP9 (1.5-fold) compared
to the untreated HUVEC control (Fig. 3.11B).
Taken together these results suggest that inhibition of TAFIa in SUM149 breast
cancer cells can increase the secretion of pro-MMP2 and pro-MMP9, and inhibition of
TAFIa in SUM149 cells can increase the secretion of pro-MMP2 and increase the
expression of MMP2 and MMP9 mRNA in HUVECs. The results therefore indicate that
TAFIa has an opposite effect to the pro-angiogenic VEGF. These results also suggest that
TAFIa is playing a different role in MMP2 and MMP9 secretion and expression in
different cell types.
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Figure 3.9 Inhibition of TAFIa in SUM149 cells increases secretion of proMMP2 and pro-MMP9, but does not affect mRNA expression of MMP2.
(A) Representative zymogram depicting gelatinolytic activity of pro-MMP9 (92 kDa),
pro-MMP2 (72 kDa) secreted by SUM149 breast cancer cells treated with either 25
µg/mL PTCI or 50 ng/mL VEGF for 24 hours. Lanes 1 and 2 are control lanes for
recombinant MMP2 (pro-MMP2 72 kDa, active MMP2 62 kDa) and pro-MMP9 (92
kDa), respectively. Lane 3 represents the control untreated SUM149 cells. Lanes 4 and 5
represent PTCI and VEGF treated SUM149 cells, respectively. Bands of gelatinolytic
activity from SUM149 media samples migrate similarly to the recombinant MMP
controls suggesting that the samples contain pro-MMP9 and pro-MMP2. Densitometry
was performed and reported as relative intensity as compared to the control. Both PTCI
and VEGF treatment significantly increased secretion of pro-MMP2 and pro-MMP9 in
SUM149 cells. Data represent results of 3-6 independent experiments and are presented
as mean ± SEM. * p<0.05, ** p<0.01 verses control. (B) MMP2 and MMP9 mRNA
levels in PTCI and VEGF treated SUM149 cells using qRT-PCR. GAPDH was used as
an internal control. Data represented as relative mRNA expression as compared to the
control from one independent experiment. PTCI treatment of SUM149 cells did not affect
mRNA expression of MMP2 or MMP9, while VEGF treatment increased mRNA
expression of both MMP2 and MMP9.
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Figure 3.10 Inhibition of TAFIa in HUVECs does not affect secretion of proMMP2, but increases mRNA expression of MMP2 and MMP9.
(A) Representative zymogram depicting gelatinolytic activity of pro-MMP2 (72 kDa)
secreted by HUVECs treated with either either 25 µg/mL PTCI or 50 ng/mL VEGF for
24 hours. Lanes 1 and 2 are control lanes for recombinant MMP2 (pro-MMP2 72 kDa,
active MMP2 62 kDa) and pro-MMP9 (92 kDa), respectively. Lane 3 represents the
control untreated HUVECs. Lanes 4 and 5 represent PTCI and VEGF treated HUVECs,
respectively. Bands of gelatinolytic activity from HUVEC media samples migrate
similarly to the recombinant pro-MMP2 control suggesting that the samples contain proMMP2. Densitometry was performed and reported as relative intensity as compared to
the control. Neither PTCI nor VEGF treatment significantly affected secretion of proMMP2 in HUVECs. Data represent results of eight independent experiments and are
presented as mean ± SEM. (B) MMP2 and MMP9 mRNA levels in PTCI and VEGF
treated HUVECs using qRT-PCR. GAPDH was used as an internal control. Data
represented as relative mRNA expression as compared to the control from one
independent experiment. Both PTCI and VEGF treatment increased mRNA expression of
MMP2 and MMP9.
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Figure 3.11 Treatment of HUVECs with conditioned media from SUM149 cells
treated with TAFIa inhibitor increases secretion of pro-MMP2 and mRNA
expression of MMP2 and MMP9.
(A) Representative zymogram depicting gelatinolytic activity of pro-MMP2 (72 kDa)
secreted by HUVECs treated with conditioned media (CM) from either 25 µg/mL PTCI
or 50 ng/mL VEGF treated SUM149 cells. Lanes 1 and 2 are control lanes for
recombinant MMP2 (pro-MMP2 72 kDa, active MMP2 62 kDa) and pro-MMP9 (92
kDa), respectively. Lane 3 represents the untreated control of untreated HUVECs. Lane 4
represents the control of HUVECs treated with untreated SUM149 CM. Lanes 5 and 6
represent HUVECs treated with CM from PTCI and VEGF treated SUM149 cells,
respectively. Bands of gelatinolytic activity from HUVEC media samples migrate
similarly to the recombinant pro-MMP2 control suggesting that the samples contain proMMP2. Densitometry was performed and reported as relative intensity as compared to
the untreated control. CM treatment of HUVECs from PTCI and VEGF treated SUM149
cells significantly increased secretion of pro-MMP2. Data represent results of 4-5
independent experiments and are presented as mean ± SEM. * p<0.05, ** p<0.01 verses
control. (B) MMP2 and MMP9 mRNA levels in HUVECs treated with CM from PTCI
and VEGF treated SUM149 cells using qRT-PCR. GAPDH was used as an internal
control. Data represented as relative mRNA expression as compared to the untreated
control from one independent experiment. Treatment of HUVECs with CM from PTCI
and VEGF treated SUM149 cells increased mRNA expression of MMP2. Treatment of
HUVECs with CM from PTCI treated SUM149 cells increased the mRNA expression of
MMP9.
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3.6 Characterization of thrombin-dependent substrate activation
of rTM EGF3-6 mutants

Different versions of recombinant thrombomodulin (rTM) consisting of the EGFlike domains 3-6 (rTM EGF3-6) were characterized for cofactor ability of thrombindependent activation of TAFI or protein C. Specifically, wild-type rTM EGF3-6, rTM
EGF3-6 V340A/D341A, and rTM EGF3-6 F376A were characterized. Wang et al.
characterized the V340A, D341A, and F376A mutations in rTM containing EGF-like
repeats 1-6 [82]. The both V340A and D341A were shown to drastically decrease TAFI
activation, while only marginally decreasing protein C activation [82]. The F376A
mutation was found to severely reduce protein C activation, while maintaining TAFI
activation [82]. The cofactor ability of rTM containing EGF-like repeats 3-6 has been
determined to have full protein C activation capability (107%) and 82% TAFI activation
capability compared to rTM containing the lectin-like domain, EGF-like repeats 1-6, and
the serine/threonine rich domain [82, 149]. These mutations in rTM containing only
EGF3-6 have yet to be characterized, but are hypothesized to maintain the substrate
activation capabilities as determined by Wang and colleagues [82].
Using the colorimetric substrate, AAFR, initial rate of TAFI activation was
quantified using the rTM EGF3-6 mutants and thrombin (Fig. 3.12A). rTM EGF3-6
V340A/D401A supported a significantly decreased initial rate of TAFI activation in the
presence of thrombin. rTM EGF3-6 F376A had a similar initial rate of TAFI activation
compared to wild-type rTM EGF3-6 in the presence of thrombin (Fig. 3.12A).
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Using the colorimetricc substrate, S-2366, initial rate of protein C activation was
quantified using the rTM EGF3-6 mutants and thrombin (Fig. 3.12B). rTM EGF3-6
V340A/D401A had a similar initial rate of protein C activation in the presence of
thrombin. rTM EGF3-6 F376A had a significantly decreased rate of protein C activation
compared to wild-type rTM EGF3-6 in the presence of thrombin (Fig. 3.12B).
The results indicate that the rTM EGF3-6 mutants have expected cofactor
abilities. rTM EGF3-6 D340A/V341A has significantly decreased TAFI activation but
retains protein C activation capability in comparison to wild-type rTM EGF3-6. rTM
EGF3-6 F376A has significantly decreased protein C activation but retains TAFI
activation in comparison to wild-type rTM EGF3-6.
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Figure 3.12 Characterization of cofactor ability of rTM EGF3-6 mutants
The cofactor ability of rTM EGF3-6 (wild-type), rTM EGF3-6 V340A/D3401A, and
rTM EGF3-6 F376A for thrombin-dependent activation of TAFI or protein C was
determined. (A) Thrombin-dependent activation of TAFI by measuring initial rate of
AAFR hydrolysis of rTM EGF3-6 mutants using 10 nM of the rTM EGF3-6 mutants and
25 nM of thrombin (IIa). TAFI was allowed to be activated by the rTM EGF3-6 mutants
and IIa for 10 minutes at room temperature before IIa was inhibited by PPACK. rTM
EGF3-6 V340A/D341A has significantly decreased TAFI activation compared to wildtype rTM EGF3-6 in the presence of IIa. Values are expressed as mean ± SEM from 3-5
independent experiments. ** p< 0.01 verses rTM EGF3-6. (B) Thrombin-dependent
activation of protein C by measuring initial rate of S-2366 hydrolysis of rTM EGF3-6
mutants using 10 nM of the rTM EGF3-6 mutants and 25 nM of IIa. Protein C was
allowed to be activated by the rTM EGF3-6 mutants and IIa for 30 minutes at 37°C
before IIa was inhibited by PPACK. rTM EGF3-6 F376A has significantly decreased
protein C activation compared to wild-type rTM EGF3-6 in the presence of IIa. Values
are expressed as mean ± SEM from three independent experiments. ** p< 0.01 verses
rTM EGF3-6.
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3.7 Effect of treatment with rTM EGF3-6 mutants on tube formation
in endothelial cells and in co-culture systems containing
endothelial and breast cancer cells
The role that TM plays in angiogenesis is not yet firmly established. Some studies
have suggested that rTM containing the EGF-like repeats and the serine/threonine-rich
domain is angiogenic [93]. Other studies have found through the lectin-like domain TM
is anti-angiogenic [95]. TM has been shown to be antimetastatic and this was found to be
dependent on the ability of thrombin to bind to TM [91]. Since inhibition of TAFIa
resulted in increased tube formation (Fig. 3.3-3.5), we decided to test the effect on
endothelial tube formation that the rTM EGF3-6 mutations would have. The
V340A/D341A mutant of rTM EGF3-6 was shown to allow thrombin dependent
activation of protein C but not TAFI, and the F376A mutant of rTM EGF3-6 was shown
to allow thrombin-dependent activation of TAFI but not protein C (Fig. 3.12). We
therefore hypothesized addition of wild-type rTM EGF3-6 would decrease endothelial
cell tube formation (i.e., have the opposite effect of inhibiting TAFIa), and that this effect
would be retained by the F376A mutant but not the V340A/D341A mutant.
Tube formation assays using HUVECs on Cultrex were used, and were treated
with either rTM EGF3-6 (wild-type), rTM EGF3-6 V340A/D41A, or rTM EGF3-6
F376A (Fig. 3.13A). Treatment with wild-type rTM EGF3-6 did not significantly affect
relative tube length (Fig. 3.13B). Treatment with rTM EGF3-6 V340A/D341A
significantly increased relative endothelial tube length compared to the control and
compared to wild-type, 1.4-fold and 1.5-fold respectively (Fig. 3.13B). Treatment with
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rTM EGF3-6 F376A significantly decreased relative endothelial tube length by 1.2-fold
compared to the control and compared to wild-type (Fig. 3.13B).
The effect on endothelial tube formation in co-culture systems consisting of breast
cancer cells using the rTM EGF3-6 mutants was also assessed. The cultures consisting of
either HUVECs and SUM149 cells (Fig. 3.14A) or HUVECs and MDA-MB-231 cells
(Fig. 3.15A) were treated with either rTM EGF3-6 (wild-type), rTM EGF3-6
V340A/D41A, or rTM EGF3-6 F376A. Both co-culture systems produced nearly
identical results compared to each other. Treatment with wild-type rTM EGF3-6 did not
affect relative endothelial tube length in either co-culture system (Fig. 3.14B & Fig.
3.15B). Treatment with rTM EGF3-6 V340A/D341A significantly increased relative
endothelial tube length compared to control and compared to wild-type by 1.3-fold in
both co-culture systems (Fig. 3.14B & Fig. 3.15B). Treatment with rTM EGF3-6 F376A
significantly decreased relative endothelial tube length compared to control by 1.2-fold in
both co-culture systems (Fig. 3.14B & Fig. 3.15B). Treatment with rTM EGF3-6 F376A
significantly decreased relative endothelial tube length compared to wild-type rTM
EGF3-6 by 1.2-fold in co-cultured HUVECs and SUM149 cells (Fig. 3.14B).
Overall, treatment with rTM EGF3-6 had no effect on endothelial tube formation,
treatment with rTM EGF3-6 rTM EGF3-6 V340A/D341A increased endothelial tube
formation, and treatment rTM EGF3-6 F376A decreased endothelial tube formation. The
results on endothelial tube formation with wild-type rTM EGF3-6 are not consistent with
our hypothesized outcome, but do suggest an anti-angiogenic role for TAFI and a proangiogenic role for protein C.
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Figure 3.13 Effect of differing cofactor ability of rTM EGF3-6 on endothelial
tube formation
(A) HUVECs labelled with Cell Tracker Orange (red) were seeded on top of Cultrex and
treated with 10 nM of either rTM EGF3-6, rTM EGF3-6 V340A/D341A, or rTM EGF3-6
F376A. Cells were imaged 18 hours after HUVECs were seeded using confocal
microscopy. Images above were obtained at 40× magnification. Scale bar, 500 µm. (B)
Quantification of endothelial tube formation. To quantify tube formation 8-10 images
were obtained at 100× magnification. Tube length was determined by measuring total
tube length divided by total tube number, and is expressed relative to that in the control
untreated cells. Values are expressed as mean ± SEM from 6-10 independent
experiments. Asterisks: **p< 0.01 verses control, daggers: †† p< 0.01 verses rTM
EGF3-6. Treatment with rTM EGF3-6 V340A/D341A significantly increased relative
tube length of HUVECs compared to control and to rTM EGF3-6. Treatment with rTM
EGF3-6 F376A significantly decreased relative tube length of HUVECs compared to
control and to rTM EGF3-6.
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Figure 3.14 Effect of differing cofactor ability of rTM EGF3-6 on endothelial
tube formation in a co-culture system with HUVECs and SUM149 cells
(A) SUM149 cells labelled with Cell Trace Far Red (green) were seeded on top of
Cultrex, after 24 hours HUVECs labelled with Cell Tracker Orange (red) were seeded on
top of the SUM149 cells and Cultrex. The co-cultures were treated with 10 nM of either
rTM EGF3-6, rTM EGF3-6 V340A/D341A, or rTM EGF3-6 F376A. Cells were imaged
18 hours after HUVECs were seeded using confocal microscopy. Images above were
obtained at 40× magnification. Scale bar, 500 µm. (B) Quantification of endothelial tube
formation. To quantify tube formation 8-10 images were obtained at 100× magnification.
Tube length was determined by measuring total tube length divided by total tube number,
and is expressed relative to that in the control untreated cells. Values are expressed as
mean ± SEM from 5-8 independent experiments. Asterisks: **p< 0.01 verses control,
daggers: †† p< 0.01 verses rTM EGF3-6. Treatment with rTM EGF3-6 V340A/D341A
significantly increased relative tube length of HUVECs compared to control and to rTM
EGF3-6. Treatment with rTM EGF3-6 F376A significantly decreased relative tube length
of HUVECs compared to control and to rTM EGF3-6.

95

96

Figure 3.15 Effect of differing cofactor ability of rTM EGF3-6 on endothelial
tube formation in a co-culture system with HUVECs and MDA-MB-231 cells
(A) MDA-MB-231 cells labelled with Cell Trace Far Red (green) were seeded on top of
Cultrex, after 24 hours HUVECs labelled with Cell Tracker Orange (red) were seeded on
top of the MDA-MB-231 cells and Cultrex. The co-cultures were treated with 10 nM of
either rTM EGF3-6, rTM EGF3-6 V340A/D341A, or rTM EGF3-6 F376A. Cells were
imaged 18 hours after HUVECs were seeded using confocal microscopy. Images above
were obtained at 40× magnification. Scale bar, 500 µm. (B) Quantification of
endothelial tube formation. To quantify tube formation 8-10 images were obtained at
100× magnification. Tube length was determined by measuring total tube length divided
by total tube number, and is expressed relative to that in the control untreated cells.
Values are expressed as mean ± SEM from 5-6 independent experiments. Asterisks:
* p<0.05, ** p< 0.01 verses control, daggers: †† p< 0.01 verses rTM EGF3-6. Treatment
with rTM EGF3-6 V340A/D341A significantly increased relative tube length of
HUVECs compared to control and to rTM EGF3-6. Treatment with rTM EGF3-6 F376A
significantly decreased relative tube length of HUVECs compared to control.
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3.8 Effect of treatment with rTM EGF3-6 mutants on proteolysis of
DQ-collagen IV by endothelial cells and by co-culture systems
containing endothelial and breast cancer cells

We next tested the effect that the rTM EGF3-6 mutants had on proteolysis of DQcollagen IV by endothelial cells and by endothelial cells in co-culture with breast cancer
cells. We hypothesized that treatment with rTM EGF3-6 V340A/D341A would increase
proteolysis of DQ-collagen IV, while treatment with rTM EGF3-6 F376A would decrease
proteolysis of DQ-collagen IV. We hypothesized this due to the results obtained in
endothelial tube formation assays using treatment with the rTM EGF3-6 mutants which
suggested an anti-angiogenic role for TAFI and a pro-angiogenic role for protein C.
HUVECs were seeded on top of Cultrex mixed with DQ-collagen IV and were
treated with either rTM EGF3-6 (wild-type), rTM EGF3-6 V340A/D41A, or rTM EGF36 F376A (Fig. 3.16A). Degradation products of DQ-collagen IV were localized
predominantly intracellularly when HUVECs were treated with the rTM EGF3-6 mutants
(Fig. 3.16A). Treatment of HUVECs with wild-type rTM EGF3-6 or rTM EGF3-6
F376A significantly decreased proteolysis of DQ-collagen IV, 1.2-fold and 1.4-fold
relative to the control, respectively (Fig. 3.16B). Treatment of HUVECs with rTM
EGF3-6 V340A/D341A significantly increased proteolysis of DQ-collagen IV, 1.9-fold
relative to the control (Fig. 3.16B). Treatment of HUVECs with rTM EGF3-6
V340A/D341A also significantly increased proteolysis of DQ-collagen IV compared to
wild-type by 2.3-fold (Fig. 3.16B).
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Co-culture systems containing endothelial cells and breast cancer cells were used
to look the effect of the rTM EGF3-6 mutants on proteolysis of DQ-collagen by both
endothelial and breast cancer cells in the same environment. HUVECs co-cultured with
SUM149 cells (Fig. 3.17A) or MDA-MB-231 cells (Fig. 3.18A) were treated with either
rTM EGF3-6, rTM EGF3-6 V340A/D41A, or rTM EGF3-6 F376A. In both co-culture
systems there was a mix of intracellular and pericellular proteolysis (Fig. 3.17A & Fig.
3.18A). The co-culture system containing HUVECs and SUM149 cells exhibited
predominately pericellular proteolysis (Fig. 3.17A). Treatment with rTM EGF3-6
V340A/D341A increased intracellular proteolysis of DQ-collagen IV in the co-culture
system containing HUVECs and MDA-MB-231 cells (Fig. 3.18A). Treatment with wildtype rTM EGF3-6 did not significantly affect proteolysis of DQ-collagen IV in either coculture system (Fig. 3.17B & Fig. 3.18B). Treatment with rTM EGF3-6 F376A decreased
proteolysis of DQ-collagen IV by 1.2-fold in the both co-culture systems compared to the
control, although this was not considered significant (Fig. 3.17B & Fig. 3.18B).
Treatment with rTM EGF3-6 F376A decreased proteolysis of DQ-collagen IV
significantly compared to wild-type by 1.4-fold in the co-culture system containing
HUVECs and SUM149 cells (Fig. 3.17B). Treatment with rTM EGF3-6 V340A/D341A
significantly increased proteolysis of DQ-collagen IV in the both co-culture systems (1.4fold in the HUVEC and SUM149 co-culture, and 1.6-fold in the HUVEC and MDA-MB231 co-culture) compared to control and compared to wild-type (1.3-fold in the HUVEC
and SUM149 co-culture, and 1.6-fold in the HUVEC and MDA-MB-231 co-culture)
(Fig. 3.17B & Fig. 3.18B).
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Overall, treatment with wild-type rTM EGF3-6 decreased proteolysis of DQcollagen IV by HUVECs alone, but did not have an effect on proteolysis of DQ-collagen
IV in either co-culture system. Treatment with rTM EGF3-6 V340A/D341A increased
proteolysis of DQ-collagen IV by HUVECs alone and by both co-culture systems.
Treatment with rTM EGF3-6 F376A decreased proteolysis of DQ-collagen IV by
HUVECs alone and by both co-culture systems. The results we obtained for the
proteolysis of DQ-collagen IV in all systems (HUVEC monoculture and both co-culture
systems) treated with the rTM EGF3-6 mutants are consistent with what we’d expect
given the effect on endothelial tube formation we saw using the rTM EGF3-6 mutants.
The effect of the rTM EGF3-6 mutants in both the endothelial tube formation assays and
the DQ-collagen IV proteolysis assays are similar. These results suggest that TAFI
activation plays an anti-angiogenic role in ECM proteolysis
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Figure 3.16 Effect of differing cofactor ability of rTM EGF3-6 on proteolysis of
DQ-collagen IV by endothelial cells
(A) HUVECs labelled with Cell Tracker Orange (red) were seeded on top of Cultrex
mixed with DQ-collagen IV in a 35 mm glass bottom culture dish and treated with 10 nM
of either rTM EGF3-6, rTM EGF3-6 V340A/D341A, or rTM EGF3-6 F376A. Cells were
imaged 18 hours after seeding HUVECs using confocal microscopy. DQ-collagen IV
cleavage products (green) were present predominantly intracellularly. Merge images
show intracellular (yellow) and pericellular proteolysis (green). Images were obtained at
600× magnification. Representative images from the equatorial plane of a Z-stack are
shown. Scale bar, 30 µm. (B) Quantification of proteolysis of DQ-collagen IV. To
quantify proteolysis three equatorial planes from 3-4 different images from one
experiment were quantified. Total integrated intensity of DQ-collagen IV florescence
divided by total HUVEC area was calculated and expressed relative to the control. Values
are expressed as mean ± SEM from five independent experiments. Asterisks: **p< 0.01
verses control, daggers: †† p< 0.01 verses rTM EGF3-6. Treatment with both rTM
EGF3-6 and rTM EGF3-6 F376A significantly decreased relative proteolysis of DQcollagen IV by HUVECs compared to control. Treatment with rTM EGF3-6
V340A/D341A significantly increased relative proteolysis of DQ-collagen IV by
HUVECs compared to control and to rTM EGF3-6.
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Figure 3.17 Effect of differing cofactor ability of rTM EGF3-6 on proteolysis of
DQ-collagen IV by co-cultured HUVECs and SUM149 cells
(A) SUM149 cells labelled with Cell Trace Far Red (blue) were seeded on top of Cultrex
mixed with DQ-collagen IV in a 35 mm glass bottom culture dish. After 24 hours
HUVECs labelled with Cell Tracker Orange (red) were seeded on top of the SUM149
cells and Cultrex mixed with DQ-collagen IV. The co-cultures were treated with 10 nM
of either rTM EGF3-6, rTM EGF3-6 V340A/D341A, or rTM EGF3-6 F376A. Cells were
imaged 18 hours after HUVECs were seeded using confocal microscopy. DQ-collagen IV
cleavage products (green) were present predominately pericellularly. Merge images show
pericellular proteolysis (green) surrounding the co-cultured cells. Images were obtained
at 600× magnification. Representative images from the equatorial plane of a Z-stack are
shown. Scale bar, 30 µm. (B) Quantification of proteolysis of DQ-collagen IV. To
quantify proteolysis three equatorial planes from 3-4 different images from one
experiment were quantified. Total integrated intensity of DQ-collagen IV florescence
divided by total combined cell area of HUVECs and SUM149 cells was calculated and
expressed relative to the control. Values are expressed as mean ± SEM from 3-7
independent experiments. Asterisks: **p< 0.01 verses control, daggers: †† p< 0.01 verses
rTM EGF3-6. Treatment with rTM EGF3-6 V340A/D341A significantly increased
relative proteolysis of DQ-collagen IV by co-cultured HUVECs and SUM149 cells
compared to control and to rTM EGF3-6.Treatment with rTM EGF3-6 F376A
significantly decreased relative proteolysis of DQ-collagen IV by co-cultured HUVECs
and SUM149 cells compared to rTM EGF3-6.
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Figure 3.18 Effect of differing cofactor ability of rTM EGF3-6 on proteolysis of
DQ-collagen IV by co-cultured HUVECs and MDA-MB-231 cells
(A) MDA-MB-231 cells labelled with Cell Trace Far Red (blue) were seeded on top of
Cultrex mixed with DQ-collagen IV in a 35 mm glass bottom culture dish. After 24 hours
HUVECs labelled with Cell Tracker Orange (red) were seeded on top of the MDA-MB231 cells and Cultrex mixed with DQ-collagen IV. The co-cultures were treated with 10
nM of either rTM EGF3-6, rTM EGF3-6 V340A/D341A, or rTM EGF3-6 F376A. Cells
were imaged 18 hours after HUVECs were seeded using confocal microscopy. DQcollagen IV cleavage products (green) were present both intracellularly and
pericellularly. Merge images show pericellular proteolysis (green) surrounding the cocultured cells. Images were obtained at 600× magnification. Representative images from
the equatorial plane of a Z-stack are shown. Scale bar, 30 µm. (B) Quantification of
proteolysis of DQ-collagen IV. To quantify proteolysis three equatorial planes from 3-4
different images from one experiment were quantified. Total integrated intensity of DQcollagen IV florescence divided by total combined cell area of HUVECs and MDA-MB231 cells was calculated and expressed relative to the control. Values are expressed as
mean ± SEM from 3-4 independent experiments. Asterisks: **p< 0.01 verses control,
daggers: †† p< 0.01 verses rTM EGF3-6. Treatment with rTM EGF3-6 V340A/D341A
significantly increased relative proteolysis of DQ-collagen IV by co-cultured HUVECs
and MDA-MB-231 cells compared to control and to rTM EGF3-6.
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Chapter 4 Discussion and Conclusions
Thrombomodulin (TM) known mostly for its role in the regulation of vascular
hemostasis, has also been shown to play an antimetastatic role in cancer. TM expression
has been shown to be inversely correlated to tumour prognosis and malignancy [86, 87].
TM has been shown to decrease invasion, proliferation, and metastasis [79, 87, 90]. A
study conducted by Horowitz et al. determined the antimetastatic effects of TM were
dependent on its ability to bind thrombin [91]. However, this study did not determine
which substrate of thrombin-TM, TAFI or protein C, was responsible for these effects.
Moreover, TAFI has been shown to inhibit pericellular plasminogen activation through
cleavage of carboxyl-terminal lysine residues in vitro and in vivo [76, 125, 126].
Pericellular plasminogen activation has been implicated in metastasis and tumour
angiogenesis through degradation of ECM, regulation of MMP activity, and release of
growth factors from ECM [36]. Higuchi et al. found TAFIa inhibited plasminogen
activation in HT1080 cells resulting in decreased invasion [128]. We therefore
hypothesized that due to the role that TAFI plays in the regulation of pericellular
plasminogen activation it was the substrate of thrombin-TM responsible for the
antimetastatic effects of TM.
Tumour angiogenesis is a hallmark of cancer: without it tumours could not grow
beyond 1-2mm3 [2, 6, 14]. Moreover, highly angiogenic tumours have greater metastatic
potential, and metastasis is responsible for 90% of cancer deaths [2]. A previous study
showed TAFIa inhibits wound healing angiogenesis on a plasma clot [130]. Another
study suggested absence of TAFI inhibited healing of colonic anastomoses through

107

overactivation of angiogenesis and plasmin [121]. These results suggest that TAFIa plays
a role in inhibition of wound healing angiogenesis and potentially tumour angiogenesis.
Plasminogen activation plays a role in tumour angiogenesis through degradation of
vascular ECM and basement membrane allowing endothelial cells to invade and
proliferate into surrounding stroma [36]. There are conflicting reports on the role of TM
in angiogenesis. Some studies suggest that it is anti-angiogenic through the lectin-like
domain, while others suggest that it is angiogenic through the EGF-like domain [93–95].
We decided to determine the role TAFIa plays in tumour angiogenesis through
inhibition of TAFIa, and through manipulation of cofactor ability of TM. In breast cancer
patients low TM is strongly correlated with poor prognosis and high relapse rate [89].
Unpublished data from our laboratory have shown that breast cancer cells, including
SUM149 and MDA-MB-231 cells, express both TM and TAFI. Unpublished data from
our laboratory also shows that TAFIa inhibits pericellular plasminogen activation in these
breast cancer cell lines. We therefore used SUM149 and MDA-MB-231 breast cancer
cells in these experiments because they provided an appropriate cellular model to
evaluate tumour angiogenesis. We found that TAFIa plays a role in inhibition of tumour
angiogenesis, and further clarified a role for TM in angiogenesis.
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4.1 Inhibition of TAFIa increases tumour angiogenesis

Through inhibition of TAFIa with PTCI there was an increase in crucial
components of angiogenesis; namely endothelial cell proliferation, invasion, tube
formation, and ECM proteolysis. Endothelial tube formation and ECM proteolysis were
also increased when TAFIa was inhibited in co-culture systems consisting of endothelial
cells and breast cancer cells. These results suggest that TAFIa plays a role in inhibition of
tumour angiogenesis.

4.1.1 Inhibition of TAFIa increases endothelial tube formation as a
function of decreased inhibition of pericellular plasminogen activation
TAFIa has been implicated as an anti-angiogenic factor in the context of wound
healing angiogenesis [130]. Guimarães et al. showed TAFIa decreased tube formation on
a 3D-plasma clot matrix [130]. This study determined that TAFIa decreased tube
formation through inhibition of plasminogen activation on a fibrin matrix [130]. To date,
no study has examined the role that TAFIa plays in endothelial tube formation in the
context of tumour angiogenesis, where plasminogen activation is pericellular, supported
by cell-surface plasminogen receptors, rather than occurring on a fibrin matrix.
Endothelial cells grown on reconstituted basement membrane form tube-like
structures in vitro that mimic angiogenesis, in which tube formation can be quantified
[134, 135]. Using this system we looked at the effect that inhibition of TAFIa had on tube
formation. Inhibition of TAFIa significantly increased tube formation expressed as the
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relative length of the endothelial cell tubes (Fig 3.3). In order to make this system
relevant in the context of tumour angiogenesis, we also examined the effect of inhibition
of TAFIa on endothelial tube formation using two different co-culture systems using
endothelial and breast cancer cells. The endothelial tube networks formed around the
cancer spheroids on the reconstituted basement membrane. Inhibition of TAFIa
significantly increased endothelial tube formation in both co-culture systems (Fig. 3.4 &
Fig. 3.5). There was no difference in the relative tube length increase due to PTCI
treatment between the HUVEC monocultures and either co-culture system. There was,
however, an apparent increase in proliferation of the endothelial cells in the MDA-MB231 and HUVEC co-culture system (Fig. 3.5) compared to the HUVEC monoculture
(Fig. 3.3), and the SUM149 and HUVEC co-culture system (Fig. 3.4). This could be due
to the fact that MDA-MB-231 cells are a more malignant cell line than HUVECs (a
noncancerous cell line) and SUM149 cells, which could lead to an increased production
of factors that increase proliferation [150].
Previous studies have shown that uPA bound to uPAR can enhance endothelial
cell organization into tubes [151]. Since uPA/uPAR can activate plasminogen [41], and
TAFIa can inhibit pericellular plasminogen activation [76, 125, 126], this could be the
mechanism of tube formation seen in our study. These results suggest that TAFIa
decreases formation of tumour angiogenesis, potentially through inhibition of pericellular
plasminogen activation.
There are some limitations to the tube formation assay used. The formation of
tube-like structures could in part be a function of increased cell proliferation or increased
cell adhesion, although this limitation could be argued to be a part of the differentiation
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process that leads to the formation of tube-like structures on Cultrex [145]. Cultrex also
contains many growth stimulating factors which leads to a gross stimulation of
endothelial cells [145]. This results in large amounts of tube-like structures in the control,
which causes increases in tube formation from pro-angiogenic factors to be less apparent
[145]. Although Cultrex has been shown to direct endothelial cell differentiation, it is
questionable whether the tube-like structures formed contain a lumen [145]. Therefore,
the tube-like structures formed may not closely resemble blood vessels [145]. There is a
lack of homogeneity in the tube-like structures formed which is another limitation of this
assay [145]. Therefore, other morphological studies will have to be completed to further
support these results, such as aortic ring assays. Angiogenic vessels grow from an aortic
ring; the microvascular outgrowth can be quantified [145]. These assays have their own
sets of limitations, such as variability of the aortic rings which can influence the
outgrowth of microvessels [145].

4.1.2 Inhibition of TAFIa increases ECM proteolysis as a function of
decreased inhibition of pericellular plasminogen activation
In order for endothelial tube formation to occur the vascular basement membrane
must be locally degraded by proteolytic enzymes [152]. Proteolysis of the ECM also
plays an important role in invasion and metastasis of tumour cells [153]. Using a 3D
live-cell proteolysis assay, we examined the effect of TAFIa inhibition on degradation of
DQ-collagen IV, a quenched fluorescent derivative of type IV collagen [136]. This assay
allows for the imaging and quantification of pericellular and intracellular proteolysis
[153]. We examined proteolysis of DQ-collagen IV by endothelial cells, and by two co111

culture systems containing endothelial cells (HUVECs) and breast cancer cells (SUM149
or MDA-MB-231 cells). The co-culture systems act to recapitulate a tumour
microenvironment [154].
Inhibition of TAFIa increased total proteolysis of DQ-collagen IV in all three
systems tested (Fig. 3.6-3.8). The HUVECs alone exhibited predominantly intracellular
proteolysis. The co-culture consisting of HUVECs and SUM149 cells exhibited both
pericellular and intracellular proteolysis (Fig. 3.7). The co-culture system consisting of
HUVECs and MDA-MB-231 cells predominantly exhibited pericellular proteolysis (Fig.
3.8). Different proteases and pathways are involved in pericellular proteolysis as
compared to intracellular proteolysis [136, 153]. The proteases involved in pericellular
proteolysis are MMPs, serine proteases (including components of the plasminogen
activation system), and cysteine proteases [136, 153]. Intracellular proteolysis involves
endocytosis of DQ-collagen IV by the live cells, and degradation of the substrate in the
lysosome [153, 155, 156]. Intracellular proteolysis can also occur after partial
degradation of DQ-collagen IV with pericellular proteases, after which endocytosis and
further degradation in the lysosome can occur [157]. In this manner the same proteolytic
enzymes can be involved in pericellular and intracellular proteolysis [157]. Within the
lysosome cysteine proteases degrade the DQ-collagen IV [136, 153]. Treatment of the
HUVEC monoculture with PTCI increased intracellular proteolysis as compared to the
control (Fig. 3.6), whereas treatment with PTCI increased pericellular proteolysis as
compared to the control in both the co-culture systems (Fig. 3.7 & Fig. 3.8). This result
suggests that inhibition of TAFIa in the breast cancer cells plays a larger role in
pericellular proteolysis than inhibition of TAFIa in the endothelial cells. Alternatively,
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these results could suggest that there is more pericellular proteolysis in a real tumour
microenvironment since the co-cultures mimic a tumour microenvironment.
Inhibition of TAFIa could lead to increased pericellular proteolysis, and
potentially intracellular proteolysis, through decreased inhibition of pericellular
plasminogen activation. This is the potential mechanism because pericellular proteolysis
can be caused by degradation of the ECM by components of the plasminogen activation
system [136, 153], and plasmin can liberate and activate MMPs from the ECM [38].
Treatment of HUVECs alone with PTCI (Fig. 3.6) increased proteolysis of DQcollagen IV more than treatment of either co-culture system with PTCI (Fig. 3.7 & Fig.
3.8). This could be due to the fact that the cancer cell lines are more malignant and
invasive then the non-cancerous HUVECs, which causes them to have inherently more
proteolytic activity. Therefore, the effect of PTCI on proteolysis of DQ-collagen IV by
the co-culture systems appears less than in the HUVEC monoculture. Unpublished data
from our laboratory have shown that there is more TAFI and TM expression in HUVECs
than either breast cancer cell line. This could suggest that there is more TAFI activation
in HUVECs compared to either breast cancer cell line. Therefore, the effect of inhibiting
TAFIa is greater in HUVECs alone than in either co-culture system. There was no
difference in relative tube length between the HUVEC monoculture and either co-culture
system (Fig. 3.3-3.5) in contrast to what is seen with the proteolysis of DQ-collagen IV in
the HUVEC monoculture compared to the co-culture systems (Fig. 3.6-3.8). This could
suggest that TAFIa plays a larger role in proteolysis than in tube formation.
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4.1.3 Differing effects of TAFIa inhibition on secretion and mRNA
expression of MMP2 and MMP9
MMP2 and MMP9 have been implicated in angiogenesis through degradation of
the ECM [53]. MMPs are also upregulated in many cancers, and have been shown to
increase invasion and metastasis by degrading the ECM [49, 50]. MMPs have been
implicated in pericellular proteolysis, and potentially in intracellular proteolysis through
partial degradation of ECM components before endocytosis and lysosomal degradation
[136, 153, 157]. Due to the significant increase in proteolysis of DQ-collagen IV by
endothelial cells and endothelial cells co-cultured with breast cancer cells when treated
with PTCI, we wanted to see the effect of TAFIa inhibition on secretion of pro-MMP2
and pro-MMP9, and mRNA expression of MMP2 and MMP9. We also wanted to
determine the effect on mRNA expression and secretion of these MMPs on breast cancer
cells alone, endothelial cells alone, and endothelial cells treated with CM from treated
breast cancer cells. These systems were used to determine if the effects on MMP
secretion and expression were cell specific, and to determine if soluble factors from
PTCI-treated breast cancer cells can influence secretion and expression of MMPs in
endothelial cells. Previous studies have shown that tumour-stromal cell interactions can
lead to expression of MMPs [139, 158]. Once pro-MMP2 or pro-MMP9 have been made
they are stored in the cytosol and are secreted by vesicles [159, 160]. Using gelatin
zymography, bands from SUM149 or HUVEC media were assumed to be pro-MMP2 and
pro-MMP9 because they migrated identically to recombinant pro-MMP2 and pro-MMP9
that were loaded as controls (Fig. 3.9-3.11). Results were also assumed to reflect a
change in secretion of pro-MMP2 and pro-MMP9 from the cells in response to PTCI or
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VEGF. Transcriptional regulation of MMP2 and MMP9 is complex and is not completely
understood, but many cytokines, oncogenes, and growth factors have been shown to
increase mRNA expression of these MMPs [161].
When SUM149 cells were treated with PTCI there was a significant increase in
the secretion of pro-MMP2 and pro-MMP9, but there was no effect on mRNA expression
of MMP2 or MMP9 (Fig. 3.9). When HUVECs were treated with PTCI there was no
effect on pro-MMP2 secretion (no pro-MMP9 secretion was detected in these cells), but
there was increased mRNA expression of both MMP2 and MMP9 (Fig. 3.10). These
results suggest that inhibition of TAFIa increases secretion and mRNA expression of
MMPs in a cell specific manner.
In order to see the effect that the tumour microenvironment has on MMP2 and
MMP9 secretion and mRNA expression in endothelial cells, CM from treated SUM149
cells was used to treat HUVECs. Treatment of HUVECs with CM from untreated
SUM149 cells resulted in a slight increase in secretion of pro-MMP2 (Fig. 3.11A).
HUVECs treated with CM from PTCI treated SUM149 cells had significantly increased
secretion of pro-MMP2 and increased mRNA expression of MMP2 and MMP9 (Fig.
3.11). These results show dynamic interplay between components of the tumour cell
microenvironment. The secreted soluble factors produced from SUM149 cells treated
with PTCI resulted in significantly increased secretion of pro-MMP2 by HUVECs, which
was not seen in HUVECs treated with PTCI. These results suggest inhibition of TAFIa in
SUM149 cells can alter soluble factors that can exert a paracrine effect on HUVECs.
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Both PTCI treated SUM149 cells, and HUVECs treated with CM from PTCI
treated SUM149 cells resulted in increased secretion of pro-MMPs, likely due to some
mechanism of stored vesicle release [159, 160]. Both PTCI treated SUM149 cells, and
HUVECs treated with CM from PTCI treated SUM149 cells resulted in increased mRNA
expression of MMP2 and MMP9. The specific mechanism of how these treatments
influenced MMP2 and MMP9 mRNA expression remain to be investigated. Many
inflammatory mediators increase the mRNA expression of MMP2 and MMP9, such as
IL-6, IL-1β, TNFα, and TNFβ [161, 162]. Interestingly, the anaphylatoxins, C3a and C5a,
induce IL-6 and IL-1β expression [163–165]. TAFIa has been shown to inactivate C3a
and C5a [117].Therefore inhibition of TAFIa could increase C3a and C5a leading to
increased IL-6 and IL-1β, and therefore increased mRNA expression of MMP2 and
MMP9. In this manner a function of TAFIa separate from pericellular plasminogen
activation could play a role in the antimetastatic effect of TAFI.
These results taken together suggest inhibition of TAFIa results in differing
secretion and mRNA expression of MMP2 and MMP9 dependent on cell type, and
TAFIa inhibited SUM149 cells secrete soluble factors that can exert a paracrine effect on
HUVECs.
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4.2 Manipulation of TM cofactor activity suggests TAFIa plays a
role in inhibition of tumour angiogenesis

TM has been shown to be antimetastatic and these effects are attributable to
thrombin binding [91]. We hypothesized that TAFI was the substrate of thrombin-TM
responsible for these effects due to its role in the inhibition of pericellular plasminogen
activation [76, 125, 126, 128]. Using different mutations of recombinant TM (rTM)
containing EGF-like repeats 3-6, responsible for substrate binding and activation, we
looked at the effect of TAFI activation on tube formation and ECM proteolysis. We
hypothesized that wild-type rTM EGF3-6 would decrease tube formation and ECM
proteolysis, since this would result in an increase in TAFIa generation. While the role of
TM in angiogenesis has not been firmly established, previous reports have shown that the
EGF-like domain of TM may be pro-angiogenic [93]. The rTM EGF3-6 V340A/D341A
mutant, on the other hand, would have no effect on these parameters because it is unable
to support TAFIa activation (Fig. 3.12). We also used rTM EGF3-6 F376A, which with
thrombin can activate TAFI but not protein C (Fig. 3.12). We hypothesized that this
mutant would show the same effects as wild-type rTM EGF3-6, as this variant retains the
ability to support TAFIa activation. The results, however, confounded our expectations.
Treatment with wild-type rTM EGF3-6 consistently had no effect on endothelial
tube formation in any system (Fig. 3.13-3.15). In regards to tube formation, rTM
containing all six EGF-like repeats (D2) and the serine/threonine domain (D3) (rTMD23)
has been previously shown to significantly increase endothelial tube formation of
HUVECs [93, 94]. Previous reports have also shown rTMD2 was less angiogenic than
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rTMD23, suggesting the serine/threonine domain has angiogenic activity [93]. The
variant of rTM we used in our experiments did not contain the serine/threonine domain,
and only contained some of the EGF-like repeats. One possible conclusion from our work
is therefore that EGF1-2 harbour pro-angiogenic activity. Treatment with wild-type rTM
EGF3-6 significantly decreased proteolysis of DQ-collagen IV by endothelial cells alone
compared to control (Fig. 3.16), but did not have a significant effect on proteolysis of
DQ-collagen IV by either of the co-culture systems used compared to control (Fig. 3.17
& Fig. 3.18). This result could suggest that HUVECs, a normal human endothelial cell
line, are more affected by the antimetastatic effects of TM than the cancer cell lines,
which are inherently more proteolytic. Our results, at first glance, appear to suggest that
EGF-like repeats 3-6 are neither pro-angiogenic nor anti-angiogenic in regards to
endothelial tube formation and ECM proteolysis (in co-culture systems).
Treatment with rTM EGF3-6 V340A/D341A significantly increased tube
formation in the endothelial monoculture and the co-culture systems containing
endothelial and breast cancer cells compared to control and compared to wild-type rTM
EGF3-6 (Fig. 3.13-3.15). Treatment with rTM EGF3-6 V340A/D341A significantly
increased proteolysis of DQ-collagen IV by endothelial cells alone and in both co-culture
systems significantly compared to control and compared to wild-type rTM EGF3-6 (Fig.
3.16-3.18). This result suggests that absence of TAFI activation increases degradation of
type IV collagen. These results are consistent with the results we obtained through
inhibition of TAFIa with PTCI.
On the other hand, treatment with rTM EGF3-6 F376A significantly decreased
tube formation in all three systems used compared to control (Fig 3.13-3.15). Treatment
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with rTM EGF3-6 F376A also significantly decreased tube formation in endothelial cells
alone and the co-culture system consisting of HUVECs and SUM149 cells compared to
wild-type rTM EGF3-6 (Fig. 3.14). Treatment with rTM EGF3-6 F376A decreased
proteolysis in all three systems in which it was tested, although the decrease was only
significant compared to control in the HUVEC monoculture (Fig. 3.16), and significant
compared to wild-type rTM EGF3-6 in the HUVEC and SUM149 co-culture (Fig. 3.17).
This mutant resulted in very little pericellular proteolysis in each of the three systems
tested (Fig. 3.16-3.18). This result suggests that this mutant results in inhibition of
proteases involved in pericellular proteolysis, such as plasmin and MMPs [157],
consistent with its ability to support TAFI activation. Inhibition of pericellular
plasminogen activation can lead to decreased plasmin and MMPs [41]. Hence, increased
activation of TAFI by rTM EGF3-6 F376A could result in decreased pericellular
proteolysis by inhibition of plasminogen activation.
These findings suggest that, in fact, the wild-type rTM EGF3-6 harbours both proand anti-angiogenic effects that essentially cancel each other out. The pro-angiogenic
effects are mediated through activation of protein C. The anti-angiogenic effects are
mediated through activation of TAFI. When activation of TAFI is prevented (the
V340A/D341A mutant), the pro-angiogenic effects of TM are observable. When
activation of PC is prevented (the F376A mutant), the anti-angiogenic effects of TM are
observable. The role of TM in angiogenesis is not fully established, but our results using
wild-type rTM EGF3-6 have added insight into its role. The lectin-like domain (D1) of
TM was found to elicit anti-angiogenic effects through use of rTM containing only the
lectin-like domain (rTMD1) [95]. rTMD1 was found to inhibit angiogenesis through
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interaction with Lewis Y antigen thereby preventing it from its pro-angiogenic activities
[95]. Previous reports have shown that rTM containing EGF-like repeats 1-6 exhibited
mitogenic effects in Swiss 3T3 fibroblast cells [166]. In addition, rTMD2 (containing
EGF1-6) and rTMD23 (containg EGF1-6 and serine/threonine-like domain) were found
to stimulate HUVEC proliferation [93]. Furthermore, rTMD23 was found to be more
mitogenic than rTMD2 [93]. Treatment with rTMD23 was shown to increase
angiogenesis in vitro and in vivo [93].We found that the EGF-like repeats 3-6 were not
mitogenic. Our results taken together with previous reports potentially pin-point the
specific domains within TM responsible for the reported angiogenic effects. The
serine/threonine-like domain may have pro-angiogenic properties because rTMD23 was
more pro-angiogenic than rTMD2 [93], and we found EGF-like repeats 3-6 are not proangiogenic. The serine/threonine-like domain facilitates the attachment of a chondroitin
sulfate (CS) moiety [78]. In fact, there are reports that CS is pro-angiogenic. CS from sea
cucumber has been shown to be pro-angiogenic in the presence of fibroblast growth
factor-2 (FGF-2) [167]. CS has also been shown to increase sprouting angiogenesis by
binding TGF-β, VEGF, and PDGF [168]. Previous reports showing EGF-like domains 16 have pro-angiogenic properties [93, 166], considered with our result that EGF-like
repeats 3-6 do not stimulate angiogenesis, suggest that EGF-like repeats 1 and 2 are
responsible for the observed pro-angiogenic effects. Our results highlight the complex
role TM plays in angiogenesis. In the full-length TM protein, the lectin-like domain is
anti-angiogenic, the serine/threonine-like domain is pro-angiogenic, and EGF-like repeats
1-2 appear to be pro-angiogenic, EGF-like repeats 3-6 appear to have both anti-
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angiogenic (through TAFI activation) and pro-angiogenic (through protein C activation)
effects.
Our results are also consistent with the idea that TAFIa is an anti-angiogenic
factor. On the other hand, the mutations of rTM EGF3-6 could be eliciting effects on tube
formation and proteolysis of DQ-collagen IV due to protein C being a pro-angiogenic
factor. The decrease in angiogenesis observed with rTM EGF3-6 F376A treatment could
have been due to a loss of protein C activation. The increase in angiogenesis observed
with rTM EGF3-6 V340A/D341A treatment could have been due to protein C activation.
The role of protein C in cancer is not fully understood. There are reports that APC
promotes proliferation, invasion, migration, angiogenesis, and DNA synthesis, as well as
inhibition of apoptosis mediated by binding of APC to EPCR [97–99, 169]. Other studies
have suggested APC limits extravasation of cancer cells, and overexpression of EPCR
reduces metastasis in vivo [101, 102]. A recent study used mutants of rTMD23 that lack
protein C activation (E357A, R385S, and D400A), and determined their effect on
angiogenesis [94]. This study found that treatment with the mutants increased
angiogenesis comparable to wild-type rTMD23, and therefore concluded that rTMD23
induced angiogenesis independent of protein C activation [94]. However, one of the
mutations used in this study (E375A) had been previously shown to abolish thrombin
binding to TM, consequently neither TAFI or protein C can be activated by this mutant
[82]. Therefore, this study cannot clearly rule out the involvement of protein C.
A key experiment yet to be completed in our studies is the use of a mutant form of
rTM EGF3-6 without the ability to bind thrombin, such as Q387P or E357A [81, 82]. The
antimetastatic effects of TM have been shown to be dependent on thrombin binding [91],
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and we found effects on angiogenesis were substrate activation dependent. We observed
a cancelation of anti-angiogenic effects of TAFI activation and pro-angiogenic effects of
protein C activation when using wild-type rTM EGF3-6, resulting in no effect on
angiogenesis. We therefore hypothesize that a mutant without the ability to bind thrombin
would also lead to no change in angiogenesis because neither TAFI nor protein C can be
activated. Our studies using PTCI to inhibit TAFIa suggested that TAFIa decreases
angiogenesis through pericellular plasminogen activation. These results support that the
results we saw using rTM EGF3-6 mutants are an effect of TAFIa, since similar effects
were seen with PTCI as were obtained with rTM EGF3-6 V340A/D341A. Further studies
will have to be completed to determine the role of protein C activation on angiogenesis
using the rTM EGF3-6 mutants. Treatment with an inhibitor of APC and rTM EGF3-6
V340A/D341A should be completed to determine the role of APC on angiogenesis. If
both the anti-angiogenic effects TAFI activation and the pro-angiogenic effects of protein
C activation are equal, inhibition of APC when treating with the V340A/D341A mutant
should result in no effect on angiogenesis since there will be neither TAFIa nor APC
generation. Similarly, an experiment using treatment of both PTCI and the F376A mutant
should be completed to determine the role of TAFIa on angiogenesis. Assuming that both
the anti-angiogenic effects TAFI activation and the pro-angiogenic effects of protein C
activation are equal, inhibition of TAFIa when treating with the F376A mutant should
result in no effect on angiogenesis since there will be neither TAFIa nor APC generation.
These experiments should help determine the anti-angiogenic and pro-angiogenic
activities of EGF3-6 of TM.
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The same trends were observed when the rTM EGF3-6 mutants were used as seen
with PTCI treatment on increased proliferation of HUVECs in the MDA-MB-231 and
HUVEC co-culture, suggesting that both the rTM EGF3-6 and PTCI treatments share a
common underlying mechanism. Similarly, treatment of HUVECs alone with the rTM
EGF3-6 mutants (Fig. 3.16) resulted in proportionally larger effects than with either coculture system (Fig. 3.17 & Fig. 3.18) on the proteolysis of DQ-collagen IV as seen with
treatment with PTCI. This again suggests treatments with rTM EGF3-6 and PTCI share a
common underlying mechanism. There was a slight increase in the effect of treatment
with rTM EGF3-6 V340A/D341A on proteolysis of DQ-collagen IV in the co-culture
system containing MDA-MB-231 cells and HUVECs (Fig. 3.18) as compared to the coculture system containing SUM149 cells and HUVECs (Fig. 3.17). Our laboratory has
found that there is less TM and TAFI expression in the more metastatic MDA-MB-231
cells than in SUM149 cells. There would likely be more TAFI available to be activated in
the SUM149 cells than the MDA-MB-231 cells. Treatment with rTM EGF3-6
V340A/D341A should have resulted in a larger increase in proteolysis in the co-culture
system containing SUM149 cells since there would be a larger overall change in the
amount of TAFI activation compared to that in the MDA-MB-231 cells. Therefore, this
result may not have been due to a difference in TAFI activation and potentially could be
attributed to protein C activation. The amount of protein C expressed in these cell lines
has not been determined. On the other hand, the amount of TAFI that can be activated by
these breast cancer cell lines could differ from the amount of TAFI expressed. Treatment
with rTM EGF3-6 F376A did not result in a significant decrease in proteolysis of DQcollagen IV compared to control in either of the co-culture systems (Fig. 3.17 & Fig.
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3.18), but there was a significant decrease in the HUVEC monoculture (Fig. 3.16). This
could suggest that using this mutant may not be effective on treatment of tumour
angiogenesis of highly metastatic cancers since these breast cancer cell lines are highly
invasive metastatic cell lines. However, by the time cancer cells become highly
metastatic treating tumour angiogenesis is usually ineffective. Therefore, these results
might suggest that treatment with rTM EGF3-6 F376A would be more effective at an
earlier stage of cancer.
Taken together these results suggest that TAFI activation, using TM as a cofactor,
plays a significant role in endothelial tube formation and on proteolysis of type IV
collagen. Our findings also represent proof-of-principle that stimulation of TAFI
activation in the tumour microenvironment using a variant of TM that cannot support
protein C activation might be a viable strategy to inhibit tumour angiogenesis.

4.3 Alternate mechanisms of TAFIa antimetastatic effects
We hypothesized that TAFIa is responsible for the antimetastatic effects of TM
through inhibition of pericellular proteolysis by cleaving carboxyl-terminal lysine
residues from plasminogen receptors. However, TAFIa can also inactivate some
inflammatory mediators that may play roles in cancer. TAFIa can inactivate these
inflammatory mediators through removal of carboxyl-terminal lysine and arginine
residues from C3a, C5a, bradykinin (BK), and thrombin-cleaved OPN (OPN-R) [77,
117].
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The anaphylatoxins, C3a and C5a, are potent leukocyte chemoattractants [77],
and have been implicated in cancer. C3a and C5a have been shown to increase
proliferation, angiogenesis, invasion, migration, and growth factor/cytokine production
[164]. As mentioned previously (4.1.3), they can increase mRNA expression of IL-6 and
IL-1β which can potentially increase MMP2 and MMP9 mRNA expression [161–165].
C3a and C5a also stimulate secretion of VEGF, the key mediator of angiogenesis [164,
170].
BK plays a role in inflammation by increasing vasodilation and vascular
permeability [77], it has also been shown to have metastatic properties. BK has been
shown to increase migration, MMP9 mRNA expression and secretion in prostate cancer
cells [171]. BK has also been shown to increase proliferation in epithelial breast cancer
cells [172]. BK has been implicated in tumour angiogenesis by promoting VEGF
expression [173].
OPN is involved in inflammation, but also has many metastatic properties [77].
OPN expression has been shown to be elevated in many cancers, especially in breast
cancer where increased expression correlates with poor prognosis [174]. OPN is involved
in cell adhesion, migration, invasion, and proliferation [174]. OPN has been implicated in
the plasminogen activation system through integrin signaling and stimulation of uPA
[174]. OPN can also up regulate pro-MMP2 [174]. OPN can induce VEGF expression,
thereby increasing angiogenesis [175]. OPN can be cleaved by thrombin resulting in a
carboxyl-terminal arginine residue (OPN-R). OPN-R has been shown to be more
metastatic that OPN through increased adhesion, migration, and spreading of various cell
types [119, 175]. OPN-R has also been shown to upregulate the proinflammatory effects
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of OPN [77]. TAFIa has been shown cleave OPN-R forming OPN-L [77]. OPN-L has
been shown to reduce the pro-inflammatory effects of OPN-R [77]. OPN-L has also been
shown to decrease cell adhesion compared to OPN-R in Jurkat cells and sinovocytes [77,
176].
Inactivation of these inflammatory mediators by TAFIa suggests that there are
alternate mechanisms of antimetastatic effects of TAFIa.

4.4 Future Directions

The results from this study suggest that TAFIa plays a role in decreasing tumour
angiogenesis. However, further experiments have to be completed to strengthen these
findings.
Specifically, we need to look at the effect on endothelial cell invasion and
proliferation, and MMP mRNA expression and secretion with the rTM EGF3-6 mutants
as completed with inhibition of TAFIa with PTCI. These experiments should be
completed to further show an effect of these mutants on angiogenesis in vitro. As
mentioned previously, to confirm the role of APC in the effects on angiogenesis of the
rTM mutants, we need to complete experiments inhibiting TAFIa and APC in these
mutants.
A stable variant of TAFI, CIIQY [177], in our laboratory has recently been shown
to inhibit breast cancer cell invasion, migration, and degradation of DQ-collagen IV
(unpublished). It is also the first direct evidence that TAFIa plays an antimetastatic role.
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This variant of TAFI should be used to determine a direct effect of TAFIa on tumour
angiogenesis in the future.
We also want to look at the effect of TAFIa on angiogenesis in vivo using
zebrafish. Zebrafish can be used as an in vivo model that allows inexpensive, higherthroughput screening than other available in vivo models [145]. Transgenic zebrafish
lines with fluorescent (GFP-labelled) blood vessels can be used to image angiogenesis
[178]. Sprouting intersegmental vessels (ISVs), and subintestinal vein (SIVs) vessels do
so by angiogenesis, and can be easily quantified [145, 179]. We could test the rTM
EGF3-6 mutants, or stable TAFI, and determine the effect of TAFIa on angiogenesis.
Mammalian tumour cells can be xenotransplanted into zebrafish embryos and used to
study tumour angiogenesis, invasion, and metastasis [179]. This system allows for the
delivery of a limited number of cells which mimics the initial stages of tumour
angiogenesis [179]. Moreover, fluorescently labelled tumour cells and vasculature can be
easily visualized allowing analysis of temporal and spatial relationship between the cells
[179]. We could fluorescently labelled MDA-MB-231 or SUM149 breast cancer cells
and inject them, along with rTM EGF3-6 mutants, or stable TAFI, and look at the effect
of TAFIa on tumour angiogenesis in vivo.
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4.5 Conclusions
In conclusion, this study determined inhibition of TAFIa with PTCI increased
angiogenesis and tumour angiogenesis in vitro by increasing cell proliferation, invasion,
endothelial tube formation, proteolysis of DQ-collagen IV, and secretion and mRNA
expression of MMP2 and MMP9. These results most likely occurred due to a decrease in
inhibition of pericellular plasminogen activation by TAFIa. Also, using rTM containing
EGF-like repeats 3-6 with differing cofactor ability, TAFIa was determined to decrease
angiogenesis and tumour angiogenesis in vitro through endothelial tube formation and
DQ-collagen IV proteolysis experiments. These effects indirectly suggest TAFIa
decreases angiogenesis. Further experiments are required to confirm the effects seen with
certain rTM EGF3-6 mutants reflected effects on protein C activation. Furthermore, a
direct effect of TAFIa on angiogenesis needs to be tested using a stable variant of TAFI.
Additionally, in vivo experiments using zebrafish need to be completed to look at both
angiogenesis and tumour angiogenesis in a more biologically relevant system. These
results are promising in suggesting an anti-angiogenic role for TAFIa, and could
eventually lead to the production of a therapeutic to prevent tumour angiogenesis using
rTM EGF3-6 F376A or a stable variant of TAFI.

128

References
1.

Weinberg, R. A. How Cancer Arises. Sci. Am. 275, 62–70 (1996).

2.

Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).

3.

Cancer statistics at a glance - Canadian Cancer Society. at
<https://www.cancer.ca/en/cancer-information/cancer-101/cancer-statistics-at-aglance/?region=on>

4.

Croce, C. M. Oncogenes and cancer. N. Engl. J. Med. 358, 502–511 (2008).

5.

Vineis, P., Schatzkin, A. & Potter, J. D. Models of carcinogenesis: An overview.
Carcinogenesis 31, 1703–1709 (2010).

6.

Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell
144, 646–674 (2011).

7.

Risau, W. Mechanisms of angiogenesis. Nature 386, 671–674 (1997).

8.

Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic
switch during tumorigenesis. Cell 86, 353–364 (1996).

9.

Bergers, G. & Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev.
Cancer 3, 401–410 (2003).

10.

Pepper, M. S. Role of the Matrix Metalloproteinase and Plasminogen Activator –
Plasmin Systems in Angiogenesis. Arterioscler. Thromb. 1104–1117 (2001).
doi:10.1161/hq0701.093685

11.

Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat.
Med. 1, 27–31 (1995).

12.

Folkman, J. Angiogenesis. Annu. Rev. Med. 57, 1–18 (2006).

13.

Folkman, J. Tumor Angiogenesis: Therapeutic Implications. N. Engl. J. Med. 285,
1182–1186 (1971).

14.

Gimbrone, M., Leapman, S., Cotran, R. & Folkman, J. Tumor Dormancy In Vivo
By Prevention of Neovascularization. J. Exp. Med. 136, 261–276 (1972).

15.

Stephenson, J. A., Goddard, J. C., Dennison, A. R. & Morgan, B. Tumour
Angiogenesis : A Growth Area — From John Hunter to Judah Folkman and
Beyond Hunter to Folkman — A Slow Beginning. J. Cancer Res. 2013, 1–6
(2013).
129

16.

Zetter, B. R. Angiogenesis and tumor metastasis. Annu. Rev. Med. 49, 407–424
(1998).

17.

Baluk, P., Hashizume, H. & McDonald, D. M. Cellular abnormalities of blood
vessels as targets in cancer. Curr. Opin. Genet. Dev. 15, 102–111 (2005).

18.

Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407,
249–257 (2000).

19.

Talmadge, J. E. & Fidler, I. J. AACR centennial series: The biology of cancer
metastasis: Historical perspective. Cancer Res. 70, 5649–5669 (2010).

20.

Chambers, A. F. & Matrisian, L. M. Changing Views of the Role of Matrix. J.
Natl. cancer insitute 89, 1260–1270 (1997).

21.

Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress.
Endocr. Rev. 25, 581–611 (2004).

22.

Senger, D. R. et al. Tumor cells secrete a vascular permeability factor that
promotes accumulation of ascites fluid. Science. 219, 983–985 (1983).

23.

Ferrara, N. & Henzel, W. J. Pituitary follicular cells secrete a novel heparinbinding growth factor specific for vascular endothelial cells. Biochem. Biophys.
Res. Commun. 161, 851–858 (1989).

24.

Ferrara, N. VEGF as a therapeutic target in cancer. Oncology 69, 11–16 (2005).

25.

Carmeliet, P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69, 4–
10 (2005).

26.

Park, J. E., Keller, G. A. & Ferrara, N. The vascular endothelial growth factor
(VEGF) isoforms: differential deposition into the subepithelial extracellular matrix
and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4, 1317–1326
(1993).

27.

Pepper, M., Ferrara, N., Orci, L. & Montesano, R. Vascular Endothelial Growth
Factor (VEGF) Induces Plasminogen Activators and Plasminogen Activator
Inhibitor-1 in Microvascular Endothelial Cells. Biochem. Biophys. Res. Commun.
181, 902–906 (1991).

28.

Mandriota, S. et al. Vascular Endothelial Growth Factor increases Urokinase
Receptor Expression in Vascular Endohelial Cells. J Biol Chem. 270, 9709–9716
(1995).

29.

Hollborn, M. et al. Positive feedback regulation between MMP-9 and VEGF in
human RPE cells. Investig. Ophthalmol. Vis. Sci. 48, 4360–4367 (2007).
130

30.

Dvorak, H. F., Brown, L. F., Detmar, M. & Dvorak, A. M. Vascular permeability
factor/vascular endothelial growth factor, microvascular hyperpermeability, and
angiogenesis. Am. J. Pathol. 146, 1029–1039 (1995).

31.

Masood, R. et al. Vascular endothelial growth factor (VEGF) is an autocrine
growth factor for VEGF receptor-positive human tumors. Blood 98, 1904–1913
(2001).

32.

Sitohy, B., Nagy, J. A. & Dvorak, H. F. Anti-VEGF/VEGFR therapy for cancer:
Reassessing the target. Cancer Res. 72, 1909–1914 (2012).

33.

Hayes, D. F. Bevacizumab treatment for solid tumors: boon or bust? JAMA 305,
506–508 (2011).

34.

Jain, R. K., Duda, D. G., Clark, J. W. & Loeffler, J. S. Lessons from phase III
clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3, 24–40
(2006).

35.

Andreasen, P. A., Egelund, R. & Petersen, H. H. The plasminogen activation
system in tumor growth, invasion, and metastasis. Cell. Mol. life Sci. 57, 25–40
(2000).

36.

Ulisse, S., Baldini, E., Sorrenti, S. & D’Armiento, M. The urokinase plasminogen
activator system: a target for anti-cancer therapy. Curr. Cancer Drug Targets 9,
32–71 (2009).

37.

Godier, A. & Hunt, B. J. Plasminogen receptors and their role in the pathogenesis
of inflammatory, autoimmune and malignant disease. J. Thromb. Haemost. 11, 26–
34 (2013).

38.

Deryugina, E. I. & Quigley, J. P. Cell surface remodeling by plasmin: A new
function for an old enzyme. J. Biomed. Biotechnol. 2012, 1–21 (2012).

39.

Plow, E. F., Doeuvre, L. & Das, R. So many plasminogen receptors: Why? J.
Biomed. Biotechnol. 2012, 1–7 (2012).

40.

Blasi, F. & Carmeliet, P. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol.
Cell Biol. 3, 932–943 (2002).

41.

Smith, H. W. & Marshall, C. J. Regulation of cell signalling by uPAR. Nat. Rev.
Mol. Cell Biol. 11, 23–36 (2010).

42.

Christensen, B., Schack, L., Kläning, E. & Sørensen, E. S. Osteopontin is cleaved
at multiple sites close to its integrin-binding motifs in milk and is a novel substrate
for plasmin and cathepsin D. J. Biol. Chem. 285, 7929–7937 (2010).

131

43.

Sidenius, N. & Blasi, F. The urokinase plasminogen activator system in cancer:
Recent advances and implication for prognosis and therapy. Cancer Metastasis
Rev. 22, 205–222 (2003).

44.

Look, M. P. et al. Pooled analysis of prognostic impact of urokinase-type
plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J.
Natl. Cancer Inst. 94, 116–128 (2002).

45.

Pepper, M. S., Vassalli, J. D., Montesano, R. & Orci, L. Urokinase-type
plasminogen activator is induced in migrating capillary endothelial cells. J Cell
Biol 105, 2535–2541 (1987).

46.

Bajou, K. et al. Absence of host plasminogen activator inhibitor 1 prevents cancer
invasion and vascularization. Nat. Med. 4, 923–938 (1998).

47.

Deng, G., Curriden, S. A., Wang, S., Rosenberg, S. & Loskutoff, D. J. Is
plasminogen activator inhibitor-1 the molecular switch that governs urokinase
receptor-mediated cell adhesion and release? J. Cell Biol. 134, 1563–1571 (1996).

48.

Stefansson, S. & Lawrence, D. A. The serpin PAI-1 inhibits cell migration by
blocking integrin αvβ3 binding to vitronectin. Nature 383, 441–443 (1996).

49.

Kessenbrock, K., Plaks, V. & Werb, Z. Matrix Metalloproteinases: Regulators of
the Tumor Microenvironment. Cell 141, 52–67 (2010).

50.

Page-McCaw, A., Ewald, A. J. & Werb, Z. Matrix metalloproteinases and the
regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8, 221–233 (2007).

51.

Van Wart, H. E. & Birkedal-Hansen, H. The cysteine switch: a principle of
regulation of metalloproteinase activity with potential applicability to the entire
matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. U. S. A. 87, 5578–
5582 (1990).

52.

Sternlicht, M. & Werb, Z. How Matrix metalloproteinases regulate cell behavior.
Annu Rev Cell Biol 17, 463–516 (2001).

53.

Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer
progression. Nat. Rev. Cancer 2, 161–174 (2002).

54.

Itoh, T. et al. Reduced angiogenesis and tumor progression in gelatinase Adeficient mice. Cancer Res. 58, 1048–1051 (1998).

55.

Vu, T. H. et al. MMP-9/gelatinase B is a key regulator of growth plate
angiogenesis and apoptosis of hypetrophic chondrocytes. Cell 93, 411–422 (1998).

132

56.

Zhou, Z. et al. Impaired endochondral ossification and angiogenesis in mice
deficient in membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci. U. S.
A. 97, 4052–4057 (2000).

57.

Lee, S., Jilan, S. M., Nikolova, G. V., Carpizo, D. & Luisa Iruela-Arispe, M.
Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and
vascular patterning in tumors. J. Cell Biol. 169, 681–691 (2005).

58.

Bodary, P. F., Wickenheiser, K. J. & Eitzman, D. T. Recent advances in
understanding endogenous fibrinolysis: implications for molecular-based treatment
of vascular disorders. Expert Rev. Mol. Med. 4, 1–10 (2002).

59.

Rasche, H. Haemostasis and thrombosis: an overview. Eur. Hear. J. Suppl. 3, Q3–
Q7 (2001).

60.

Boffa, M. B. & Koschinsky, M. L. Curiouser and curiouser: Recent advances in
measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in
understanding its molecular genetics, gene regulation, and biological roles. Clin.
Biochem. 40, 431–442 (2007).

61.

Wu, K. K. & Thiagarajan, P. Role of endothelium in thrombosis and hemostasis.
Annu. Rev. Med. 47, 315–331 (1996).

62.

Ruggeri, Z. M. Platelets in atherothrombosis. Nat. Med. 4, 1227–1234 (2002).

63.

Bouma, B. N. & Mosnier, L. O. Thrombin activatable fibrinolysis inhibitor
(TAFI)--how does thrombin regulate fibrinolysis? Ann. Med. 38, 378–388 (2006).

64.

Nesheim, M. Thrombin and fibrinolysis. Chest 124, 33–39 (2003).

65.

Opal, S. M. & Esmon, C. T. Bench-to-bedside review: functional relationships
between coagulation and the innate immune response and their respective roles in
the pathogenesis of sepsis. Crit. Care 7, 23–38 (2003).

66.

Dahlbäck, B. & Villoutreix, B. O. Regulation of blood coagulation by the protein
C anticoagulant pathway: Novel insights into structure-function relationships and
molecular recognition. Arterioscler. Thromb. Vasc. Biol. 25, 1311–1320 (2005).

67.

Broze, G. J. & Higuchi, D. A. Coagulation-dependent inhibition of fibrinolysis:
role of carboxypeptidase-U and the premature lysis of clots from hemophilic
plasma. Blood 88, 3815–3823 (1996).

68.

Foley, J. H., Kim, P. Y., Mutch, N. J. & Gils, A. Insights into thrombin activatable
fibrinolysis inhibitor function and regulation. J. Thromb. Haemost. 11, 306–315
(2013).

133

69.

Plow, E. F., Freaney, D. E., Plescia, J. & Miles, L. A. The plasminogen system and
cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell
type. J. Cell Biol. 103, 2411–2420 (1986).

70.

Mosnier, L. O., Meijers, J. C. M. & Bouma, B. N. Regulation of fibrinolysis in
plasma by TAFI and protein C is dependent on the concentration of
thrombomodulin. Thromb. Haemost. 85, 5–11 (2001).

71.

Esmon, C. T. The Protein C Pathway. Chest 124, 26S–32S (2003).

72.

Esmon, N. L., Owen, W. G. & Esmon, C. T. Isolation of a membrane bound
cofactor for thrombin catalyzed activation of protein C. J. Biol. Chem. 257, 859–
864 (1982).

73.

Rezaie, A. R. Regulation of the protein C anticoagulant and antiinflammatory
pathways. Curr. Med. Chem. 17, 2059–2069 (2010).

74.

Nesheim, M. et al. Thrombin, thrombomodulin and TAFI in the molecular link
between coagulation and fibrinolysis. Thromb. Haemost. 78, 386–91 (1997).

75.

Bajzar, L., Morser, J. & Nesheim, M. TAFI, or plasma procarboxypeptidase B,
couples the coagulation and fibrinolytic cascades through the thrombinthrombomodulin complex. J. Biol. Chem. 271, 16603–16608 (1996).

76.

Redlitz, A., Tan, A. K., Eaton, D. L. & Plow, E. F. Plasma Cabrboxypeptidases as
Regulators of the Plasminogen System. J. Clin. Invest. 96, 2534–2538 (1995).

77.

Myles, T. et al. Thrombin Activatable Fibrinolysis Inhibitor, a Potential Regulator
of Vascular Inflammation. J. Biol. Chem. 278, 51059–51067 (2003).

78.

Conway, E. M. Thrombomodulin and its role in inflammation. Semin.
Immunopathol. 34, 107–125 (2012).

79.

Zhang, Y. et al. Thrombomodulin Modulates Growth of Tumor Cells Independent
of its. J. Clin. Invest. 101, 1301–1309 (1998).

80.

Wen, D. et al. Human thrombomodulin: Complete cDNA sequence and
chromosome localization of the gene. Biochemistry 26, 4350–4357 (1987).

81.

Nagashima, M., Lundh, E., Leonard, J. C., Morser, J. & Parkinson, J. F. Alaninescanning mutagenesis of the epidermal growth factor-like domains of human
thrombomodulin identifies critical residues for its cofactor activity. J. Biol. Chem.
268, 2888–2892 (1993).

134

82.

Wang, W., Nagashima, M., Schneider, M., Morser, J. & Nesheim, M. Elements of
the primary structure of thrombomodulin required for efficient thrombin-activable
fibrinolysis inhibitor activation. J. Biol. Chem. 275, 22942–22947 (2000).

83.

Boffa, M. C. & Karmochkine, M. Thrombomodulin: an overview and potential
implications in vascular disorders. Lupus 7, S120–S125 (1998).

84.

Glaser, C. B. et al. Oxidation of a specific methionine in thrombomodulin by
activated neutrophil products blocks cofactor activity: A potential rapid
mechanism for modulation of coagulation. J. Clin. Invest. 90, 2565–2573 (1992).

85.

Li, Y., Kuo, C., Shi, G. & Wu, H. The role of thrombomodulin lectin-like domain
in inflammation. J. Biomed. Sci. 19, 34 (2012).

86.

Horowitz, N. A. & Palumbo, J. S. Mechanisms coupling thrombomodulin to tumor
dissemination. Thromb. Res. 129, S119–S121 (2012).

87.

Menschikowski, M. et al. Regulation of thrombomodulin expression in prostate
cancer cells. Cancer Lett. 322, 177–184 (2012).

88.

Ogawa, H. et al. Expression of thrombomodulin in squamous cell carcinoma of the
lung: its relationship to lymph node metastasis and prognosis of the patients.
Cancer Lett. 149, 95–103 (2000).

89.

Kim, S. J. et al. Thrombomodulin is a new biological and prognostic marker for
breast cancer: an immunohistochemical study. Anticancer Res. 17, 2319–2323
(1997).

90.

Hosaka, Y., Higuchi, T., Tsumagari, M. & Ishii, H. Inhibition of invasion and
experimental metastasis of murine melanoma cells by human soluble
thrombomodulin. Cancer Lett. 161, 231–240 (2000).

91.

Horowitz, N. A. et al. Thrombomodulin is a determinant of metastasis through a
mechanism linked to the thrombin binding domain but not the lectin-like domain.
Blood 118, 2889–2895 (2011).

92.

Weiler-Guettler, H. et al. A targeted point mutation in thrombomodulin generates
viable mice with a prethrombotic state. J. Clin. Invest. 101, 1983–1991 (1998).

93.

Shi, C. S. et al. Evidence of human thrombomodulin domain as a novel angiogenic
factor. Circulation 111, 1627–1636 (2005).

94.

Kuo, C. H. et al. FGFR1 mediates recombinant thrombomodulin domain-induced
angiogenesis. Cardiovasc. Res. 105, 107–117 (2015).

135

95.

Kuo, C. H. et al. The recombinant lectin-like domain of thrombomodulin inhibits
angiogenesis through interaction with Lewis Y antigen. Blood 119, 1302–1313
(2012).

96.

Bouwens, E. A. M., Stavenuiter, F. & Mosnier, L. O. Mechanisms of anticoagulant
and cytoprotective actions of the protein C pathway. J. Thromb. Haemost. 11,
242–253 (2013).

97.

Van Sluis, G. L., Büller, H. R. & Spek, C. A. The role of activated protein C in
cancer progression. Thromb. Res. 125 Suppl , S138–S142 (2010).

98.

Spek, C. A. & Arruda, V. R. The protein C pathway in cancer metastasis. Thromb.
Res. 129, S80–S84 (2012).

99.

Uchiba, M. et al. Activated protein C induces endothelial cell proliferation by
mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circ.
Res. 95, 34–41 (2004).

100. Beaulieu, L. M. & Church, F. C. Activated protein C promotes breast cancer cell
migration through interactions with EPCR and PAR-1. Exp. Cell Res. 313, 677–
687 (2007).
101. Van Sluis, G. L. et al. Endogenous activated protein C limits cancer cell
extravasation through sphingosine-1-phosphate receptor 1-mediated vascular
endothelial barrier enhancement. Blood 114, 1968–1973 (2009).
102. Bezuhly, M. et al. Role of activated protein C and its receptor in inhibition of
tumor metastasis. Blood 113, 3371–3374 (2009).
103. Antoń, I. et al. Receptor of activated protein C promotes metastasis and correlates
with clinical outcome in lung adenocarcinoma. Am. J. Respir. Crit. Care Med. 186,
96–105 (2012).
104. Hendriks, D., Scharpé, S., van Sande, M. & Lommaert, M. P. Characterisation of a
carboxypeptidase in human serum distinct from carboxypeptidase N. J. Clin.
Chem. Clin. Biochem. 27, 277–285 (1989).
105. Campbell, W. & Okada, H. An arginine specific carboxypeptidase generated in
blood during coagulation or inflammation which is unrelated to carboxypeptidase
N or its subunits. Biochem. Biophys. Res. Commun. 162, 933–939 (1989).
106. Eaton, D. L., Malloy, B. E., Tsai, S. P., Henzel, W. & Drayna, D. Isolation,
molecular cloning, and partial characterization of a novel carboxypeptidase B from
human plasma. J. Biol. Chem. 266, 21833–21838 (1991).

136

107. Wang, W., Hendriks, D. F. & Scharpé, S. S. Carboxypeptidase U, a plasma
carboxypeptidase with high affinity for plasminogen. J. Biol. Chem. 269, 15937–
15944 (1994).
108. Bajzar, L., Manuel, R. & Nesheim, M. E. Purification and characterization of
TAFI, a thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 270, 14477–
14484 (1995).
109. Bajzar, L. & Nesheim, M. The effect of activated protein C on fibrinolysis in cellfree plasma can be attributed specifically to attenuation of prothrombin activation.
J. Biol. Chem. 268, 8608–8616 (1993).
110. Lin, J. H. H. et al. Identification of human thrombin-activatable fibrinolysis
inhibitor in vascular and inflammatory cells. Thromb. Haemost. 105, 999–1009
(2011).
111. Hori, Y. et al. Insulin enhanced thrombin-activable fibrinolysis inhibitor
expression through PI3 kinase/Akt pathway. Int. J. Mol. Med. 15, 265–268 (2005).
112. Marx, P. F. et al. Crystal structures of TAFI elucidate the inactivation mechanism
of activated TAFI: A novel mechanism for enzyme autoregulation. Blood 112,
2803–2809 (2008).
113. Boffa, M. B., Wang, W., Bajzar, L. & Nesheim, M. E. Plasma and recombinant
thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared
with respect to glycosylation, thrombin/thrombomodulin-dependent activation,
thermal stability, and enzymatic properties. J. Biol. Chem. 273, 2127–2135 (1998).
114. Valnickova, Z. et al. Post-translational modifications of human thrombinactivatable fibrinolysis inhibitor (TAFI): Evidence for a large shift in the
isoelectric point and reduced solubility upon activation. Biochemistry 45, 1525–
1535 (2006).
115. Mao, S. S., Cooper, C. M., Wood, T., Shafer, J. A. & Gardell, S. J.
Characterization of plasmin-mediated activation of plasma procarboxypeptidase B.
Modulation by glycosaminoglycans. J. Biol. Chem. 274, 35046–35052 (1999).
116. Marx, P. F., Dawson, P. E., Bouma, B. N. & Meijers, J. C. M. Plasmin-mediated
activation and inactivation of thrombin-activatable fibrinolysis inhibitor.
Biochemistry 41, 6688–6696 (2002).
117. Campbell, W. D., Lazoura, E., Okada, N. & Okada, H. Inactivation of C3a and
C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol.
Immunol. 46, 131–134 (2002).

137

118. Smith, L. L. et al. Protein Chemistry and Structure : Osteopontin N-terminal
Domain Contains a Cryptic Adhesive Sequence Recognized by Osteopontin Nterminal Domain Contains a Cryptic Adhesive Sequence Recognized by α9β1
Integrin. J. Biol. Chem. 271, 28485–28491 (1996).
119. Senger, D. R., Perruzzi, C. A., Papadopoulos-Sergiou, A. & Van de Water, L.
Adhesive properties of osteopontin: regulation by a naturally occurring thrombincleavage in close proximity to the GRGDS cell-binding domain. Mol. Biol. Cell 5,
565–574 (1994).
120. Renckens, R. et al. Absence of Thrombin-Activatable Fibrinolysis Inhibitor
Protects against Sepsis-Induced Liver Injury in Mice. J. Immunol. 175, 6764–6771
(2005).
121. Te Velde, E. A. et al. Impaired healing of cutaneous wounds and colonic
anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J.
Thromb. Haemost. 1, 2087–2096 (2003).
122. Romer, J. et al. Impaired wound healing in mice with a disrupted plasminogen
gene. Nat. Med. 2, 287–292 (1996).
123. Boffa, M. B. TAFI and wound healing: Closing a knowledge gap. J. Thromb.
Haemost. 1, 2075–2077 (2003).
124. Drew, A. F., Liu, H., Davidson, J. M., Daugherty, C. C. & Degen, J. L. Woundhealing defects in mice lacking fibrinogen. Blood 97, 3691–3698 (2001).
125. Swaisgood, C. M., Schmitt, D., Eaton, D. & Plow, E. F. In vivo regulation of
plasminogen function by plasma carboxypeptidase B. J. Clin. Invest. 110, 1275–
1282 (2002).
126. Okumura, N., Koh, T., Hasebe, Y., Seki, T. & Ariga, T. A novel function of
thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in
growth-promoted hepatocytes in primary culture. J. Biol. Chem. 284, 16553–
16561 (2009).
127. Reijerkerk, A. et al. Tumor growth and metastasis are not affected in thrombinactivatable fibrinolysis inhibitor-deficient mice. J. Thromb. Haemost. 2, 769–779
(2004).
128. Higuchi, T., Nakamura, T., Kakutani, H. & Ishii, H. Thrombomodulin suppresses
invasiveness of HT1080 tumor cells by reducing plasminogen activation on the
cell surface through activation of thrombin-activatable fibrinolysis inhibitor. Biol.
Pharm. Bull. 32, 179–185 (2009).

138

129. Atkinson, J. M., Pullen, N. & Johnson, T. S. An inhibitor of thrombin activated
fibrinolysis inhibitor (TAFI) can reduce extracellular matrix accumulation in an in
vitro model of glucose induced ECM expansion. Matrix Biol. 32, 277–287 (2013).
130. Guimarães, A. H. C. et al. TAFI and pancreatic carboxypeptidase B modulate in
vitro capillary tube formation by human microvascular endothelial cells.
Arterioscler. Thromb. Vasc. Biol. 27, 2157–2162 (2007).
131. Mock, W. L. & Stanford, D. J. Anisylazoformylarginine: A superior assay
substrate for carboxypeptidase B type enzymes. Bioorganic Med. Chem. Lett. 12,
1193–1194 (2002).
132. Sakata, T. et al. Study of chromogenic substrate on protein C activity assay--in
patients treated with warfarin. Japanese J. Clin. Pathol. 38, 937–941 (1990).
133. Cell
Proliferation
Reagent
WST-1.
<http://lifescience.roche.com/shop/products/cell-proliferation-reagent-wst-1>

at

134. Grant, D. S., Lelkes, P. I., Fukuda, K., Kleinman, H. K. & Al, G. Intracellular
Mechanisms Involved in Basement Membrane. Vitr. Cell. Dev. Biol. 27A, 327–
336 (1991).
135. Kubota, Y., Kleinman, H. K., Martin, G. R. & Lawley, T. J. Role of laminin and
basement membrane in the morphological differentiation of human endothelial
cells into capillary-like structures. J. Cell Biol. 107, 1589–1598 (1988).
136. Sameni, M., Dosescu, J., Moin, K. & Sloane, B. F. Functional Imaging of
Proteolysis: Stromal and Inflammatory Cells Increase Tumor Proteolysis. Mol.
Imaging 2, 159–175 (2003).
137. Sloane, B. F., Sameni, M., Podgorski, I., Cavallo-Medved, D. & Moin, K.
Functional imaging of tumor proteolysis. Annu. Rev. Pharmacol. Toxicol. 46, 301–
315 (2006).
138. Sameni, M. et al. Imaging and quantifying the dynamics of tumor-associated
proteolysis. Clin. Exp. Metastasis 26, 299–309 (2009).
139. Mohamed, M. M. et al. Interleukin-6 increases expression and secretion of
cathepsin B by breast tumor-associated monocytes. Cell. Physiol. Biochem. 25,
315–324 (2010).
140. Wang, L. et al. Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by
erythropoietin-activated endothelial cells promote neural progenitor cell migration.
J. Neurosci. 26, 5996–6003 (2006).

139

141. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using
real-time quantitative PCR and the 2-∆∆CT Method. Methods 25, 402–408 (2001).
142. Clare, G. M., Gronenborn, A. M., Nilges, J. M. & Ryan, C. A. Three-Dimensional
Structure of Potato Carboxypeptidase Inhibitor in Solution. A Study Using Nuclear
Magnetic Resonance , Distance Geometry , and Restrained Molecular Dynamics.
Biochemistry 26, 8012–8023 (1987).
143. Ryan, C. A., Hass, G. M. & Kuhn, R. W. Purification and Properties of a
Carboxypeptidase Inhibitor from Potatoes. J. Biol. Chem. 249, 5495–5500 (1974).
144. Foley, J. H., Kim, P. & Nesheim, M. E. Thrombin-activable fibrinolysis inhibitor
zymogen does not play a significant role in the attenuation of fibrinolysis. J. Biol.
Chem. 283, 8863–8867 (2008).
145. Staton, C. A. et al. Current methods for assaying angiogenesis in vitro and in vivo.
Int. J. Exp. Path. 85, 233–248 (2004).
146. Cavallo-Medved, D. et al. Live-cell imaging demonstrates extracellular matrix
degradation in association with active cathepsin B in caveolae of endothelial cells
during tube formation. Exp. Cell Res. 315, 1234–1246 (2009).
147. LeBleu, V. S., Macdonald, B. & Kalluri, R. Structure and function of basement
membranes. Exp. Biol. Med. 232, 1121–1129 (2007).
148. Toth, M., Sohail, A. & Fridman, R. Assessment of gelatinases (MMP-2 and MMP9) by gelatin zymography. Methods Mol. Biol. 878, 121–35 (2012).
149. Parkinson, J. F., Nagashima, M., Kuhn, I., Leonard, J. & Morser, J. Structurefunction studies of the epidermal growth factor domains of human
thrombomodulin. Biochem. Biophys. Res. Commun. 185, 567–576 (1992).
150. Holliday, D. L. & Speirs, V. Choosing the right cell line for breast cancer research.
Breast cancer Res. 13, 215 (2011).
151. Schnaper, H. W. et al. Plasminogen activators augment endothelial cell
organization in vitro by two distinct pathways. J. Cell. Physiol. 165, 107–118
(1995).
152. Van Hinsbergh, V. W. M., Engelse, M. A. & Quax, P. H. A. Pericellular proteases
in angiogenesis and vasculogenesis. Arterioscler. Thromb. Vasc. Biol. 26, 716–728
(2006).
153. Sameni, M., Moin, K. & Sloane, B. F. Imaging Proteolysis by Living Human
Breast Cancer Cells. Neoplasia 2, 496–504 (2000).

140

154. Sameni, M. et al. Imaging and quantifying the dynamics of tumor-associated
proteolysis. Clin. Exp. Metastasis 26, 299–309 (2009).
155. Ahram, M. et al. Rac1-induced endocytosis is associated with intracellular
proteolysis during migration through a three-dimensional matrix. Exp. Cell Res.
260, 292–303 (2000).
156. Sameni, M., Dosescu, J. & Sloane, B. F. Imaging proteolysis by living human
glioma cells. Biol. Chem. 382, 785–788 (2001).
157. Everts, V., Van Der Zee, E., Creemers, L. & Beertsen, W. Phagocytosis and
intracellular digestion of collagen, its role in turnover and remodelling. Histochem.
J. 28, 229–245 (1996).
158. Tang, Y., Kesavan, P., Nakada, M. T. & Yan, L. Tumor-stroma interaction:
positive feedback regulation of extracellular matrix metalloproteinase inducer
(EMMPRIN) expression and matrix metalloproteinase-dependent generation of
soluble EMMPRIN. Mol. Cancer Res. 2, 73–80 (2004).
159. Taraboletti, G. et al. Shedding of the matrix metalloproteinases MMP-2, MMP-9,
and MT1-MMP as membrane vesicle-associated components by endothelial cells.
Am. J. Pathol. 160, 673–680 (2002).
160. Ginestra, A. et al. Urokinase Plasminogen-Activator and Gelatinases Are
Associated with Membrane-Vesicles Shed by Human HT1080 Fibrosarcoma Cells.
J. Biol. Chem. 272, 17216–17222 (1997).
161. Mauviel, A. Cytokine regulation of metalloproteinase gene expression. J. Cell.
Biochem. 53, 288–295 (1993).
162. Kossakowska, A. E. et al. Interleukin-6 regulation of matrix metalloproteinase
(MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1)
expression in malignant non-Hodgkin’s lymphomas. Blood 94, 2080–2089 (1999).
163. Sayah, S., Ischenko, A. M., Zhakhov, A., Bonnard, A. S. & Fontaine, M.
Expression of cytokines by human astrocytomas following stimulation by C3a and
C5a anaphylatoxins: Specific increase in interleukin-6 mRNA expression. J.
Neurochem. 72, 2426–2436 (1999).
164. Rutkowski, M. J., Sughrue, M. E., Kane, A. J., Mills, S. A. & Parsa, A. T. Cancer
and the complement cascade. Mol. Cancer Res. 8, 1453–1465 (2010).
165. Monsinjon, T. et al. Regulation by complement C3a and C5a anaphylatoxins of
cytokine production in human umbilical vein endothelial cells. FASEB J. 17,
1003–1014 (2003).

141

166. Hamada, H. et al. The epidermal growth factor-like domain of recombinant human
thrombomodulin exhibits mitogenic activity for Swiss 3T3 cells. Blood 86, 225–
233 (1995).
167. Tapon-Bretaudière, J. et al. A fucosylated chondroitin sulfate from echinoderm
modulates in vitro fibroblast growth factor 2-dependent angiogenesis. Mol. cancer
Res. 1, 96–102 (2002).
168. Jan, S. Le et al. Functional overlap between chondroitin and heparan sulfate
proteoglycans during VEGF-induced sprouting angiogenesis. Arterioscler.
Thromb. Vasc. Biol. 32, 1255–1263 (2012).
169. Beaulieu, L. M. & Church, F. C. Activated protein C promotes breast cancer cell
migration through interactions with EPCR and PAR-1. Exp. Cell Res. 313, 677–
687 (2007).
170. Nozaki, M. et al. Drusen complement components C3a and C5a promote choroidal
neovascularization. Proc. Natl. Acad. Sci. U. S. A. 103, 2328–2333 (2006).
171. Yu, H., Lin, T. & Tang, C. Bradykinin enhances cell migration in human prostate
cancer cells through B2 receptor/PKCδ/c-Src dependent signaling pathway.
Prostate 73, 89–100 (2013).
172. Greco, S. et al. Bradykinin stimulates cell proliferation through an extracellularregulated kinase 1 and 2-dependent mechanism in breast cancer cells in primary
culture. J. Endocrinol. 186, 291–301 (2005).
173. Yu, H. et al. Bradykinin promotes vascular endothelial growth factor expression
and increases angiogenesis in human prostate cancer cells. Biochem. Pharmacol.
87, 243–253 (2014).
174. El-Tanani, M. K. et al. The regulation and role of osteopontin in malignant
transformation and cancer. Cytokine Growth Factor Rev. 17, 463–474 (2006).
175. Senger, D. R. et al. Stimulation of endothelial cell migration by vascular
permeability factor/vascular endothelial growth factor through cooperative
mechanisms involving the αvβ3 integrin, osteopontin, and thrombin. Am. J.
Pathol. 149, 293–305 (1996).
176. Sharif, S. A. et al. Thrombin-activatable carboxypeptidase B cleavage of
osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid
arthritis. Arthritis Rheum. 60, 2902–2912 (2009).
177. Ceresa, E. et al. Comparative evaluation of stable TAFIa variants: Importance of
α-helix 9 and β-sheet 11 for TAFIa (in)stability. J. Thromb. Haemost. 5, 2105–
2112 (2007).
142

178. Lawson, N. D. & Weinstein, B. M. In vivo imaging of embryonic vascular
development using transgenic zebrafish. Dev. Biol. 248, 307–318 (2002).
179. Tobia, C., Gariano, G., De Sena, G. & Presta, M. Zebrafish embryo as a tool to
study tumor/endothelial cell cross-talk. Biochim. Biophys. Acta - Mol. Basis Dis.
1832, 1371–1377 (2013).

143

Vita Auctoris

NAME:

Jennifer Balun

PLACE IF BIRTH:

Windsor, ON

YEAR OF BIRTH:

1991

EDUCTATION:

University of Windsor
B.Sc. Honours Biochemistry with Thesis with distinction
Windsor, ON, 2013
University of Windsor
M.Sc. in Chemistry and Biochemistry
Windsor, ON, 2015

144

